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ABSTRACT
EXPLOITATION AND REGULATION OF APOPTOTIC CASPASES
FEBRUARY 2017
SCOTT J. ERON, B.S. SUNY GENESEO
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Jeanne A. Hardy
Caspases are the cysteine proteases that govern apoptotic cell death. The regulation of
these enzymes is critical in order to restrain their death-inducing capabilities until the
appropriate moment. Infidelity of caspase regulation and activation underlies a plethora
of human diseases ranging from cancer to neurodegeneration. This establishes a pressing
need for comprehensive studies of the apoptotic caspases in order to understand all
aspects of their regulation, activation, substrate preferences, structure, and function. A
detailed structural view of caspase regulation would have lasting implications for future
therapeutic avenues targeting caspase function or apoptosis. This dissertation chronicles
caspase regulation by phosphorylation as well as zinc. A mechanistic approach
uncovering the precise means by which caspases and kinases co-regulate one another
offers multiple avenues for therapeutic intervention. In addition, the influence of zinc on
caspase activity at biologically relevant concentrations alters the perspective on zinc
regulation of apoptosis. Lastly, this work utilizes the knowledge derived from these
mechanistic studies for an application in which the cell death inducing potential of an
executioner caspase is harnessed by delivering the caspase to a population of cancer cells.
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CHAPTER I
INTRODUCTION
Apoptosis Depends on Caspases
All multicellular eukaryotes depend on one critical biological pathway that
dictates cell life and cell death. A programmed cell death cascade known as apoptosis has
proven to be imperative to all metazoans, influencing a myriad of processes including
organismal development,1 differentiation,2 maintaining homeostasis of cell populations,3
and elimination of damaged cells.4 This gene directed execution is so advantageous
because it circumvents inflammation, leakage of cell contents, and does not damage the
surrounding cells. This clean and methodical removal of cells begins with an energy
dependent set of biochemical mechanisms that result in distinct morphological changes,
including blebbing of the cell membrane, overall cell shrinkage, nuclear fragmentation,
chromatin condensation, DNA fragmentation and global mRNA decay. Ultimately,
internal fragments of cell debris are packaged into apoptotic bodies and excreted, where
they are quickly phagocytosed and degraded.
At the heart of this favorable cell death pathway are the caspases, a family of
influential cysteine proteases who effectively manage this potentially lethal process.
These caspases derive their name from their enzymatic function: using a cysteine for thiol
chemistry in the active site to preferentially cleave after aspartate residues contained
within a particular recognition motif. The proper regulation of the caspases is absolutely
paramount to ensure that apoptosis occurs at the appropriate moment only under
deliberate stimulation. Inappropriate apoptosis plays a major role in a plethora of diseases
at both ends of the spectrum. Consequently, increased apoptosis is a factor in classic
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neurodegenerative diseases such as Alzheimer’s5–7 and Huntington’s8,9 disease, as well as
ischemic injury10 and AIDS.11 Meanwhile, a suppression of apoptosis is observed in
many types of cancer12–15 and in autoimmune disorders.16
The Apoptotic Pathway and the Activation of Caspases
Apoptosis comes from the Greek word meaning “falling off,” referring to the
falling of leaves from a tree. Scientists have studied the concept of programmed cell
death for (arguably) centuries, with examples ranging from observations of dying bark on
oak trees to insect metamorphosis to neuronal death during embryonic development.
However, it was not until 1972 that Kerr et al.17 coined the term apoptosis while
examining morphological changes in hepatocyte development. The idea of an encoded
program for cell suicide was brought to light.
The investigation of just 131 cells in a small nematode opened the window
through which we now look at the mechanism of apoptosis. While observing the
development of the nematode C. elegans, Horvitz and colleagues found that of the 1090
somatic cells of this worm, 131 of these cells die in a controlled fashion at specific stages
during development.1 Amazingly, this was a consistent observation for each worm as it
matured. The enzymes responsible for this programmed cell death (e.g. ced9 in C.
elegans) were found to be homologous to human cysteine proteases, which are the
caspases we know today. The study of this process behind gene-directed elimination of
cells has since surged with researchers all over the globe who recognize the tremendous
therapeutic potential of being able to dictate cell life or death.
This thesis aims to interrogate the regulation of the apoptotic caspases and exploit
the knowledge gained for eventual therapeutic purposes. This begins by understanding
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the activation mechanisms that trigger apoptosis. Apoptosis can be induced by multiple
signals resulting in activating the initiation phase of cell death (Figure 1). This typically
follows two main pathways: (1) the extrinsic pathway dependent on death receptors, or
(2) the mitochondrially triggered intrinsic pathway. There is a third granzyme dependent
cascade, which will not be discussed in detail here. However, an important observation is
that all three initiation events converge on the activation of executioner caspases,
emphasizing the critical role caspases play during apoptotic cell death.
	
  

	
  

Figure 1: The Apoptotic Pathway
The extrinsic and intrinsic apoptotic pathways are dependent on caspase activity. They begin by
activating the upstream initiator caspases (procaspase-8 and -9 are activated by the DISC and
apoptosome complexes respectively), which in turn cleave their substrates, the downstream
executioner caspases. Both pathways converge on the activation of procaspase-3, -6, and -7, which
are cleaved to generate caspase-3, -6 and-7, and which proceed to dismantle the cell in an orderly
fashion through the cleavage of a myriad of specific substrates, ultimately terminating the cell.
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The family of apoptotic caspases is broken down into initiator caspases -2, -8, -9,
and -10, as well as executioner caspases -3, -6, and -7. The initiators act upstream,
dependent on a trigger (dimerization or binding to an activating platform like the DISC or
apoptosome) that enhances their ability to cleave and activate the downstream
executioner caspases. Both the extrinsic and intrinsic apoptotic pathways rely on this
cascade of caspase cleavage and activation events (Figure 1). The extrinsic pathway
utilizes death receptors of the tumor necrosis factor (TNF) family, wherein stimulation of
the receptors forces them to congregate at the cell surface and transmit the death signal
through binding an intracellular ligand. This transfers information to the cytoplasmic
region where formation of a death inducing signaling complex (DISC)18 can recruit
caspase-8 and caspase-1019 via their death effector domains (DED). Following
recruitment, these initiator caspases dimerize and then activate via a cleavage event.20
This allows them to now cleave and activate the executioner caspases who then proceed
to dismantle a myriad of downstream apoptotic targets.
The intrinsic apoptotic pathway is stimulated by various stress responses such as
hypoxia, radiation, or viral infection. This program of cell death is contingent on
permeabilizing the mitochondria, which relies on the action of the Bcl-2 family of
proteins. This family consists of both pro-apoptotic and anti-apoptotic regulators (for
review see Gross et al.21). Under normal conditions, the anti-apoptotic Bcl-2, Bcl-xL,
Bcl-w, and Mcl-1 (among others) act in concert to inhibit the pro-apoptotic proteins Bax
and Bak. When upstream signals activate this cascade, BH3 only proteins block Bcl-2,
Bcl-xL, Bcl-w, and Mcl-1, thus sequestering their anti-apoptotic activity. This allows Bax
and Bad to form complexes at the mitochondrial outer membrane, which results in pore
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formation and release of cytochrome c.22 Apoptotic protease activating factor-1 (Apaf-1)
with the help of dATP, bind cytochrome c and form a heptameric complex known as the
apoptosome.23 This enormous complex can recruit monomeric caspase-9 via its caspase
activation and recruitment domain (CARD) and significantly enhance its activity.24
Caspase-9 then cleaves and activates executioner caspases -3 and -725 for them to carry
out the execution phase of apoptosis.
Both the extrinsic and intrinsic apoptotic cascades converge on the executioner
caspases, highlighting the pivotal role they play in this powerful biological process.
Controlling the activity of these enzymes would dictate life and death within cell
populations, underscoring their therapeutic potential. It is with this in mind that we and
others have pursued the exploration of understanding these proteases on a molecular
level, with a particular focus on their regulation and activation.
Characteristics of Caspases
Ultimately, it is the caspases that drive the apoptotic machine during programmed
cell death, making it imperative that we understand this powerful class of enzymes. This
appreciation begins with activation. Due to their cell death inducing potential, apoptotic
caspases are held in an inactive (uncleaved) zymogen form, also referred to as
procaspases. An activating event must first occur in order to convert these proteins to
highly functioning proteases. An extremely diverse set of stimuli can set this into motion,
but it begins with the upstream initiator caspases. These are typically found in their
monomeric zymogen (pro) form, and activation occurs via an induced proximity model.
Whether it be caspase-8 associating with the DISC complex, or caspase-9 being recruited
to the apoptosome (see above), the initiator caspases typically require the assistance of
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other proteins for activation. Meanwhile, the executioner caspases naturally exist as
dimers and their activation occurs upon cleavage by initiator caspases at their intersubunit
linker.
Despite differences in activation, the caspase architecture is consistent across the
apoptotic family. Executioner caspases are functional as homodimers, with each
monomer comprised of a prodomain at their N-terminus, followed by a large and small
subunit, which is connected by an intersubunit linker (Figure 2A). The length of the Nterminal

prodomain

is

quite

variable, with initiators typically
having lengthy recruitment regions
(ranging from 138 to 216 amino
acids) and executioners having
short regions closer to 20 amino
acids. To reach maximum activity,
caspases require cleavage of their
intersubunit linker in order to
properly form the active site.
Interestingly, executioner caspases
are

obligate

dimers,

with

processing of the linker necessary
for full catalytic activity. This
linker

rests

across

the

dimer

interface and only after cleavage

	
  

	
  

Figure 2: Caspase Architecture
(A) Domain architecture of an executioner caspase
displaying the obligate homodimer. Each monomer is
comprised of a prodomain, a large subunit, an intersubunit
linker, and a small subunit. Arrows indicate processing sites
where upstream initiator caspases cleave and activate the
executioner. (B) Cartoon representation of a canonical
caspase. Gray coloring indicates the N-terminal region,
which is modeled in because it cannot be seen
crystallographically. The large and small subunits are shaded
light blue and dark blue respectively, along with a
tetrapeptide substrate DEVD in each active site. The four
critical and mobile loops are also labeled in one active site,
including L2’ from the opposite monomer.

6	
  

can it be liberated, where it proceeds to act as a loop assisting in formation of the active
site on the opposite monomer.
There are two active sites per caspase homodimer and each is comprised of four
critical mobile loops: L2, L3, L4, from one monomer and L2’ from the opposite
monomer (Figure 2B). The orientation of these loops is absolutely essential for proper
binding and cleavage of substrate.26 These flexible loops can sample different
conformational states throughout the life of the protein, and a dynamic equilibrium exists
between these states (Figure 3). Loop positioning has been thoroughly investigated with
the executioner caspase-7 by x-ray crystallography. The procaspase-7 zymogen,27 mature
(cleaved) unliganded (apo) caspase-7,27,28 and substrate-bound caspase-729 crystal
structures have all been solved and combine to create a detailed understanding of loop
positioning. In the uncleaved zymogen caspase-7 the active site loops are mobile and are
not observed to be locked down to form the catalytic cleft. L2, which includes the
catalytic cysteine C186, is held in the “down” conformation across the dimer interface. In
addition, L3 and L4 are disordered. After cleavage of the intersubunit linker the mature
caspase-7 is generated, and L2 is free to swing upward and make critical contacts with
other active site loops including L4 and L2’. These interactions help form the proper
active site loop bundle and allow the catalytic cysteine to rotate into a position amenable
for substrate hydrolysis. Finally, several structures have been solved with an active site
inhibitor bound, displaying all four loops in the proper orientation for binding and
cleaving substrate. Notably, L2’ acts as a buttress for the L2 loop in the active site of the
opposite monomer.26 It is important to note that a reversal of the active site loops back to
the zymogen-like state have been observed by the addition of allosterically inhibiting
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small molecules such as FICA and DICA (Figure 3).30 This will trap L2’ in the “down”
conformation across the dimer interface and expel loop 3 from the active site. These
observations underscore the mobility of these loops and the importance of proper active
site geometry in order to recognize and process substrates.
Within each active site exists a catalytic dyad consisting of a cysteine and
histidine to carry out the chemistry of catalysis. The caspase active sites have a strong
specificity for acidic residues at
the P1 cleavage site,31 typically
cleaving

after

an

aspartate

residue on the protein substrate.
However,

glutamate

and

phosphoserine can occasionally
be

recognized

by

some

caspases.32 The active site is also
relatively conserved among all
the apoptotic caspases, which
makes

targeting

caspase

a

specific

orthosterically

an

extremely difficult task. Turning
to allosteric regulation could
provide a means to manipulate
the

activity

of

individual

caspases in a selective fashion.

	
  

	
  

Figure 3: Caspase-7 Conformational Equilibrium between States
In the absence of any inhibitor caspase-7 primarily exists in the
zymogen state (top). When bound to a small molecule in the active
site the loops become organized and the equilibrium is shifted toward
a conformation with a stable loop bundle (middle). Reversal to now
favoring the zymogen state when bound to an allosteric inhibitor such
as FICA or DICA (bottom).
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The generation of a map of sensitive allosteric sites across the caspase family would
provide new avenues to exploit individual caspases therapeutically.
Regulation
After the initiation of apoptosis, cells destined to die do so quickly and
cooperatively. The cell death machinery is extremely efficient, primarily due to caspase
activity. The executioner caspases have been documented to have hundreds of
downstream substrates that are specifically cleaved, and in many cases the products have
new functions based on this permanent posttranslational modification. Due to its
staggering death potential, the apoptotic pathway and the caspases in particular require
strict regulation intracellularly. Dysregulation can have dramatic effects. The majority of
cancers have eluded the apoptotic response and therefore promote tumorigenesis or resist
chemotherapies. Conversely, excess cell death and unwanted caspase activity has
promoted the phenotypic impacts of neurodegenerative diseases such as Alzheimer’s and
Huntington’s disease.
Numerous studies targeting caspases have aimed to either enhance or suppress
apoptosis, although it is important to note that none have successfully completed clinical
trials yet. Several molecules have been developed to activate caspases, particularly
caspase-3, for use in cancer therapy. In particular, a high-throughput screen identified
procaspase activating compound 1 (PAC-1).33 It was determined that the mechanism of
procaspase-3 activation by PAC-1 was indirect, and was in fact due to PAC-1 chelating
labile zinc bound to procaspase-3. It is well established that zinc inhibits procaspase-334
and caspase-3,35 and PAC-1 was able to relieve that inhibition and sensitize procasapase3 to activation. Clinical trials began on this compound in early 2015.36 Other compounds
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currently under pursuit for apoptosis activation target other junctures in the apoptotic
cascade that aim to activate caspases indirectly. One compound of interest is ABT-26337
(navitoclax), currently in clinical trials.38 This compound binds to three anti-apoptotic
proteins Bcl-2, Bcl-xL, and Bcl-w,39 thus blocking their function and allowing proapoptotic Bcl proteins to permeabilize the mitochondrial outer membrane. This is a
method to activate the intrinsic apoptotic pathway. However, some particular cancers
overexpress other anti-apoptotic proteins, including Mcl-1, which can compensate for the
loss of function of its inhibited Bcl-2 cousins after treatment with ABT-263 (for review
see Williams et al.40).41–43 Therefore, combination therapies are also currently under
pursuit.44,45
Another exciting application for activating the apoptotic pathway is the delivery
of a caspase directly to any unwanted cell or population of cells. Protein therapeutics
offer a variety of advantages over small molecules, including a more nuanced function
with less off-target potential as well as catalytic opportunity that small molecules do not
afford. The idea of caspase delivery is beginning to be explored, but the vehicle for such
a delivery faces a variety of challenges including: reversibly encapsulating the caspase
cargo, a timed intracellular release, and maintaining the native/active form of the
protease. The development of nanogels to form a protein-polymer conjugates has been
shown to meet these strict requirements and has successfully delivered active caspases
which dose dependently eliminated a population of cancer cells.46 Expanding this
approach has enormous potential for both caspase delivery and, in theory, delivery for
any hydrophilic protein cargo.
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Contrasting this school of thought, there has also been an effort to block caspase
activation. Certain neurological diseases, such as Alzheimer’s disease, have been
associated with enhanced irregular apoptosis. In addition, caspase-3 and -6 have been
associated with disease onset, with studies suggesting they directly cleave amyloid
precursor protein and tau.6,47 As a result, many labs have been investigating the
controlled silencing of this caspase activity specifically related to these neurological
disorders. In addition, caspase inhibitors have been investigated for diseases or injuries
that result in detrimental apoptosis. One example includes chronic hepatitis virus C
infection that results in unwanted programmed cell death of hepatocytes.48 Others involve
battling excess apoptosis after ischemic injury, wherein a caspase inhibitor may provide
benefit after stroke, brain injury, or an organ transplant.49–51
Taken together, it is evident that there is a pressing need to study the variety of
mechanisms of caspase regulation, activation, and suppression. The dysregulation of
these enzymes has dramatic consequences and is associated with a plethora of diseases.
By learning how to manipulate caspase function we may be able to make key therapeutic
advances that take advantage of new, more specific mechanisms of regulation. In
addition, with a strong focus on allostery we can uncover functionally sensitive sites on
each individual caspase as a means of specific control.
Natural Regulation of the Apoptotic Caspases
The activity of apoptotic caspases is kept in check by layers of regulation that
specifically modulate their biological roles. This begins with the fact that they are
initially translated as inactive zymogens, but cellular control over proteolytic function
becomes infinitely more complicated as the labyrinth of biological pathways engage and

	
  

11	
  

intersect. It has become clear that natural regulation for the caspases has evolved at
allosteric sites due to the unique role and regulation of each caspase. The entire family of
enzymes catalyze the same reaction yet they display different biological roles and are
regulated quite differently. Nature has embedded a record for this within the primary and
tertiary structure of each caspase, with two notable recurring themes (1) posttranslational
modifications, particularly phosphorylation and (2) inhibition via zinc binding. Although
every apoptotic caspase is subject to these same two regulatory signals, each enzyme
responds differently with a nuanced regulatory mechanism. Regulation is not only
important to modulate apoptotic function, but also pivotal in non-apoptotic roles.
Caspases have been increasingly implicated in a variety of non-apoptotic pathways such
as immunity and cell behavior (for review see Kuranaga, 201252), for which
responsibilities must be monitored.
Understanding any allosteric regulation could be extremely useful from a
therapeutic perspective, and evidence for this continues to emerge. For example, a unique
exosite on the N-terminal region of caspase-7 has been shown to enhance its recognition
of particular apoptotic protein substrates.53 This enhancement is observed despite the fact
that the close homolog caspase-3 shares the same sequence specificity as caspase-7 and
displays a greater intrinsic activity compared to caspase-7.54 Further investigation into
this sensitive N-terminal region could create an opportunity to specifically control
caspase-7 activity. Implications for this grow in significance with continued discoveries
that the similar executioners caspase-7 and caspase-3 actually have functionally distinct
roles in apoptosis.55
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Posttranslational modifications also play an enormous role in caspase regulation.
Caspases can be proteolytically modified, nitrosylated,56 ubiquitinated,57,58 and
glutathionylated.59

But

the

most

prevalent

posttranslational

modification

is

phosphorylation (for review see Dagbay et al.60). Every apoptotic caspase can be
phosphorylated (Figure 4), and this typically leads to inactivation. What is so intriguing is
the fact that this same signal, the addition of a phosphate group, has such a
mechanistically differential impact on function for each independent caspase. In some
cases, multiple phosphorylation events on the same caspase result in extremely different
modes of regulation. In addition, phosphorylation can have differential effects on
substrate processing. For example, caspase-6 is phosphorylated at S257, leading to

	
  

Figure 4: Phosphorylation of the Apoptotic Caspases
The apoptotic caspases are extensively phosphorylated, often leading to a decrease in catalytic activity.
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inactivation.61 The phosphomimic S257D showed no self-activation potential and could
not turnover a tetrapeptide substrate, however, it could cleave its own prodomain. The
fact that caspase-6 recognizes different substrates uniquely suggests that exosites exist
and that control over certain substrates is possible. This has enormous potential due to the
influence caspase-6 has on neurodegenerative diseases; it would be incredibly powerful if
one could block cleavage of harmful targets such as amyloid precursor protein, but retain
caspase-6 activity for favorable biological substrates.
Phosphorylation by a variety of kinases has emerged as one of the most
significant and influential forms of posttranslational modification on the caspases.62–66
This phosphorylation typically leads to inactivation. However, caspases have been found
to cleave kinases and alter their function, and in a number of cases the substrate kinase is
the same enzyme that phosphorylates that particular caspase (for review see Kurokawa et
al.67). This creates a dynamic interplay between these two enzymes, with each attempting
to modulate the other with cell life and death hanging in the balance. Phosphorylation can
act directly on the apoptotic caspases themselves, but kinases can also phosphorylate
caspase substrates and alter the ability of the caspase to act on the newly modified
substrate. For example, phosphorylation of phospholipase C-γ1 on a tyrosine residue sits
adjacent to its caspase cleavage site. This addition of a phosphate blocks proteolytic
processing by caspase-3 and -7.68 Conversely, some phosphorylation sites promote
caspase cleavage. In PKCδ for example, a tyrosine phosphorylation event by Src kinase
stimulates cleavage by caspase-3.69 Meanwhile, caspase cleavage of kinases results in
altered forms of the respective kinases, which can have interesting downstream effects.
Caspase processing can (1) separate inhibitory domains and possibly activate the kinase

	
  

14	
  

for further downstream apoptotic applications70 (2) alter localization within the cell, such
as exposing a nuclear localization signal,71 and (3) transform substrate specificities of the
kinase itself.72 These events have dramatic implications for the morphological changes
that occur during cell death, and they certainly open possibilities for positive feedback
loops during the apoptotic cascade.
The interplay between caspases and the p21-activated kinase (PAK2) is an
important example, which is the basis for one chapter in this thesis. PAK2 is a
ubiquitously expressed kinase with implications in a variety of biological pathways
including cell motility, mitosis, survival, and apoptosis. In its full-length form PAK2
stimulates cell survival,73,74 however, when cleaved by caspases it adopts a pro-apoptotic
function. Caspase cleavage removes the autoinhibitory domain75 and allows the kinase
domain to be transported to the nucleus76 where it can phosphorylate a new set of protein
substrates that amplify the apoptotic response. Many forms of cancer have taken
advantage of this duality by hyperactivating the full-length PAK2 and hijacking its antiapoptotic activity.77 In fact, PAK2 has been found to phosphorylate and inactivate the
executioner caspase-7,64 which would alter the ability of the cell to undergo apoptosis. As
a result, PAK2 has been linked to resistance to chemotherapeutic agents. This example
highlights the battle between caspases and kinases. In cancer, many caspases are losing
this battle to phosphorylation by overexpressed kinases. Understanding the mechanism of
inhibition by phosphorylation could inform scientists about (1) ways in which cancer is
outlasting treatment and resisting chemotherapies and (2) continue to compile regions
across the caspase family that are sensitive and able to modulate enzyme activity.
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Regulation by metals is another powerful means to exert control over enzymatic
activity. Notably, zinc has been found to be a vital cell regulator with recent discoveries
putting more and more emphasis on zinc as a crucial biological regulator (for review see
Fukada et al.78). In fact, recent investigations confirmed nearly 3,000 proteins bind zinc,
which is approximately 10% of the human proteome.79 The influence of zinc extends to
numerous biological processes, which is further emphasized by the fact that zinc affects a
variety of proteins including transcription factors, enzymes, growth factors, receptors,
and adapters (to name a few). Recently, the concept of cellular zinc buffering80 has
surfaced as an important regulation technique for maintaining appropriate zinc
concentrations while managing this array of biological processes. The discovery of zinc
importers and exporters have uncovered relationships between zinc and numerous
cellular functions.81 In addition, the importance of metallothioneins as zinc storage
proteins adds a layer of complexity while analyzing the pool of available intracellular
zinc. Maintaining zinc homeostasis is therefore a critical regulatory endeavor. Even a
small disturbance in balancing the zinc concentration can have dramatic biological
effects, including the activation or suppression of apoptosis.82
The apoptotic caspases are inhibited by zinc,83–85 and in fact the entire apoptotic
pathway has susceptibility to zinc regulation (for review see Truong-Tran et al.86). Even
small fluctuations in zinc concentration can disrupt cellular homeostasis and stimulate
survival or force apoptosis. While caspase inhibition by zinc is well established,
determining the mechanism of inhibition is still in its infancy. It was assumed that zinc
bound to the caspase active site because of the cysteine-histidine dyad and the
nucleophilicty of the catalytic cysteine. However, recent studies of caspase-9 demonstrate

	
  

16	
  

that in addition to binding at the active site, the zinc also binds to an allosteric site.87 But
even more exciting, investigation of caspase-6 revealed that zinc did not bind at the
active site at all, but only to an allosteric region.88 This scrutiny at the molecular level
suggests that zinc binding could be nuanced to each caspase. This again highlights how
the same signal, the binding of zinc, has differential means of regulation in regards to the
caspases. In addition, understanding each zinc binding site and its mechanism of altered
protein function will only help build a map of allostery from which we can learn to
control caspase function.
The Caspase Potential
The power and potential of the apoptotic caspases is staggering, requiring a tight
regulatory network. Dysregulation has disastrous consequences for the cell, with many
disease implications.

The focus of this thesis centers on caspase regulation by

phosphorylation and zinc, as well as exploiting the cell death potential of caspase-3 via
targeted nanogel delivery. By understanding how these enzymes are regulated we can
build an understanding of their structure and function that can aid in design efforts for
therapeutic prospects. Specifically, chapter two will focus on how phosphorylation
regulates caspase-7 function, with an application to chemotherapeutic resistance in
cancers. Chapter three discusses a more global theme of zinc inhibition amongst the
apoptotic caspases. Chapter four will conclude with delivering the executioner caspase-3
to cancer cells utilizing a redox-responsive nanogel vehicle. Ultimately, this thesis aims
to expand the knowledge of caspase regulation with a strong focus on structural biology
in order to intensify caspase therapeutic potential.
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CHAPTER II
DUAL SITE PHOSPHORYLATION OF CASPASE-7 BY PAK2 BLOCKS
APOPTOTIC ACTIVITY BY TWO DISTINCT MECHANISMS
The majority of this chapter has been published: Eron, S.J., Raghupathi, K., Hardy, J.A.
Dual site phosphorylation of caspase-7 by PAK2 blocks apoptotic activity by two distinct
mechanisms. Structure. (2016).
Abstract
Caspases, the cysteine proteases that execute apoptosis, are tightly regulated via
phosphorylation by a series of kinases. Although all apoptotic caspases work in concert to
promote apoptosis, different kinases regulate individual caspases. Several sites of
caspase-7 phosphorylation have been reported, but without knowing the molecular
details, it has been impossible to exploit or control these complex interactions, which
normally prevent unwanted proliferation. During dysregulation, PAK2 kinase plays an
alternative anti-apoptotic role, phosphorylating caspase-7 and promoting unfettered cell
growth and chemotherapeutic resistance. PAK2 phosphorylates caspase-7 at two sites,
inhibiting activity using two different molecular mechanisms, before and during
apoptosis. Phosphorylation of caspase-7 S30 allosterically obstructs its interaction with
caspase-9, preventing intersubunit linker processing, slowing or preventing caspase-7
activation. S239 phosphorylation renders active caspase-7 incapable of binding substrate,
blocking later events in apoptosis. Each of these mechanisms is novel, representing new
opportunities for synergistic control of caspases and their counterpart kinases.
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Introduction
Tens of billions of cells die each day by the controlled cell death pathways of
apoptosis. Apoptotic programmed cell death is fundamental for all multicellular
eukaryotes and is critical for organismal development, differentiation, eliminating
damaged cells, and maintaining homeostasis. Dysregulation of apoptosis has been linked
to diseases including cancer,1–4 autoimmune disorders,5 and neurodegeneration.6,7 In
particular, transformation to a cancerous phenotype occurs when cells establish barriers
to apoptosis and develop resistance to signals designed to eliminate malignant
abnormalities via apoptosis.
The apoptotic cascade is ultimately dependent on the activation of the caspase
family of cysteine proteases. These enzymes dismantle the cell by cleaving a diverse set
of protein substrates8 with a specificity for acidic residues, typically aspartate, at P19
although glutamate10 and phosphoserine can also be recognize.11 Apoptotic caspases are
divided into two classes: the initiator caspases (caspase-8, -9, and -10) and their
substrates, the executioner caspases (caspase-3, -6, and -7), which cleave specific cellular
targets to invoke cell death. Caspases are functional as homodimers, with each monomer
made up of an N-terminal prodomain, one large, and one small subunit (Figure 1A). As a
means of inherent regulation, executioner caspases are translated as inactive procaspase
zymogens, with distinct cleavage events required for zymogen activation. Initiator
caspases propagate the apoptotic signal by cleaving downstream executioner caspases at
their intersubunit linker. Prior to cleavage, this linker rests across the dimer interface.12
Cleavage of the intersubunit linker generates loops 2 and 2’ (L2 and L2’), which, in the
active, substrate-bound conformation, lock together the substrate-binding groove on the

	
  

25	
  

opposite monomer (Figure 1B).13 This results in a dramatic conformational change in the
dynamic active-site loop bundle from a zymogen state to an active state. Cleaved
executioners can also experience a reversal to the zymogen-like state by small
molecules,14 which forces a loop rearrangement that traps L2’ over the dimer interface
and results in the expulsion of loop 3 from the active site pocket. Following activation in
the cell, each executioner caspase cleaves over a hundred substrates15,16 to propagate the
well-ordered termination of the dying cell.
Due to their cell death inducing potential, caspase activation and downstream
activity is tightly regulated on multiple levels, with phosphorylation as one of the primary
means to manage apoptotic caspase activity17–23. In fact, caspases and kinases co-regulate
each other, resulting in an intricate interplay of dramatic post-translational modifications
that ultimately impact cell death and survival.24–26 Together apoptotic caspases are
recognized to initiate and execute cell death, but their individual roles continue to come
to light. Even highly related caspases play non-overlapping biological roles and are
independently regulated by inhibitor proteins, zinc, and posttranslational modifications.27
Interactions with kinases are a major contribution to the unique regulation of individual
caspases. The delicate nature of this balance between caspases and kinases has been
exploited by a number of cancers,28,29 which have developed resistance to apoptosis, even
after stimulation by chemotherapeutic agents.17,30
Many cancers have capitalized on the vast signaling capacity of various kinases to
manipulate cell processes.31 One particular example is the dysregulation of p21 activated
kinase 2 (PAK2, γ-PAK).32,33 PAK2, the only ubiquitously expressed PAK, plays a role
in a variety of biological pathways including cell motility, mitosis, survival, and
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apoptosis. Interestingly, PAK2 plays a dual role in the context of apoptosis: active fulllength PAK2 stimulates cell survival30,34 while cleavage of the autoinhibitory domain
results in propagation of the pro-apoptotic response.35,36 This duality is dictated by the
relationship of PAK2 with caspase cleavage37 PAK2 is cleaved by the executioner
caspase-3 at D212, which separates the PAK2 kinase domain and autoinhibitory
domains.38 The phosphorylated kinase domain, PAK2p34, is then translocated to the
nucleus39 where it phosphorylates a new set of substrates, which in turn promote
programmed cell death. A number of breast cancer cell lines have shown hyperactivity of
PAK2,32 which tips the scale to favor full-length PAK2 and results in reduced levels of
apoptosis. Full-length, active PAK2 stimulates cell survival through multiple
mechanisms, including caspase phosphorylation.17 This overactivity has further been
linked to resistance to chemotherapeutic agents.
The complexity of the caspase-kinase crosstalk has been intensified with the
discovery that a pathway involving PAK2 is able to phosphorylate the executioner
caspase-7 at three distinct residues: S30, T173, and S239.17 Although PAK2 and caspase7 co-localize and co-immunoprecipitate, whether this phosphorylation of caspase-7 is
mediated by PAK2 directly or by another kinase in that pathway was not fully elucidated
by prior work. Phosphorylation of all three residues S30, T173, and S239 is reported to
silence caspase-7 enzymatic activity, but the contribution from each individual site has
not been studied nor has the mechanism of inhibition been determined. As a result of a
total loss in caspase-7 activity, phosphorylation by PAK2 leads to a reduction in
apoptosis. In addition, knockdowns of PAK2 in various breast cancer cell lines lead to
increased apoptosis levels when stimulated with chemotherapeutics including
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staurosporine or doxorubicin17 underscoring that PAK2 is critical in curtailing caspase-7
activity.
Here, we elucidate the molecular mechanism by which PAK2 phosphorylation
inhibits caspase-7 function. Understanding the regulation of this executioner caspase has
implications in cancer resistance and apoptotic activation. Our results show that PAK2
inhibits caspase-7 by two divergent mechanisms prior to and following caspase
activation: initial phosphorylation allosterically slows activation by upstream initiator
caspases by impeding cleavage at the intersubunit linker and a second phosphorylation
site directly blocks substrate binding. Identifying and resolving the molecular mechanism
behind both regulatory phosphorylation events provides valuable insight into
therapeutically relevant means to control programmed cell death.
Results
The S239E Phosphomimetic Inactivates Caspase-7
Phosphorylation of caspase-7 by a PAK2-dependent pathway inactivates caspase7 and this appears to attenuate apoptosis in several breast cancers after stimulation by
chemotherapeutic agents.17 Caspase-7 phosphorylation by PAK2 occurs at three sites:
S30, T173, and S239 (Figure 5A), but the impact of phosphorylation at these individual
sites on caspase-7 function or their mechanisms of regulating caspase-7 have not been
investigated. Prior to activation, caspase-7 exists as a zymogen. Proteolytic cleavage by
upstream initiator caspases at the prodomain (D23) and the intersubunit linker
(D198/D206) generates the active form of caspase-7 comprising large and small subunits
of caspase-7 (Figure 5B). In the small subunit, S239 sits below the substrate-binding
groove on loop 3, which is part of the active-site loop bundle. T173 is located at the
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Figure 5:	
  Sites of caspase-7 phosphorylation by PAK2 and kinetics of phosphomimetic variants
(A) Domain structure of caspase-7 highlighting the three reported sites of phosphorylation by PAK2
as ℗. Caspase-7 is cleaved and thereby activated by upstream initiator caspases (cleavage sites
indicated by arrows). The full-length procaspase-7 dimer is processed to remove the prodomain, and
at the intersubunit linker to form the large (light blue) and small (dark blue) subunits making active,
cleaved caspase-7.
(B) Three phosphorylation sites (orange sticks) are present in the caspase-7 dimer consisting of two
large (light blue) and small (dark blue) subunits. The N-terminus of active caspase-7, which is
dynamic and unstructured, has not been resolved crystallographically, so a model of the S30 region
has been added (gray). The prodomain (residues 1- 23) is not shown. S239 sits below the active site
in loop 3 and T173 rests at the bottom of the 160s helix. The active site of caspase-7 is composed of
four loops from one half of the dimer (L1, L2, L3, L4) and one loop from the opposite half of the
dimer (L2’).
(C) Kinetic data of phosphomimetic variants. Substitution at S239, but at no other reported
phosphorylation site, has a dramatic effect on caspase-7 activity.	
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bottom of the 160s helix, whereas S30, in the highly mobile N-terminal region, has not
been resolved by any caspase-7 crystal structures.
To explore the impacts of phosphorylation, each of the three reported
phosphorylation sites were replaced by glutamate to generate phosphomimetic variants,
mirroring the negative charge and steric bulk of phospho-serine or -threonine. To ensure
that activity was monitored in a cleaved (active) form, each phosphomimetic was
expressed from a constitutively two-chain construct in which the large and small subunits
are independently expressed.40 Neither S30E nor T173E had a significant effect on
caspase-7 kinetics (Figure 5C). However, S239E had a dramatic effect on caspase-7
activity, dropping the catalytic efficiency by nearly three orders of magnitude as
compared to the wild-type enzyme.
The introduction of negative charges in combination with steric bulk are two
attributes that enable phosphorylation to have such significant effects on protein function.
We next aimed to determine whether size, charge, or both, were responsible for the
S239E loss of activity. Substituting S239 with Gln, retains the size of the Glu but
removes the contribution of a negative charge. Conversely, the S239D variant retains the
negative charge but removes the bulk. Both S239Q and S239D resulted in a significant
drop in catalytic efficiency, but neither as dramatic as S239E, suggesting that both size
and charge play a large role in inhibiting caspase-7 activity at S239. Notably, all three
mutations (S239E, S239D, and S239Q) had a significant effect on KM, highly suggesting
that phosphorylation at S239 interferes directly in a steric manner with substrate binding.
In addition, there was an effect on kcat for the S239E mutation, suggesting a disruption to
the catalytic machinery. However, this kcat effect was much less pronounced with the Gln
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and Asp mutations, further suggesting that both size and charge together are responsible
for inhibition.
Caspase-7 is Phosphorylated by PAK2 at S239 on the Small Subunit
To investigate PAK2 phosphorylation of the caspase-7 small subunit, which
contains S239, we performed an in vitro phosphorylation assay.

PAK2 T402E, a

constitutively active, auto-activating variant was pre-activated with ATP then incubated
with [γ-32P] ATP and wild-type caspase-7 or the S239A variant, which cannot be
phosphorylated at residue 239 (Figure 6A). Based on the low activity of S239E, we
anticipated phosphorylation on the small subunit. We observed active caspase-7
completely cleaved PAK2 at D212 (Figure 7) to generate the kinase and autoinhibitory
domains. In addition, in both the wild-type caspase-7 and S239A reactions, a
phosphorylated band similar in molecular weight to the small subunit of caspase-7
appeared. To determine whether this 14 kDa band was a cleavage product of PAK2 or the
small subunit of caspase-7, we repeated the in vitro phosphorylation assay on
catalytically inactive caspase-7 (C186A, Figure 6B), which was expressed using the
constitutively two chain construct. PAK2 cannot be cleaved by inactive caspase-7
C186A. The lack of the 14 kDa band with inactive caspase-7 confirms that the band is
indeed a cleavage product of PAK2. Contrary to our expectations, we did not observe
small subunit phosphorylation under these conditions.
These results demonstrate the difficulty in dissecting the competitive interplay
between caspase-7 and PAK2. If active caspase-7 predominates, it cleaves PAK2 before
PAK2 can phosphorylate the caspase-7 small subunit, which inactivates caspase-7. We
sought a reagent that could block caspase-7 activity thereby preventing cleavage of
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Figure 6: PAK2 phosphorylates the caspase-7 small subunit at S239
(A) PAK2 phosphorylates caspase-7 at multiple sites as assessed by autoradiography by [γ-32P] ATP and
compared to coomassie stained gels. The caspase-7 large subunit is phosphorylated rapidly, with
phosphorylation observed even before the zero time point could be processed. PAK2 autophosphorylation
indicates that PAK2 is active. After three hours, PAK2 is cleaved by caspase-7 resulting in multiple bands
of cleaved PAK2.
(B) PAK2 phosphorylates catalytically inactive caspase-7 (C186A) at the large subunit. Because caspase7 is not active, no cleaved PAK2 is observed.
(C) After incubation with a cysteinyl-2-pyridyl disulfide protecting group (PG), which blocks the catalytic
cysteine, caspase-7 can be phosphorylated by PAK2 on both the large and small subunits. Substituting
S239 (small subunit) with alanine results in the complete loss of caspase-7 phosphorylation on the small
subunit, confirming PAK2 phosphorylates the caspase-7 small subunit at S239.
(D) After incubation with the PG both the wild-type caspase-7 and C290S were phosphorylated by PAK2
on the large subunit. The C290S variant prevents PG binding to this C290, which has known allosteric
implications. Serine substitution at C290 results in a dramatic loss in small subunit phosphorylation at
S239 by PAK2. The band intensity for small subunit phosphorylation is quantified in the bar graph at
right, which shows the mean ± error represented as SD from three independent experiments.
(E) The dynamic loop bundle at the active site can adopt different conformations. Alignment of three
crystal structures reveals that unliganded caspase-7 (blue, PDB ID 3IBF) is distinct from the full-length
procaspase-7 (green, PDB ID 1GQF) and from caspase-7 bound to the allosteric inhibitor DICA (tan,
PDB ID 1SHJ). In all three conformations C290 sits on β-strand 6, however, the base of loop 3 is in a
dramatically different conformation. The unliganded structure loses β-character on β5 while both the fulllength procaspase-7 zymogen and the DICA-bound structures extend β5 and expel loop 3 from this
allosteric pocket at the dimer interface. Binding PG at C290 provides considerable steric bulk that is
expected to force loop 3 of the unliganded caspase-7 (blue loop 3) to adopt a loop-accessible
conformation (tan loop 3) as seen when DICA binds at this cysteine, C290.
In all panels of this figure, all caspase-7 variants were expressed from the constitutively two-chain
construct, which produces the large (1-198) and small (199-303) subunits of caspase-7 as two independent
polypeptides.
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PAK2. Due to the location of
S239, it was important that the
reagent not fill the substratebinding groove and thereby
limit accessibility of S239. To
meet

these

criteria

we

developed a cysteine protecting
group

(PG,

L-cysteinyl-2-

pyridyl disulfide, Figure 8A).
PG (Figure 8B) modifies and
inactivates

the

catalytic

Figure 7: Caspase-7 cleaves PAK2 at D212
Catalytic amounts of casp-7 CT S30A/T173A were incubated
with PAK2 T402E or PAK2 D212N/T402E. Each PAK2
variant was first allowed to autoactivate with [γ-32P] ATP for
ten minutes at 30°C. Concentrations of substrate (PAK2
variants) to caspase were varied from a 1:1 to 1:100 ratio.
PAK2 cleavage into two fragments (p34 and p27) by casp-7
was assessed after 1 hour by autoradiography. The casp-7 lane
is a positive control of casp-7 CTC wild-type with PAK2
T402E in a 1:1 ratio.

	
  

	
  
cysteine via reversible thiol chemistry,41 but because of its small size, does not fill the full
substrate-binding groove. In the presence of PG, PAK2 clearly phosphorylated the small
subunit of wild-type caspase-7 at S239, since no phosphorylation of S239A was observed
(Figure 6C). In addition, the PAK2 remains uncleaved and the large subunit of caspase-7
is phosphorylated at the same levels as with unprotected caspase-7 demonstrating that
S239 can indeed be phosphorylated by PAK2.
In addition to silencing the caspase-7 activity, the PG plays an orthogonal role at a
second site, altering the equilibrium ensemble of the active-site loops by binding to a
known allosterically acting cysteine (C290). Upon activation by cleavage at the
intersubunit linker, caspase-7 experiences a rearrangement of its loops, which sample
multiple conformations. For example, caspase-7 bound to the small molecule DICA (at
C290) forces loop 3 to adopt a more accessible conformation, with an increased exposure
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to solvent. We realized that binding of the
PG at C290 should increase the accessibility
of this region by forcing loop 3 into a more
accessible

conformation.

To

test

this

hypothesis, we mutated C290 to Ser,
blocking the ability of the PG to bind at the
allosteric Cys. We observed a decrease in
	
  

Figure 8: Caspase-7 WT can recover full
activity after silencing with PG
(A) Structure of the L-cysteinyl-2-pyridyl
disulfide protecting group (PG).
(B) Incubating wild-type casp-7 with 50-fold
excess of PG results in a complete loss of activity.
This inhibition is fully reversible upon addition of
a reducing agent (10mM DTT used here).
Unliganded casp-7 (no PG) or liganded casp-7
(plus PG) were treated with 10mM DTT. Casp-7
activity was assessed by monitoring cleavage of
the fluorogenic substrate DEVD-AMC. Liganded
casp-7 was able to regain full activity with
activity (RFU/s) statistically indistinguishable
(Student’s t test resulted in a P value of >0.05)
from untreated casp-7 under the same reducing
conditions. Data is represented as mean ± S.D.	
  

phosphorylation on the small subunit of
caspase-7 C290S compared to wild-type
(Figure 6D). We did not observe a similar
decrease when C186 was mutated to Ala
(Figure 9) suggesting that PG binding to
C290, but not C186, was responsible for
loop movement and availability of S239 to
phosphorylation by PAK2.

Thus, it appears that PG binding to C290 acts analogously to binding of other
small molecules at C290, resulting in a structural change to loop 3 (Figure 6E). In
unliganded caspase-7 (Figure 6E, blue) loop 3 is structured and protrudes inwards toward
C290. When a small molecule, like DICA or PG binds at C290, loop 3 is forced upward
in a loop accessible conformation that may resemble the zymogen full-length procaspase7 (Figure 6E, green) or caspase-7 bound to DICA (Figure 6E, tan). This conformational
shift increases the solvent accessibility of loop 3, including S239. The PG thus served
two purposes (1) to silence caspase-7 activity allowing PAK2 to remain uncleaved so that
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Figure 9: Caspase-7 wild-type
and
C186A
are
both
phosphorylated on the small
subunit in the presence of
protecting group.
Both casp-7 wild-type and
catalytic knockout (C186A)
were reacted with PG and then
phosphorylated
with
preactivated PAK2.
Phosphorylation was monitored
by autoradiography. The small
subunit is phosphorylated in a
similar fashion indicating PG
binding at C186 is not
responsible
for
PAK2
phosphorylation at S239.	
  

	
  
phosphorylation could proceed and (2) to alter the equilibrium of the caspase-7 active-site
loop bundle to favor the solvent accessible conformation of loop 3, which includes the
phosphorylation site S239. It is clear that phosphorylation of S239 occurs exclusively
when loop 3 is in an exposed, loop-accessible conformation. This suggests either that
S239 is only available for phosphorylation under certain conditions, or that PAK2 can
distinguish these two distinct conformations of caspase-7.
S239E Phosphomimetic Structure Suggests the Mechanism of Inhibition by
Phosphorylation
To determine the molecular mechanism of inhibition by phosphorylation at S239
we solved the crystal structure of the unliganded (apo) cleaved form of the caspase-7
S239E phosphomimetic at 2.2 Å resolution (Table 1). This caspase-7 phosphomimetic
shares the same overall fold with all previously crystallized caspase-7 structures,
including those unbound and bound to substrate. The heterotetrameric core consists of 12
β strands flanked by 10 α helices, and two symmetrical active sites made up a dynamic
active-site loop bundle. Loop 3 sits just below the active site and contains R233, a critical
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PDB ID
Data Collection
Beamline
Resolution Range (Å)
Unique Reflections
Redundancy
Completeness (%)
I/σ (I)
Rsym
Space Group
a = b (Å)
c (Å)
α = β (°)
γ (°)
Refinement
Rwork/Rfree (%)
Average B Factor (Å2)
Residue Range Built
RMSD
Bond Lengths (Å)
Bond Angles (°)
Ramachandran Plot (%)
Preferred
Allowed
Outliers

	
  

5K20
NSLS X6A
76.98-2.20
(2.24-2.20)
43,569
10.9
99.53
37.4 (1.8)
0.076
P3221
88.76
185.14
90
120
19.1/22.8
66.3
58-198, 211-303
0.017
1.7659
95.4
4.6
0.0

Values in parentheses are for the highest resolution bin.
RMSD, root-mean-square deviation
Table 1: Crystallographic data collection and statistics for the caspase-7 S239E variant

residue for binding substrate (Figure 10A). In both the unliganded mature structure
(3IBF) and the substrate-bound structure (1F1J), this arginine is positioned identically
(Figure 10B). R233 acts as an anchor poised to make four pivotal hydrogen bonds with
the preferred DEVD tetrapeptide substrate. R233 interacts with both the Glu in the P3
position of the peptide substrate as well as the essential Asp side chain in the P1 position.
Meanwhile, two additional hydrogen bonds are made with the carbonyl and nitrogen
stemming from the R233 backbone. This behavior of R233 is in contrast to its behavior in
the S239E structure.
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The

structure

of

unliganded

caspase-7 S239E suggests a two-factor
mechanism by which phosphorylation of
S239

inhibits

caspase-7.

First,

the

position of loop 3 has been perturbed by
the phosphomimetic (Figure 10C). The
bulk from the introduced Glu side-chain
at position 239, which mimics the
phosphoserine in length and negative
charge, forces the entire loop 3 to shift
outwards toward a solvent channel. This
reorients R233 away from the active site
pocket so it can no longer make critical
bonds with the substrate (Figure 10C). In
addition, the phosphomimetic introduces
a negative charge in the precise region
where an aspartate would bind in the S1
pocket. This inhibitory mechanism is
consistent with the kinetic data (Figure
5C), which suggested both size (S239Q)
and

charge

(S239D)

worked

in

combination to inhibit caspase-7 activity
after

	
  

modification

at

S239.

Thus,

	
  

Figure 10: Phosphorylation at caspase-7 S239
sterically blocks substrate binding
(A) Global alignment of the unliganded caspase-7
S239E phosphomimetic crystal structure (light blue)
and the unliganded wild-type caspase-7 (dark gray,
PDB ID 3IBF). Loop 3, which contains the S239E
mutation, undergoes a clear shift in conformation.
(B) R233 interactions are essential for substrate
binding and specificity. In both active-site liganded
(gray, PDB ID 1F1J) and unliganded (dark gray,
PDB ID 3IBF) caspase-7 structures, R233 is
positioned to form two essential side-chain
hydrogen bonds (black dots) that are critical for
binding substrate (DEVD, orange sticks), anchoring
it in place for catalysis.
(C) The unliganded S239E phosphomimetic crystal
structure (blue) shows a dramatic shift in loop 3,
with the introduced glutamate forcing R233 out of
the position compatible for binding substrate. In
addition, the introduction of a negative charge in the
P1 pocket would electrostatically repel an aspartate
residue from the substrate.	
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phosphorylation at S239 is effective at silencing activity of an already active caspase-7
once apoptosis has been initiated.
Caspase-7 Phosphorylation Occurs on the Large Subunit Primarily at S30
Phosphorylation of caspase-7 by
PAK2 was also observed on the large
subunit (Figure 6). This phosphorylation
event was so fast that it occurred before the
zero timepoint sample could be processed.
In

addition,

the

large

subunit

was

phosphorylated regardless of the cleavage
state of PAK2 (Figure 6A-C). Despite the
overwhelmingly fast phosphorylation by
PAK2 in the large subunit, no effect on the
catalytic rate of cleaved caspase-7 was
observed (Figure 11).
To determine if this phosphorylation
occurred at the reported sites on the large
subunit, S30 and T173 were individually

	
  

Figure 11: Caspase-7 wild-type activity is not
affected by PAK2 phosphorylation.
Casp-7 wild-type CTC was allowed to incubate
in PAK2 activity buffer in the presence and
absence of autoactivated PAK2 and 1mM ATP.
After a 60 minute incubation at 30°C the
activity of the control caspase and the
phosphorylated caspase was assessed by
monitoring cleavage of the casp-7 fluorogenic
peptide substrate DEVD-AMC. Assays were
carried out in casp-7 activity assay buffer at
100 nM enzyme concentration. A student’s t
test resulted in a P value of >0.05 indicating the
control and the phosphorylated casp-7 are
statistically identical. Data is represented as
mean ± S.D.

	
  
replaced by alanine, a non-phosphorylatable residue. These substitutions were made in
the background of caspase-7 catalytic site inactivation (C186A), which was used to
prevent PAK2 from being cleaved. PAK2 did not phosphorylate S30A/C186A but did
phosphorylate C186A and T173A/C186A. This was true for both full-length and cleaved
caspase-7, indicating that S30 is the primary phosphorylation site on the caspase-7 large
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subunit (Figure 12A). The ratios of the band intensities for the 32P:commassie stained
bands were similar for FL C186A (2.14) and cleaved C186A (2.17) as well as for FL
T173A/C186A (2.17) and cleaved T173A/C186A (2.11) suggesting that phosphorylation
at S30A occurs similarly on the zymogen and the cleaved forms of caspase-7.
Phosphorylation of Caspase-7 Diminishes Processing by Initiator Caspases
Given that S239 phosphorylation directly impacts catalytic activity, it was
surprising that the predominant site of phosphorylation, S30, had no direct effect on
caspase-7 catalytic function. This suggested that S30 phosphorylation might play an
orthogonal functional role. Executioner caspases including caspase-7 are dependent on
activation by upstream initiator caspases including caspase-8 and -9, which cleave the
intersubunit linker of full-length procaspase-7 at D198 or D206, generating active
caspase-7. To determine if phosphorylation of the full-length caspase-7 impacted
processing by initiator caspases, full-length caspase-7 C186A was phosphorylated by
autoactivated PAK2 in the presence of [γ-32P] ATP or not phosphorylated in the no ATP
condition. Phosphorylation was confirmed by autoradiography. Phosphorylated or
unphosphorylated caspase-7 was then subject to cleavage by either caspase-9 or caspase8. Unphosphorylated caspase-7 was cleaved by caspase-9 completely at the intersubunit
linker after 3 hrs (Figure 12B). In contrast, phosphorylated caspase-7 was cleaved more
slowly by caspase-9. Remaining full-length caspase-7 was quantified at each time point.
We observed a significant decrease in the rate of cleavage when caspase-7 was
phosphorylated (Figure 12C). Phosphorylated caspase-7 was also cleaved more slowly by
caspase-8 (Figure 12D-E). For both initiator caspases, 30% less full-length caspase-7 was
cleaved in the timecourse of the experiment. Notably, PAK2 has no effect on the function
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Figure 12: Phosphorylation on caspase-7 slows processing by upstream initiator caspases
(A) PAK2 phosphorylates the large subunit in both full-length (FL) and in the cleaved state of
caspase-7. The two reported phosphorylation sites in the large subunit were individually mutated to
alanine. Lack of [γ-32P] ATP labeling of S30A suggests that phosphorylation primarily occurs at
S30 on the caspase-7 large subunit and not at T173. All caspase-7 constructs contain the C186A
mutation of the catalytic cysteine to prevent self-cleavage. Cleavage was monitored by coomassie
stained SDS-PAGE and 32P autoradiography was used to confirm phosphorylation.
(B,D) Cleavage of full-length (FL) caspase-7 by upstream initiators caspase-9 (B) or caspase-8 (D)
at the intersubunit linker. The addition of ATP activates PAK2 and stimulates caspase-7
phosphorylation, which slows the ability of caspase-9 or caspase-8 to cleave FL caspase-7 at the
intersubunit linker.
(C, E) Quantification of FL caspase-7 remaining in (B,D) upon cleavage by caspase-9 (C) or
caspase-8 (E). Values and error bars represent the mean ± SEM for measurements from three
independent experiments.
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of either caspase-8 or caspase-9 under these assay conditions (Figure 13A-B) and does
not phosphorylate caspase-9 at all (Figure 13C), indicating that the decrease in processing
is the result of phosphorylation of caspase-7.

Figure 13: Caspase-8 and caspase-9 activity is unaffected by PAK2
(A) Casp-8 and (B) casp-9 activity was assayed over a ten minute time course monitoring cleavage of
the fluorogenic substrate LEHD-AFC. Enzymes were incubated with autoactivated PAK2 T402E
(black bars, +ATP) or PAK2 T402E alone (white bars, No ATP) and activity was assessed at three time
points. This experiment was performed in identical fashion to the caspase cleavage assays of full-length
casp-7 (Figure 4B and 4D). Data is represented as mean ± S.D.
(C) Autoactivated PAK2 was allowed to incubate with casp-9 for up to 18 hours with [γ-32P] ATP. No
bands for casp-9 appeared via autoradiography, suggesting PAK2 is unable to phosphorylate casp-9
under these assay conditions. In addition, full length casp-7 was incubated with casp-9 and
autoactivated PAK2 for 18 hours as a positive control to demonstrate (i) PAK2 is active because it
phosphorylates the large subunit of casp-7 and (ii) that casp-9 is active because it is able to cleave full
length casp-7.	
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Phosphorylation at S30 Slows Processing of Caspase-7 at the Intersubunit Linker
By substituting alanine, a non-phosphorylatable residue, at each of the reported
PAK2 sites in the caspase-7 large subunit (T173 and S30), we interrogated the
contribution of phosphorylation at these sites to cleavage by caspase-9 (Figure 14A).
Caspase-7 T173A/C186A was incubated with PAK2 in the presence or absence of [γ-32P]
ATP and subsequently treated with active caspase-9 (Figure 14A-B). The cleavage
pattern was nearly identical to caspase-7 C186A (Figure 12B), suggesting
phosphorylation at T173 plays no role in slowing cleavage by caspase-9 at the
intersubunit linker. In contrast, the cleavage pattern for full-length caspase-7

	
  

Figure 14: Phosphorylation at S30 on caspase-7 slows processing by caspase-9
(A) Caspase-7 phosphorylation sites T173 and S30 were replaced by alanine in the background of the
C186A mutation of the catalytic cysteine to prevent self-cleavage. Caspase-7 T173A and S30A were
treated with PAK2 with or without [γ-32P] ATP, then subjected to cleavage by caspase-9. Caspase-7
T173A/C186A was cleaved faster in the absence of ATP, with rates resembling caspase-7 FL C186A.
Caspase-7 S30A/C186A was cleaved at a similar rate in the presence or absence of ATP.
(B, C) Quantification of cleavage in (A) of caspase-7 variants by caspase-9: T173A/C186A (B) or
S30A/C186A (C). The nearly identical rate of cleavage of S30A with or with out ATP suggests that S30
phosphorylation is responsible for slowing cleavage of caspase-7 FL by caspase-9. Values and error
bars represent the mean ± SEM of triplicates and are representative of three independent experiments.
In all panels of this figure, all caspase-7 variants were expressed from a full-length construct which
produces residues 1-303 as a single polypeptide chain.	
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S30A/C186A was identical in the presence or absence of phosphorylation (Figure
14A,C). This data strongly suggests that phosphorylation by PAK2 at S30 has
considerable impact on the ability of caspase-9 to cleave caspase-7 at the intersubunit
linker (residues 198-206).
Phosphorylation at S30 Interrupts the Binding Interaction between Caspase-7 and
Caspase-9
S30 and the cleavage sites in the
intersubunit linker (D198/D206) are distal
in sequence, and due to the disorder in all
structures of the caspase-7 prodomain, it is
difficult to draw specific conclusions
about the spatial proximity of these two
regions. Nevertheless, phosphorylation at
caspase-7 S30 clearly impacts the ability
of caspase-9 to cleave caspase-7 at the
intersubunit

linker.

Fluorescence

polarization of FITC-labeled caspase-7 in
the presence of a caspase-9, which forms
constitutive dimer,42 showed a strong (1.8
µM) interaction (Figure 15A, 16A-C). In
these experiments catalytically inactive
caspase-7 and -9 were used to prevent
cleavage if either caspase during the

	
  

	
  

Figure 15: The interaction between caspase-7
and caspase-9 is disrupted by phosphorylation
at S30
(A) Fluorescently labeled uncleaved caspase-7 FL
C186A interacts by fluorescence polarization with
caspase-9 constitutive dimer (cDimer) C287A.
(B) Phosphorylating caspase-7 FL C186A prior to
a caspase-9 titration dramatically impacts the KD.
(C) Replacing S30 with a non-phosphorylatable
alanine abrogates phosphorylation by PAK2,
enabling a caspase-7: caspase-9 interaction.	
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reaction. When FITC-caspase-7 C186A was incubated with autoactivated PAK2 to allow
phosphorylation prior to the caspase-9 titration, the KD weakened substantially, to greater
than 27 µM (Figure 15B). This suggests that phosphorylation at S30 blocks the caspase7:caspase-9 interaction. Consistent with that interpretation, repeating the experiment with
caspase-7 S30A/C186A, which is non-phosphorylatable at position 30, shows a similarly
strong interaction (KD = 1.7 µM, Figure 15C) even in the presence of active PAK2. These
data confirm the observation (Figure 12C and 14C) that phosphorylation at S30 has a
profound effect on how the initiator caspase-9 interacts with the executioner caspase-7 at
the initiation stage of apoptosis and may suggest that the N-terminal region of caspase-7
is critical for direct binding to caspase-9.

Figure 16: Fluorescence polarization controls
(A) Casp-7 C186A was fluorescently labeled with FITC and fluorescence anisotropy was measured
over a casp-9 titration. Casp-7 C186A alone (filled circles), casp-7 C186A incubated in the
presence of PAK2 and the absence of ATP (empty squares), and casp-7 C186A with ATP
(triangles) all showed overlapping curves indicating addition of these molecules has no effect on
casp-7 interacting with casp-9.
(B) Free lysine labeled with FITC was incubated with casp-9 at various concentrations and the
fluorescence anisotropy was measured. A constant tumbling was observed even at high casp-9
concentrations, suggesting FITC itself does not interact with casp-9.
(C) Casp-7 C186A was labeled with FITC as before and fluorescence anisotropy was measured over a
casp-3 titration. Only a small change in anisotropy was observed, demonstrating that fluorescently
labeled casp-7 C186A does not behave in a similar manner with every caspase and has a unique
curve with casp-9.

	
  

	
  
Non-phosphorylatable Caspase-7 is Cleaved Faster by Caspase-9 Intracellularly
It is clear that in vitro, phosphorylation at S30 leads to slower cleavage of
caspase-7 by caspase-9 at the intersubunit linker. To observe the impact of S30

	
  

44	
  

phosphorylation in a biological context we used MCF7 cells, a widely used breast cancer
model. MCF7 cells are intrinsically deficient for caspase-3, putting the burden of
executioner apoptotic activity on caspase-7. In addition, MCF7 cells overexpress PAK2,
which phosphorylates caspase-7 intracellularly. MCF7 cells were transiently transfected
with either phosphorylatable or non-phosphorylatable (S30A) caspase-7. Both transfected
variants carried the catalytically inactivating C186S substitution to prevent caspase-7
self-processing.

As

predicted,

following

transfection

of

MCF7

cells,

non-

phosphorylatable caspase-7 (S30A/C186S) was processed by added caspase-9
significantly faster than was phosphorylatable caspase-7 (C186S) (Figure 17 A-B).
After observing the inhibitory effects of phosphorylation of caspase-7 at S30 in the
MCF7 cellular milieu, we hypothesized that we would observe a similar effect in growing
cells. MCF7 cells transiently transfected with caspase-7 C186S or S30A/C186S were
treated with both ABT-263, a Bcl-2 inhibitor, and A1210477, an Mcl2 antagonist, which
together stimulate the intrinsic apoptotic pathway and activate caspase-9

43

. Monitoring

the appearance of the cleaved and activated caspase-7 (Figure 17 C-D) revealed that
caspase-7 S30A/C186S was processed from the full-length form to the cleaved form
faster than the C186S variant. This suggests that, as was the case in vitro, when S30 is
available for phosphorylation by PAK2, this site becomes phosphorylated, decreasing
binding, recognition, and cleavage by caspase-9. Thus it becomes clear that PAK2
regulates caspase-7 activity by inhibiting active (cleaved) caspase-7 through
phosphorylation at S239, as well as preventing or dramatically slowing caspase-7
activation by caspase-9 due to phosphorylation at S30.
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Figure 17: S30 phosphorylation regulates caspase-7 processing intracellularly
(A) Caspase-7 FL C186S or S30A/C186S were transiently transfected into MCF7 cells. Activated
caspase-9 cleaved caspase-7 FL S30A/C186S faster than C186S in MCF7 lysates. Caspase-7 and
histone deacetylase-1 (HDAC-1; a loading control) were observed by immunoblotting.
(B) The band intensity of the remaining FL caspase-7 transfected variants was quantified and
normalized to the HDAC-1 loading control. The non-phosphorylatable caspase-7 variant S30A was
cleaved faster by caspase-9 than caspase-7 containing native phosphorylatable S30. Data are shown as
means ± S.D. from experiments performed on three separate days; the asterisks indicate a statistically
significant increase in cleavage (** p<0.01) as determined by the Student’s t test.
(C) Caspase-7 FL C186S or caspase-7 FL S30A/C186S were transiently transfected into MCF7 cells
and treated with two compounds known to activate caspase-9 via the intrinsic apoptotic pathway (ABT263 and A1210477). Cells undergoing apoptosis cleaved caspase-7 FL S30A/C186S faster than C186S.
Caspase-7 and histone deacetylase-1 (HDAC-1; a loading control) were monitored by immunoblotting.
(D) The band intensity of the appearance of cleaved caspase-7 was quantified and normalized to the
HDAC-1 loading control. The non-phosphorylatable S30A/C186S variant was cleaved approximately
1.4 fold faster than the C186S counterpart. Data are shown as means ± S.D. from experiments
performed on three separate days; the asterisks indicate a statistically significant increase in cleavage (*
p<0.05) as determined by the Student’s t test.	
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Discussion
The regulation of caspases is paramount for determining whether cells live or die.
Global regulation of apoptotic caspases has proven to be heavily modulated by
phosphorylation, with extensive phosphorylation on both initiator and executioner
caspases typically leading to inactivation (for review see Kurokawa and Kornbluth25;
López-Otín and Hunter44). Prior to this work, the molecular details of these inactivating
events have been sparse. Emerging regulatory themes have demonstrated an intricate
complexity, with caspases as kinase substrates and kinases as caspase substrates. Biases
in this interplay that favor cell survival influence diseases of proliferation, like cancer. In
the caspase-7:kinase co-regulation, PAK2 hyperactivity is observed to contribute to a
cancerous phenotype, with enhanced cell survival and chemotherapeutic resistance.17
Our results mechanistically highlight the functional relevance of PAK2 directly
phosphorylating the apoptotic target caspase-7 and demonstrate how PAK2 impacts
caspase-7 activity independently prior to (S30 phosphorylation) or after (S239
phosphorylation) caspase-7 activation in apoptosis. The first mechanism slows initial
activation by allosterically disrupting the ability of initiator caspases to activate fulllength procaspase-7 prior to apoptosis, while the second mechanism involves direct
blocking of substrate from binding to active caspase-7 during apoptosis (Figure 18).
Phosphorylation at S30 interrupts the binding interaction of caspase-7 with the
initiator, caspase-9, and thereby slows caspase-7 cleavage at the distal intersubunit linker.
Phosphorylation has been observed to directly block cleavage at the intersubunit linker of
several caspases, including caspase-2,45 caspase-3,46 caspase-8,29,47 and murine caspase9.48 A recent study identified a phosphorylation site distal from the intersubunit linker
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Figure 18: PAK2 uses distinct mechanisms at two sites of phosphorylation: S30 blocks caspase-7
zymogen activation while S239 directly disrupts substrate cleavage
The intrinsic apoptotic cascade proceeds when intracellular stresses promote release of cytochrome c
from the mitochondria. Cytochrome c and Apaf-1 constitute the apotosome, which recruits and activates
initiator caspase-9. Activated caspase-9 binds the full-length procaspase-7 zymogen, likely through
interactions with the N-terminal region containing S30. Caspase-9 activates caspase-7 through cleavage
at the intersubunit linker. Active caspase-7 continues the execution of apoptosis by processing over a
hundred downstream substrates including p23, PARP, and other caspases. In addition, cleavage of
PAK2 by caspases results in a release of the autoinhibitory domain (AID) and signals the kinase domain
(KD) to be transported to the nucleus where phosphorylation of new targets propagates the apoptotic
response. When active, full-length PAK2 can supersede cell death by performing either of two distinct
phosphorylation events on caspase-7. Phosphorylation (℗) at S30 interrupts the interaction between
caspase-9 with the caspase-7 zymogen (repelling red lines), thus slowing zymogen activation at the
early stages of apoptosis. PAK2 phosphorylation on active caspase-7 at S239 occurs most rapidly when
the active-site loops adopt a zymogen like conformation but abolishes activity in all forms of caspase-7
by directly blocking substrate binding.
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cleavage site that decreases caspase-8 processing through the sequential action of two
kinases via an as yet unknown mechanism.49 Phosphorylation of S30 of caspase-7 is the
first report of direct allosteric regulation of zymogen activation in caspases, where
phosphorylation at a distal site impacted intersubunit linker cleavage. In many previous
cases the phosphorylation sites that impact the rate of activation were located either on
the linker itself or directly adjacent in the immediate flanking sequence, suggesting that
phosphorylation at those linker sites directly prevents binding of the activating caspase by
introduction of a charged residue. Inhibition by phosphorylation at S30 is the first
example revealing details of a one-step allosteric mechanism where a distant site is
utilized to control caspase maturation from the zymogen to the active form. We know of
no other proteases for which this mechanism of phosphorylation regulating zymogen
activation by a single kinase has been reported, but one might speculate that zymogen
activation of other caspases or other proteases may likewise be allosterically modulated
by relevant kinases. This identification of a vulnerable allosteric site on caspase-7 opens
the door for future modulation of caspase-7 activation by both caspase and kinase
modulators.
S30 sits in the N-terminal region of caspase-7. Our data suggest that this region
may be critical for directly mediating the interaction of caspase-7 with caspase-9,
potentially through an exosite interaction, that leads to zymogen activation. This Nterminal region has never been structurally characterized as it has been disordered in the
many structures of caspase-7. Nevertheless, this region has proven to be critical for the
participation of caspase-7 in apoptosis using allosteric mechanisms. An exosite at a basic
lysine patch (K38KKK) assists in the recognition of specific caspase-7 substrates.50 While
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little is known about the region, it appears to be critical for caspase-7 specific activities.
For example, the K38KKK is not present in caspase-3 and is one example of how caspase7 is able to fulfill its non-redundant apoptotic roles during the demolition phase. The
PAK2 motif containing S30 is not present in caspase-3. We have also observed that
PAK2 does not phosphorylate caspase-3 in this N-terminal region in vitro (data not
shown), which further suggests that this region of caspase-7 is a region that is critical for
regulation of caspase-7 specifically.
While phosphorylation of caspase substrates has been observed to block their
cleavage by caspases, our work is the first to show that phosphorylation of an active-site
loop in a caspase directly blocks substrate binding, thus inactivating active caspase-7 and
later during apoptosis. The crystal structure of caspase-7 phosphomimetic S239E
suggests that steric bulk and charge from phosphorylation results in a misalignment of the
active-site loop 3. This mechanism is similar to that observed for caspase-6
phosphorylation of S257 by Ark5 kinase, which leads to misalignment of the loops in the
substrate binding groove and inactivation of caspase-6.51 Many lines of evidence have
suggested that active-site loop conformations are critical for caspase function. Cleavage
of the intersubunit linkers liberates two loops which can reorganize to facilitate substrate
binding. Mechanisms like those utilized by PAK2 and Ark5 take advantage of the
requirement for precise positioning of the loops to enable substrate binding and cleavage.
Small molecules and mutations that organize52 or disorganize14,53 the active site loops
have proven to be effective activators or inhibitors. The discovery of the dimer-interface
allosteric site in caspases led to speculation that a naturally-occurring regulatory smallmolecule might bind and inactivate caspase-7. Our observation that S239 becomes
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accessible upon binding small molecules at this allosteric site (containing C290) may
suggest that such a molecule would be synergistic with PAK2, enabling phosphorylation
at S239, thereby inhibiting caspase-7 activity in a covalent, and perhaps more stable,
manner. Future caspase therapeutics may fruitfully focus on this adaptable regulatory
mechanism exploited by PAK2.
Together, phosphorylation of PAK2 at both S30 and S239 combine to exert
powerful control over the activation and subsequent activity of caspase-7. The effects of
phosphorylation are maximized by taking advantage of a dual mechanism: an initial
phosphorylation at S30 is responsible for slowing the critical activation event of
intersubunit linker cleavage followed by a second modification on S239 to disrupt the
active site loops and directly block substrate binding (Figure 18). This phenomenon,
wherein one kinase engages two different molecular mechanisms that each lead to the
same overall cellular outcome, has been observed for other kinase-substrate pairs.
Ribosomal protein S6 kinase β-1 (S6K1) phosphorylation of insulin receptor substrate 1
(IRS-1) at S1101 blocks its interaction with PI3K, leading to insulin resistance.54 When
alternative IRS-1 sites, S307/S312 are phosphorylated by S6K1, it enhances proteasomal
degradation, also leading to insulin resistance.55,56 This pattern of regulation can also be
observed for transcriptional regulation by the forkhead box proteins (FOXO). FOXO1 is
phosphorylated by protein kinase B (PKB/Akt) at three sites, T24, S256, and S319,57
which results in a loss of transcriptional activity. Similar to PAK2 regulation of caspase7, PKB phosphorylation utilizes different mechanisms of inhibition to achieve the same
overall biological goal. Phosphorylation at S256 limits FOXO1 DNA binding.58
Meanwhile, phosphorylation at S319 creates a consensus sequence for CK1 to
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phosphorylate additional serine residues at positions 322 and 325.59 This tight grouping
of modified serines promotes the nuclear export of FOXO1, decreasing FOXO1 activity
by a different mechanism. In these patterns of regulation, one kinase modifies a single
substrate at multiple sites, which each exert mechanistically independent but biologically
synergistic effects. This synergy in impact is perhaps expected, as uncorrelated outcomes
would be non-productive. Thus, it is likely that full-length PAK2 would only play antiapoptotic roles that have biological synergy to caspase-7 phosphorylation under related
conditions.
In addition to S30 and S239, T173 has also been reported to be phosphorylated by
PAK2.17 We have not observed phosphorylation of T173 under any conditions nor have
we observed any functional effect of phosphomimetics at this residue. This could be
because i) we have not explored the requisite conditions for phosphorylation, or ii) T173
is not a bonafide modification site but can only be recognized in a peptide, such as those
used to identify this site,17 not in an intact protein, or iii) T173 is a bystander residue,
which has no functional effect upon phosphorylation. The concept of bystander residues
is replete in the kinase literature. Our work on S30 demonstrates that even for functional
phosphorylation events, it can be difficult to decipher the role phosphorylation at a given
site might play. It is possible that we may not have found the right conditions for T173
phosphorylation by PAK2, but if T173 is a target of PAK2 under conditions where S30
and S239 are phosphorylated it should likewise have an anti-apoptotic effect. We may
likewise predict that if phosphorylation of T173 by PAK2 has a different (e.g. antiapoptotic) functional effect, we would expect to observe it only under very different
cellular conditions. Additionally, it is possible that each of the three sites of
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phosphorylation are utilized under different biological conditions, providing nuanced
control of caspase-7 activity by PAK2.
These findings illuminate the molecular details of a kinase inhibiting an apoptotic
caspase. The implications extend to cancer resistance, suggesting a hyperactive PAK2 is
able to limit apoptotic cell death and resist apoptotic stimulation by chemotherapeutic
agents. In addition, our results pinpoint an allosteric region on a key apoptotic
contributor, where alterations result in a slowed maturation and potential control over an
executioner caspase. The significance of this regulation could extend beyond cancer
resistance and apoptotic activation. Recent discoveries have implicated caspase-7 in
inflammation,60,61 defense against L. pneumophila infection,62 osteogenesis,63 and tooth
development,64 all of which show caspase-7 has distinct roles from caspase-3. These nonapoptotic roles could share regulation by phosphorylation and the mechanistic details
uncovered here.
Finally, our increased mechanistic understanding of details of this caspase:kinase
interplay may guide precision therapeutic approaches that exploit synergies between
caspase and kinase directed modulators. Likewise, identification of the S30 site as critical
for interaction with caspase-9 may implicate this S30 region in playing a role in the
recognition of other caspase-7 substrates. If this is the case, synthetic inhibitors that block
the S30 region, mimicking S30 phosphorylation, may prevent cleavage of the subset of
substrates that utilize the S30 region for binding. This is contrast to active-site directed
inhibitors, which like S239 phosphorylation, block cleavage of all caspase-7 substrates.
S30-mimicking inhibitors that offered precision control of substrate selection would be
unprecedented in the realm of synthetic caspase regulation.
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Materials and Methods
DNA expression constructs and Antibodies
Human caspase-7 cDNA in pET 23b was a gift from Guy Salvesen.65 Human caspase-9
cDNA in pET 23b66 was purchased from Addgene. Human caspase-8 cDNA in pET 15b
was a gift from JB Denault. Human p21 activated kinase 2 (PAK2) cDNA in pET 28b
was a gift from John Kuriyan’s lab. The protecting group (PG, cysteinyl-2-pyridyl
disulfide) was synthesized as previously described.41 Dulbecco’s modified Eagle’s
medium (DMEM) and all other cell culture supplements were purchased from Gibco
(Life Technologies). The pLX304 vector containing the caspase-7 cDNA for transient
transfections was obtained from Harvard Plasmid. The caspase-7 antibody for detecting
the large subunit and the HDAC-1 antibody were purchased from Cell Signaling
Technologies.
Generation of Caspase-7 Variants
All wild-type and mutant versions of caspase-7 were expressed from a pET23b vector
with a carboxy-terminal His6-tag. The full-length caspase-7 construct encodes residues 1303, while a constitutively-two-chain corrected (CTC) construct was designed to produce
the large (1-198) and small (199-303) subunits of caspase-7 as two independent
polypeptides. All variants that were generated in either construct were created using
QuikChange (Stratagene) site-directed mutagenesis. All DNA sequences were verified by
DNA sequencing (Genewiz).
Generation of Caspase-9 Constitutive Dimer
Caspase-9 exists primarily as a monomer in solution, as seen by SEC.67 A constitutively
dimeric caspase-9 has been reported, which decreases the distribution of caspase-9
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monomers in solution and increases the more biologically relevant dimer.42 In this
dimeric caspase-9, 5 residues at the dimer interface of caspase-9 were replaced with the
residues from caspase-3. We followed this strategy, and replaced the codons for residues
402-406 to the caspase-3 equivalent C-I-V-S-M on the C-terminus of caspase-9 C287A
using Phusion site directed mutagenesis (Thermo Scientific).
Caspase-7 Expression and Purification
Plasmids encoding human caspase-7 and all variants were transformed into BL21(DE3)
E. coli cells. Cultures were grown in 2xYT media with ampicillin (100 µg/mL,
ThermoFisher) at 37°C until they reached an OD600 of 0.6. The temperature was reduced
to 18°C and cells were induced with 1 mM Isopropyl β-D-1-thiogalactopyranoside
(IPTG) for 18 hours. Cell pellets were stored at -80°C, freeze-thawed and lysed in a
microfluidizer (Microfluidics, Inc.) in a buffer containing 50 mM sodium phosphate pH
8.0, 300 mM NaCl, and 2 mM imidazole. Lysed cells were centrifuged at 27,000 rcf to
remove cellular debris. The supernatant was loaded onto a 5 mL HiTrap Ni-affinity
column (GE Healthcare). The column was washed with a buffer of 50 mM sodium
phosphate pH 8.0, 300 mM NaCl, and 50 mM imidazole. Caspase-7 was eluted with a
step gradient to 300 mM imidazole. The eluted fraction was diluted 6-fold into a buffer
containing 20 mM Tris pH 8.5 and 2 mM DTT to reduce the salt concentration. This
protein was loaded onto a 5 mL HiTrap Q column (GE Healthcare). The column was
developed with a linear NaCl gradient. Protein eluted in 120 mM NaCl and was assessed
for purity by SDS-PAGE and stored at -80°C in elution buffer.
For several sets of experiments it was imperative that the caspase-7 retained its fulllength uncleaved zymogen form, however, during expression in E. coli the prodomain is
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cleaved off over time. Therefore, full-length caspase-7 was induced for only 10 min at
37°C before harvesting the cells.
Caspase-8 Expression and Purification
The expression construct encoding human caspase-8 was transformed into BL21(DE3) E.
coli cells. Cultures were grown in 2xYT media with ampicillin (100 µg/mL,
ThermoFisher) at 37°C until they reached an OD600 of 0.6. The temperature was reduced
to 25°C and cells were induced with 1 mM Isopropyl β-D-1-thiogalactopyranoside
(IPTG) for 3 hours. Cell pellets were stored at -80°C, freeze-thawed and lysed in a
microfluidizer (Microfluidics, Inc.) in a buffer containing 50 mM sodium phosphate pH
8.0, 500 mM NaCl, and 2 mM imidazole. Lysed cells were centrifuged at 27,000 rcf to
remove cellular debris. The supernatant was loaded onto a 5 mL HiTrap Ni-affinity
column (GE Healthcare). The column was washed with a buffer of 50 mM sodium
phosphate pH 8.0, 500 mM NaCl, and 8 mM imidazole. Caspase-8 was eluted with a step
gradient to 300 mM imidazole. The eluted fraction was diluted 6-fold into a buffer
containing 20 mM Tris pH 8.5 and 2 mM DTT to reduce the salt concentration. This
sample was loaded onto a 5 mL HiTrap Q column (GE Healthcare). The column was
developed with a linear NaCl gradient. Caspase-8 eluted in 120 mM NaCl and was
assessed for purity by SDS-PAGE and stored at -80°C in elution buffer.
Caspase-9 Expression and Purification
An expression construct for full-length human caspase-9 was transformed into BL21
(DE3) E. coli cells. The cultures were grown in 2xYT media with ampicillin (100 µg/mL,
ThermoFisher) at 37°C until they reached an OD600 of 0.9. The temperature was reduced
to 15°C and cells were induced with 1 mM IPTG to express soluble His-tagged caspase-
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9. Cells were harvested after 3 hrs to obtain single site processing at D315.67 Cell pellets
stored at -80°C were freeze-thawed and lysed in a microfluidizer (Microfluidics, Inc.) in
50 mM sodium phosphate pH 8.0, 300 mM NaCl, 2 mM imidazole. Lysed cells were
centrifuged at 27,000 rcf to remove cellular debris. The filtered supernatant was loaded
onto a 5 mL HiTrap Ni-affinity column (GE Healthcare). The column was washed with
50 mM sodium phosphate pH 8.0, 300 mM NaCl, 2 mM imidazole until the absorbance
returned to baseline. The protein was eluted using a 2-100 mM imidazole gradient over
the course of 270 mL. The eluted fractions containing protein of the expected molecular
weight and composition were diluted 10-fold into a buffer containing 20 mM Tris pH 8.5
and 5 mM DTT to reduce the salt concentration. This caspase-9 sample was loaded onto a
5 mL HiTrap Q column (GE Healthcare). The column was developed with a linear NaCl
gradient and eluted in a buffer containing 20 mM Tris pH 8.5, 180 mM NaCl, and 5 mM
DTT. The eluted protein was stored at -80°C in the elution buffer and was analyzed by
SDS-PAGE for purity.
PAK2 T402E Expression and Purification
An expression construct for human p21 activated kinase 2 (PAK2) T402E was
transformed into BL21(DE3) E. coli cells. Cultures were grown in 2xYT media with
kanamycin (40 µg/mL, ThermoFisher) at 37°C until they reached an OD600 of 0.6. The
temperature was reduced to 25°C and cells were induced with 1 mM Isopropyl β-D-1thiogalactopyranoside (IPTG) for 3 hours. Cell pellets were stored at -80°C, freezethawed and lysed in a microfluidizer (Microfluidics, Inc.) in a buffer containing 50 mM
sodium phosphate pH 8.0, 300 mM NaCl, 0.05% Tween-20, and 2 mM imidazole. Lysed
cells were centrifuged at 27,000 rcf to remove cellular debris. The supernatant was
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loaded onto a 5 mL HiTrap Ni-affinity column (GE Healthcare). The column was washed
with a buffer of 50 mM sodium phosphate pH 8.0, 300 mM NaCl, 0.05% Tween-20, and
10 mM imidazole. PAK2 was eluted with a step gradient to 300 mM imidazole. The
eluted fraction was diluted 6-fold into a buffer containing 20 mM Tris pH 8.5 and 2 mM
DTT, to reduce the salt concentration. This protein sample was then loaded onto a 5 mL
HiTrap Q column (GE Healthcare). The column was developed with a linear NaCl
gradient. Protein eluted in 120 mM NaCl and was assessed for purity by SDS-PAGE and
stored at -80°C in elution buffer.
Activity Assays
For kinetic measurements of caspase activity, 100 nM freshly purified protein was
assayed over the course of 7 minutes in a caspase-7 activity-assay buffer containing 100
mM HEPES pH 7.5, 5 mM CaCl2, 10% PEG 400, 0.1% CHAPS, and 5 mM DTT. For
substrate titrations, a range of 0-200 µM of the fluorogenic substrate DEVD-AMC, (Nacetyl-Asp-Glu-Val-Asp-AMC (7-amino-4-methylcoumarin), Enzo Lifesciences; Ex. 365
nm / Em. 495 nm), was added to initiate the reaction. Assays were performed in triplicate
at 37°C in 100 µL volumes in 96-well microplate format using a Molecular Devices
Spectramax spectrophotometer. Initial velocities versus substrate concentration were fit
to a rectangular hyperbola using GraphPad Prism (Graphpad Software) to determine the
kinetic parameters KM and kcat. Enzyme concentrations were determined by active-site
titrations with the quantitative inhibitor DEVD-CHO (N-Acetyl-Asp-Glu-Val-AspAldehyde; Enzo Lifesciences) or z-VAD-FMK (Z-Val-Ala-Asp-fluoromethylketone;
Enzo Lifesciences). Active-site titrations were incubated over a period of 2 hours in
activity assay buffer. Optimal labeling was observed when protein was added to DEVD-
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CHO or z-VAD-FMK solvated in DMSO in 96-well V-bottom plates, sealed with tape,
and incubated at room temperature in a final volume of 200 µL. 90 µL aliquots were
transferred to black-well plates in duplicate and assayed with 50-fold molar excess of
substrate. The protein concentration was determined to be the lowest concentration of
DEVD-CHO or z-VAD-FMK inhibitor at which full inhibition was observed.
Caspase-8 and caspase-9 kinetics were assessed as described above, using the peptide
substrate LEHD-AFC (N-acetyl-Leu-Glu-His-Asp-AFC (7-amino-4trifluoromethylcoumarin), Enzo Life Sciences; Ex. 380 nm/ Em. 505 nm). In addition
each assay was performed in the enzyme’s preferred activity assay buffer (see Materials
and Methods).
In vitro Phosphorylation Assays
Purified recombinant PAK2 T402E was first allowed to auto-activate by incubation with
1 mM ATP in PAK2 activity buffer (50 mM Tris pH 7.5, 20 mM MgCl2, 0.1 mM EDTA,
2 mM DTT) for 1 hour at 30°C. This activated kinase was then incubated with caspase-7
variants at a 20:1 caspase:kinase ratio. Additionally, [γ-32P] ATP (10 µCi/µL) was added
to radioactively label phosphorylation on the caspase subunits. Reactions were resolved
by SDS-PAGE and visualized by autoradiography using a Typhoon FLA 7000 (GE
Healthcare). Band quantification was carried out by ImageQuant software (GE
Healthcare) using a set of [γ-32P] ATP standards.
PAK2 is also a substrate of caspase-7, and under certain conditions caspase-7 will
cleave PAK2. In order to silence this enzymatic activity, but still run the in vitro
phosphorylation assay, active forms of caspase-7 could be silenced by incubation with a
protecting group (PG, L-cysteinyl-2-pyridyl disulfide)41 that targets free activated
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cysteines on the caspase. Prior to the in vitro phosphorylation assay, 20 µM caspase-7
was incubated with 2 mM PG for 1 hour in 20 mM Tris pH 7.5, 100 mM NaCl, and was
buffer exchanged to reduce the concentration of reductant (DTT) remaining after
purification. This inactive caspase-7 was then used in an identical fashion to the in vitro
phosphorylation assay described above.
Caspase-7 S239E Crystallization and Data Collection
Purified caspase-7 S239E (CTC construct) in a buffer containing 120 mM NaCl and 20
mM Tris buffer, pH 8.0, was concentrated using Millipore Ultrafree 3K NMWL
membrane concentrators (Millipore) to 18 mg/mL as assessed by absorbance at 280 nm.
Crystal trays were setup at room temperature and grown in 3 µL hanging drop trays with
mother liquor consisting of 2.1 M sodium formate and 300 mM sodium citrate, pH 5.5, in
a 2:1 ratio of protein to mother liquor. Crystals grew to a maximum of 240 µm × 340 µm
in 3 days at 20°C. Crystals were cryoprotected in 20% ethylene glycol in mother liquor
with a 60 second incubation, and then frozen by rapid immersion in liquid N2. Diffraction
data was collected at Brookhaven National Laboratories National Synchrotron X6A
beamline (Upton, NY).
Structure Determination
X-ray data was indexed, integrated, and scaled using HKL2000 software68 and well
defined diffraction spots were observed to 2.2 Å. Crystallographic phases were generated
by molecular replacement using 3IBF as a search model for PhaserMR,69 part of the
CCP4 software suite.70 To avoid bias, substrate binding loops were omitted from the
search model and rebuilt into unambiguous electron density. Structures were refined
using iterative rounds of rebuilding in Coot71 and refinement in Refmac572 using
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individual B-factors. Water and formate molecules were modeled into the structures,
verified with refinement, and checked by stereo-chemical viability. A final round of
refinement with NCS restraints imposed was performed in Phenix.73
Caspase Cleavage Assays
To monitor the impact of caspase-7 phosphorylation on cleavage of full-length caspase-7
by the initiators caspase-8 or -9, caspase-7 zymogen was first incubated with PAK2. In
this experiment all of the caspase-7 variants had the catalytic cysteine mutated to alanine
(C186A) in order to ensure that all observed cleavage was from the initiator caspases.
Caspase-7 full-length C186A and phosphoknock-outs (S30A, T173A) were first
incubated with pre-activated PAK2 (as described above) or with PAK2 in the absence of
ATP, in PAK2 activity buffer for 3 hours at 30°C. Additionally, [γ-32P] ATP (10 µCi/µL)
was added to radioactively label phosphorylation on the caspase subunits. The equivalent
volume of water was added to each reaction in the “no ATP” controls. Treated caspase-7
was then diluted to 3 µM in caspase-9 activity assay buffer (100 mM MES pH 6.5, 20%
PEG 400, and 5 mM DTT) or in caspase-8 activity assay buffer (10 mM PIPES pH 7.2,
0.1 M NaCl, 1mM EDTA, 10% sucrose, 0.05% CHAPS, and 5 mM DTT). The
corresponding initiator caspase was added at a final concentration of 500 nM. The
reaction was quenched at each time point by the addition of SDS sample buffer and
boiled for 10 minutes.

Cleavage was assessed by SDS PAGE analysis and band

quantification was determined using Image Lab software (Bio-Rad).
Fluorescence Anisotropy
Fluorescence anisotropy was monitored using a SpectraMax M5 plate reader (Molecular
Devices) with a fixed excitation wavelength set to 485 nm and an emission wavelength
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set to 525 nm. Full-length caspase-7 C186A or full-length caspase-7 S30A/C186A was
labeled with fluorescein isothiocyanate isomer 1 (FITC; Sigma) in 0.1 M sodium
bicarbonate buffer at pH 9.0. After labeling, unreacted FITC was removed from labeled
caspase-7 by buffer exchanging with 3K MWCO filters into 100 mM Tris pH 7.5 and 100
mM NaCl. A fixed concentration of 20 nM labeled protein was subject to a serial dilution
of caspase-9 constitutive dimer C287A from 40 µM to 10 nM. All measurements were
taken at 25°C after a one hour incubation.
Cell Culture and Transfection
MCF7 breast cancer cells were cultured in Dulbecco’s modified Eagle medium (DMEM)
supplemented with 10% fetal bovine serum, 4.5 g/L D-glucose, 1 mM sodium pyruvate,
100 mg/mL streptomycin, 100 units/mL penicillin, and 1% Glutamax.

Cells were

incubated at 37°C in a humidified atmosphere maintained at 5% CO2. Cells were
transiently transfected using Lipofectamine 3000 (Invitrogen) according to the
manufacturer instructions. Transfection was assessed by comparative immunoblotting of
transfected and non-transfected cells.
Immunoblotting
Cellular proteins from transfected MCF lysates were first separated by SDS-PAGE. Each
well of a 12% acrylamide gel was loaded with 20 µg of total protein from lysates.
Proteins were then electrotransferred onto a polyvinylidene difluoride (PVDF)
membrane. The membranes were washed overnight in a 3% BSA blocking solution
containing Tris-buffered saline with 0.1% Tween-20. The following day the membrane
was probed with primary antibodies. Both the caspase-7 antibody (recognizing the large
subunit) and the HDAC-1 antibody (loading control) were obtained from Cell Signaling
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Technologies. Antibody-antigen complexes were then washed and blotted with goat antirabbit IgG-peroxidase conjugates (Jackson ImmunoResearch Labs). After a final washing
in TBST, the membrane was introduced to the enhanced chemiluminescent substrate for
horseradish peroxidase (HRP) and detected according to the manufacturer’s instructions
(ThermoFisher Kit) using a ChemiDocMP (Biorad Laboratories Inc.).
MCF7 Lysate Cleavage Assay
MCF cells were first washed twice with ice-cold 1x PBS and were then lysed in 50 mM
Tris pH 7.4, 150 mM NaCl, 1% Triton X-100, and protease inhibitors (1 mM 4-(2aminoethyl)benzenesulfonyl fluoride, 0.8 µM aprotinin, 29 µM bestatin, 10 µM pepstatin,
1.3 mM EDTA) and phosphatase inhibitors (5 mM β-glycerophosphate, 20 mM sodium
fluoride and 200 µM sodium orthovanadate) on ice for 30 minutes, then were centrifuged
at 20,000 rcf for 20 minutes at 4°C. Quantification of total protein levels in the
supernatant were determined using the bicinchoninic acid assay (Pierce). An equal
amount of total protein was then subject to caspase-9 cleavage by the addition of 0.93
µg/µL of purified recombinant human caspase-9.
MCF7 Whole Cell Caspase-7 Cleavage Assay
MCF7 cells were grown to ~90% confluency and then plated in six well plates with one
million cells per well. Cells were transiently transfected with caspase-7 C186S DNA or
caspase-7 S30A/C186S DNA using Lipofectamine 3000 (Invitrogen) according to the
manufacturer instructions. Cells were then treated with DMSO, staurosporine (STS; 1
µM), or apoptosis inducing compounds (ABT-263 and A1210477; 10 µM) for three
hours. After incubation with compounds, cells were trypsinized and washed twice with
ice-cold 1x PBS buffer. Cells were then lysed as described previously and lysates were

	
  

63	
  

quantified using the bicinchoninic acid assay (Pierce). An equal amount of total protein
was loaded into each well of a 12% acrylamide gel and cleaved caspase-7 was detected
by western blot analysis. Protocol for Immunoblotting is in the supplementary
information.
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CHAPTER III
ZINC INHIBITION OF THE APOPTOTIC CASPASES -3, -6, -7, AND -8
The majority of this chapter will be submitted: Eron, S.J., MacPherson, D.J., Dagbay, K.,
Hardy, J.A. Zinc Inhibition of the Apoptotic Caspases -3, -6, -7, and -8. (2016).
Introduction
Until recently the magnitude of the impact of zinc on a wide array of biological
processes was vastly underappreciated. It has now become clear that zinc plays
fundamental roles in growth, development, metabolism, gene transcription, and signaling.
A large body of work has established both structural and catalytic roles for zinc in
biology, and more recent investigations have observed zinc acting as a signaling factor.1,2
In addition, sequence analysis suggests that up to 10% of the human proteome has
potential zinc binding sites.3 The functional roles of these sites remain a large unsolved
mystery. In this chapter we undertake uncovering the roles of a few of these zinc-binding
sites in caspases.
The regulation of intracellular zinc is imperative for maintaining proper
homeostasis, and the extent of this regulation is remarkable. Whereas levels of other
metals are controlled by a small number of transporters (e.g. one for iron), levels of zinc
are tightly controlled by no fewer than 14 zinc importers and 9 zinc exporters in humans,
as well as metallothioneins as intracellular zinc buffering proteins (for review see Kimura
and Kambe4). The complexity of this underscores the importance of tightly regulating
and controlling zinc levels. It is estimated that total cellular zinc concentrations reach
hundreds of micromolar, but the “free” or “available” zinc pool is estimated to be in the
high picomolar to low nanomolar range.5–8 This stark contrast between high total zinc
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levels and low available zinc further emphasizes the tight regulation involved in
maintaining zinc homeostasis. Small fluxes in the available pool of zinc can have
dramatic consequences. This has been observed during fertilization and early human
development with the detection of zinc sparks,9 as well as the zinc wave acting as a
signaling event.1 This zinc wave is mediated by zinc importers that pump excess zinc into
the cytosol, directly inactivating phosphatases,10,11 which as a result also leads to
activation of kinases.12 In addition, ZIP7, a zinc importer, has been identified as being
overexpressed in breast cancer,13 suggesting a link between cancer progression and
excess zinc.14 This is an example of how small changes in available zinc have substantial
cellular implications and motivates our pursuit of detailed biochemical characterizations
of zinc binding to important cellular targets.
Apoptosis is a crucial biological pathway that is highly susceptible to regulation
by zinc (for review see Truong-Tran et al15). Caspases are at the heart of this cell death
process and their activity is essential in order for apoptotic programmed cell death to
occur. There has been mounting evidence that zinc plays an inhibitory role by blocking
caspase activity16–19 and thus serving an anti-apoptotic function. Caspases are proteases
that use a cysteine-histidine catalytic dyad, both of which are necessary components for
hydrolysis of protein substrates. Apoptotic caspases are separated into two types, the
upstream initiator caspases and their substrates, the downstream executioner caspases.
The executioner caspases -3, -6, and -7 exist as homodimers and require cleavage at their
intersubunit linker in order to achieve full activity. In contrast, the activity of the initiator
caspases -8, -9, and -10 is dependent on a trigger, such as dimerization or binding to an
activating platform. Caspase-9 is activated on the heptameric apoptosome.20 In the case
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of caspase-8, a death inducing signaling complex (DISC) on the cytosolic face of the cell
membrane recruits monomeric procaspase-8 via its death effector domain (DED).
Caspase-8 is subsequently activated in an oligomeric dependent manner.21 Caspase-8
requires both dimerization and cleavage in order to be activated.22
Because zinc functions as a regulator and cellular signal, dysregulation of zinc
homeostasis can have dramatic effects, and links to Alzheimer’s,23 cancer,24 and
diabetes25,26 have been reported. Thus, it is imperative to uncover the molecular details of
zinc-mediated inhibition as potential therapeutic avenues. There is a notable benefit to
interrogating zinc regulation of caspases due to their direct role in maintaining cell life or
death. Previous investigations have defined inhibitory sites for zinc on both caspase-918
and caspase-6,19 and caspase-3 has been accumulating information for several years
regarding potential zinc-binding sites.27–30 However, details about zinc binding in
caspase-7 and -8 are entirely lacking. The inhibition of caspases by zinc has potential to
occur at the catalytic cysteine-histidine dyad since both residues are robust zinc ligands.
Indeed, caspase-9 is inhibited by zinc through binding at the active site cysteine.
However, further analysis revealed a second zinc binding to caspase-9 at an exosite
below the 210s helix (Figure 19).18 In addition, caspase-6 crystallographic studies
established that zinc binds to an allosteric site and not the catalytic dyad in the active site
(Figure 19).19 Meanwhile, caspase-3 has been proposed to bind zinc via its catalytic
histidine and a proximal methionine, rather than the reactive cysteine.29 However, it has
been shown that caspase-3 is inhibited at extremely low concentrations down to 1.7 nM.27
These previous studies provide evidence that zinc inhibition may be nuanced for each
caspase and may occur at biologically relevant, low levels of available zinc.
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In this investigation we have pursued detailed biochemical characterization of
zinc inhibition for caspase-3, -6, -7, and -8. We have evidence that zinc selectively
inhibits these caspases amongst a panel of relevant metals. Moreover, the zinc inhibition
of these caspases occurs at biologically relevant levels of available zinc, in the low
nanomolar range. We also interrogated the mechanisms of inhibition and found zinc does
indeed have an affinity for the active site of caspase-7 and the catalytic cysteine for
caspase-8. In addition, zinc has a destabilizing effect on caspase-8 and its oligomeric
state by disrupting its ability to form the dimer necessary for activity. This provides key
molecular details that establish a deeper understanding of zinc regulating caspases and
apoptosis.

	
  

Figure 19: Known Zinc Binding Sites in Caspases
Previous investigations have found that caspase-9 (represented by PDB 1JXQ) binds zinc at the
active site as well as at an exosite at the bottom of the 210s helix. Conversely, caspase-6 binds a
single zinc at a defined allosteric site, but does not bind zinc at the active site (PDB 4FXO).
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Results
Zinc Inhibits Caspases from Cleaving Peptide and Protein Substrates
Zinc has been shown to have an inhibitory effect on apoptosis, with a specific
negative influence on the caspase activity.16 Previous investigations have taken a
mechanistic approach to zinc inhibition of caspase-619 and -9,18 while others have
interrogated certain aspects of caspase-3 binding zinc.28,29,31 However, each individual
caspases has numerous interactive surface elements as well as a reactive cysteine
nucleophile in the active site, both of which create potential for binding zinc or a variety
of biologically relevant metals. Therefore, the effect of a panel of biologically relevant
metals was tested on the two primary executioner caspases (caspase-3 and -7) as well as
the initiator caspase-8, which have not been investigated previously. Each of these
apoptotic caspases were treated with a panel metals at 250 nM for one hour, and their
activity was subsequently assessed by the ability to cleave a preferred fluorogenic
tetrapeptide substrate (Figure 20 A-C). Both the executioner caspases-3 and -7 were
tested

with

their

preferred

substrate

DEVD-AMC

(acetyl-Asp-Glu-Val-Asp-

aminomethylcoumarin) and caspase-8 was tested with LEHD-AMC (acetyl-Leu-Glu-HisAsp-aminomethylcoumarin). Among the biologically relevant metals, zinc and only zinc
was able to inhibit all three caspases under investigation. Due to the variation of the
counter ions in the panel, both ZnCl2 and ZnSO4 were tested in order to eliminate the
counter ion as a possible reason for inhibition. In addition, cadmium was tested for all
three caspases because it shares similar properties to zinc: a group 12 metal with a d10
valence electron configuration. Cadmium had a marginal effect on the ability of caspase7 to cleave its peptide substrate (84% activity remained), a more significant effect on
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Figure 20: Zinc Inhibits Caspase-3, -7, and -8 from Cleaving Peptide and Protein Substrates
A panel of biologically relevant metals were independently incubated with caspase-3 (A), caspase-7
(B), and caspase-8 (C) and the effect of each metal was assessed by monitoring cleavage of a
fluorogenic tetrapeptide substrate. Data are shown as the mean ± SD for three separate experiments on
three separate days. The effect of each metal was then tested on individual caspases cleaving a protein
substrate: (D) caspase-3 cleaving PAK2 (E) caspase-3 cleaving PARP (F) caspase-7 cleaving PAK2 and
(G) caspase-8 cleaving the catalytically inactive caspase-7 full-length substrate.	
  

	
  

caspase-3 (39% activity remained), and an almost complete inhibitory effect on caspase-8
(12% activity remained) (Figure 20 A-C).
Peptide substrates such as DEVD-AMC and LEHD-AMC occupy only the
substrate-binding groove of the respective caspase. In addition to peptide substrates, it is
important to understand the effect of each metal on the ability of the caspase to cleave a
biologically relevant protein substrate. While hydrolyzing a protein substrate, the caspase
is predicted to make contacts beyond the amino acids proximal to the active site, at
exosites such as those that have been identified in the caspase-7 N-terminal region.32,33 It
would be informative to ascertain whether or not these additional contacts have an effect
on the metal-mediated caspase inhibition, as this may be a means to identify other
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caspase exosites. First, caspase-3 was incubated with each metal for one hour, and the
cleavage reaction was then initiated by addition of the protein substrate, PAK2 (Figure
20D). Both ZnCl2 and ZnSO4 completely inhibited substrate cleavage and cadmium had a
similar effect. Previous reports have suggested that other metals have an inhibitory effect
on caspase-3, including copper and cobalt.28,31 We did not observe a copper or cobaltmediated inhibition. To confirm this observation, the assay was repeated with another
caspase-3 substrate, PARP (Figure 20E), as done in previous work.28 Similar to the PAK2
substrate, only zinc and cadmium had an inhibitory effect under these conditions.
Caspase-7 and caspase-8 were subjected to the metal panel in an identical fashion
to caspase-3. Caspase-7 cleavage of the protein substrate PAK2 was inhibited by both
ZnCl2 and ZnSO4, but no other biologically relevant metal (Figure 20F). However,
cadmium had an inhibitory effect. This was a surprising result based on the previous
observation that cadmium had only a slight effect on caspase-7 cleaving a peptide
substrate. Lastly, caspase-8 was tested by incubation with the downstream protein
substrate caspase-7 (Figure 20G). The caspase-7 substrate was the full-length zymogen
protein with the active site cysteine mutated to an alanine (C186A) in order to prevent
any self-processing. For caspase-8, zinc and only zinc had a significant impact on
cleavage of a protein substrate. However, copper and cadmium seemed to have a minor
impact on cleavage. This result for cadmium is counter to what was observed with the
peptide substrate (Figure 20C), suggesting that multiple metal sites may be relevant in
caspase-8 function and inhibition.
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Biologically Relevant Zinc Concentrations Inhibit Caspase-3, -6, -7, and -8
Although it is clear that zinc selectively inhibits caspase-3, -7, and -8 (Figure 20)
as well as caspase-6,19 this inhibition will only be biologically relevant at certain
affinities. While total intracellular zinc concentrations are estimated to be in the
micromolar range,6 available zinc concentrations are tightly controlled at much lower
levels, estimated to be high picomolar or low nanomolar.6 Therefore, it is imperative that
while making in vitro measurements at low zinc concentrations that the system be
carefully managed so that the available zinc concentration can be tested. In order to
achieve such control, we used zinc-buffering systems11 and calculated the available zinc
concentration utilizing the online calculator, MaxChelator. By deliberately choosing each
buffer component and taking advantage of known zinc binding constants we were able to
set specific free zinc ion levels and prevent large fluctuations in free zinc concentration.
HEPES buffer at pH 7.5 was used due its low binding capacity for zinc34 and TCEP as
the reducing agent in order to avoid excess thiols that can coordinate heavy metals.35 In
addition, the zinc buffering reagent was carefully chosen based on the buffering capacity
and the concentration range of zinc under investigation. The experiment was also
performed in the absence of a buffering agent in order to assess the effect of zinc
buffering on the catalytic activity of these caspases.
After careful consideration of the buffer, caspase-3, -6, -7, and -8 were subjected
to a titration of increasing zinc concentrations and assayed for remaining activity. This
was done in the absence of zinc buffering (Figure 21, gray lines) and the presence of a
zinc buffer (Figure 21, black lines), which allowed the available zinc concentration to be
reported. Under zinc-buffering conditions there was a significant shift in IC50 values
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Figure 21: Buffered Zinc Conditions Reveal Biologically Relevant Inhibition
Dose response curves of caspase activity (10 nM) with increasing concentrations of zinc. A preferred
tetrapeptide substrate was used for each caspase. Titrations were carried out under non-buffering
conditions for zinc (gray lines) and repeated under zinc buffering conditions (black lines). Each titration
was done in duplicate on three separate days with values represented as means ± SEM and fit for the
IC50 value.

	
  

	
  

Table 2: Parameters for Zinc Inhibition of Caspases under Metal Buffering Conditions and
Unbuffered Conditions
The zinc buffer utilized for caspase-3, -6, and -8 was NTA and citrate was used for caspase-7. All
zinc calculations were done using MaxChelator. Inhibition constants were calculated assuming a
mixed model of inhibition, with the exception of caspase-6 (*), which was assumed to be
noncompetitive based on previous determination of allosteric binding of zinc.
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relative to the unbuffered conditions. With zinc buffering the inhibition constants for all
caspases were in the biologically relevant range of zinc concentrations (Table 2).
Caspase-3, -7, and -8 were then assayed, under buffered conditions, at various
concentrations of zinc to determine the zinc inhibition constants (Figure 22). The curves
for all three caspases best fit to a mixed model of inhibition, and Ki values were
calculated based on a global fit.

	
  

Figure 22: Kinetic Fits to Determine Inhibition Constants
Zinc inhibition of caspase-3 (top), caspase-7 (middle), and caspase-8 (bottom). A global fit of
Michaelis-Menten hyperbolas was used to determine the mode of inhibition and extract the inhibition
constant Ki. The mixed model of inhibition represented the best fit for each caspase.
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Determining the Stoichiometry of Zinc Binding in Caspases
Zincon,
indicator,

a

was

colorometric
used

to

zinc

determine

Zn:Caspase stoichiometries. Zincon is a
low affinity zinc chelator (KD= 12 µM)36,37
that undergoes a change in absorbance
spectra as it binds zinc. Zinc binding can
be detected by monitoring the absorbance
increase at 620 nm. Thus, zinc was titrated
into a sample containing zincon and
caspase at increasing molar equivalents to
determine the zinc-binding stoichiometry
for each caspase (Figure 23). Only after a
colorometric response is detected have all
the

caspase

zinc-binding

sites

been

occupied, indicating the number of zincs
binding per caspase monomer. Caspase-3,
-7, and -8 were found to bind three, one,
and

two

zincs

respectively.

Stoichiometries for caspase-3 and -7 agree
with

previously

reported

	
  

Figure 23: Stoichiometry of Zinc Binding
Zincon was used as a colormetric zinc indicator in
order to determine the stoichiometries of zinc
binding for caspase-3, -7, and -8. Molar
equivalents of zinc were added to a mixture of
caspase and the zincon indicator. Absorption
spectra recorded at 620 nm indicate a zincon
response after three molar equivalents for
caspase-3 (top), one equivalent for caspase-7
(middle), and two equivalents for caspase-8
(bottom). Each graph represents the mean ± SEM
for three separate experiments on three separate
days.

	
  

results.19

Caspase-8 was observed to bind two zincs, although the shape of the zincon response
curve suggested that the two zincs bind with different affinities. A slight rise in the
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absorbance at two molar equivalents of zinc could indicate a competition with the zincon
reporter. This suggests that caspase-8 and the zincon bind the zinc with similar affinities
around 12 µM.
Zinc Binds to the Caspase-8 Catalytic Dyad and Impacts Oligomeric Structure
The cysteine-histidine catalytic dyad is well conserved across the caspase family.
These two residues are also very frequently found together in zinc-binding sites, and so it
has been postulated that the caspase catalytic dyad is a likely zinc binding site.18,19,27 To
test this hypothesis in caspase-8, the catalytic cysteine (C360) was replaced by alanine in
order to ablate zinc-binding properties at this site. The stoichiometry of zinc binding for
the caspase-8 wild-type (Figure 24A) and the C360A variant (Figure 24B) were assessed
by zincon assay. Replacement of the catalytic cysteine of caspase-8 with the non-zinc
binding residue alanine significantly altered its ability to bind zinc. The stoichiometry
shifted to less than two zincs per monomer of caspase-8, suggesting that the catalytic
dyad is responsible for binding one of the zincs.
Size exclusion chromatography and analytical ultracentrifugation sedimentation
velocity experiments have demonstrated that aspase-8 exists in an equilibrium between a
monomeric and dimeric state.38,39 At a concentration of 30 µM caspase-8 is
approximately 69% monomer. In addition, dimerization is required in order for the
protein to be active.22 Active site-binding inhibitors, like substrate mimics, can strongly
influence the equilibrium to favor the dimeric state.38 We sought to determine if zinc has
any influence on the oligomeric state of the caspase-8 through size exclusion
chromatography. When caspase-8 was incubated alone and loaded onto a sizing column,
it eluted with 67% monomer and 33% dimer (Figure 24C). This observation agrees well
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with previous investigations of caspase-8 oligomeric state distributions.38 After
incubation with an active site-binding inhibitor, zVAD-FMK (carbobenzoxy-Val-AlaAsp-fluoromethylketone), the ratio shifted as expected38 to 37% monomer and 63%
dimer (Figure 24D). However, after incubation with zinc, the distribution favored the
monomer (Figure 24E). The caspase-8 monomer peak represented 90% of the total
protein load, with only 10% eluting in the dimeric state (Figure 24E,F). This observation
suggests that the mechanistic action for zinc inhibition of caspase-8 involves preventing
the protein from reaching the dimeric state necessary to enable substrate cleavage.

Figure 24: Zinc Binds to the Active Site of Caspase-8 and Influences the Oligomeric State
Zinc binding to caspase-8 (A) and caspase-8 C360A (B) was measured by monitoring the absorbance at
620 nm in the presence of the colormetric zinc indicator, zincon, and increasing concentrations of zinc.
(C) The oliogomeric state of caspase-8 was monitored by elution from a size exclusion column, with
two dominant peaks correlating to the caspase-8 dimeric state and monomeric state. (D) Caspase-8 was
incubated with an inhibitor, zVAD-FMK, which is known to increase the concentration of the dimeric
state. The distribution of monomer and dimer was monitored by SEC. (E) The distribution of caspase-8
monomeric and dimeric states in the presence of ZnCl2 assessed by SEC. (F) A graphical representation
of quantified volumes under each curve representing the monomeric or dimeric states of caspase-8
alone, in the presence of zVAD, or in the presence of ZnCl2. These quantifications represent the mean ±
SEM for three separate experiments on three separate days.
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Zinc Binding Destabilizes Caspase-8
Due to the fact that zinc binding shifts the caspase-8 conformation to favor the
monomeric state, we hypothesized that zinc destabilizes caspase-8. Thermal stability
assays were conducted using differential scanning fluorimetry in order to assess caspase8 stability in the presence and absence of zinc. Fluorescence of a protein-binding dye
(SYPRO Orange), which increases in fluorescence when bound to hydrophobic residues
that become exposed during denaturation, was monitored as a function of temperature.
Wild-type caspase-8 was subjected to a melting curve in the absence of zinc or after
incubation with ZnCl2 and ZnSO4 at 50 µM (Figure 25A). Both zinc salts destabilized
caspase-8 by approximately 3°C (Table 3). Likewise, both zinc salts destabilized caspase8 C360A by a similar amount (5°C, Figure 25B). Given that removing the active site
cysteine (C360A) had a significant effect on the stoichiometry of zinc binding (Figure
24A,B), this suggests that the zinc binding site that leads to destabilization, and loss of
dimer, is not at the catalytic dyad.
In contrast to the impact of zinc, caspase-8 binding to the tetrapeptide substratelike inhibitor IETD (acetyl-Ile-Glu-Thr-Asp-aldehyde), has an extremely stabilizing
effect, with an observed Tm increase of 27°C (Figure 25C). This increase in stability in
the presence of substrate-like inhibitors has been observed previously as caspase-7 is
stabilized by 17°C upon binding of DEVD-aldehyde.40 This is likely a result of
stabilizing the dynamic active site loops upon formation of a caspase-8 dimer. After
observing this extreme stabilization event, we probed the effect of zinc on dimerization of
caspase-8. After incubation with the inhibitor, the caspase-8 was exposed to increasing
concentrations of zinc. Substrate-bound caspase-8 was destabilized by zinc exposure, and
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Figure 25: Zinc Destabilizes Caspase-8
The thermal stability of caspase-8 was interrogated by differential scanning fluorimetry using the
SYPRO Orange fluorescent dye. A melting curve was generated for (A) caspase-8 wild-type alone,
after incubation with ZnCl2, and after incubation with ZnSO4 and repeated for (B) caspase-8 C360A,
a catalytically inactive variant. (C) Caspase-8 thermal stability was then investigated after incubation
with a known peptide substrate, IETD, which contained an aldehyde moiety that reversibly reacts
with the active site cysteine of caspase-8. This caspase-8-IETD was then incubated with zinc. (D)
Caspase-8 C360A thermal melts after incubation with the aldehyde IETD inhibitor.	
  

	
  
Table 3: Thermal Stability Tm Measurements
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a slight increase in the monomer population was observed. Meanwhile, caspase-8 with
the C360A substitution at the catalytic cysteine was unable to attain the stabilization shift
from incubation with the substrate-like inhibitor IETD (Figure 25D) because it is unable
to covalently bind to the IETD inhibitor. Nevertheless, we consistently observe that both
wild-type and C360A caspase-8 are destabilized by zinc. This correlates with the ability
of zinc to promote monomerization of caspase-8 and suggests that the zinc binding site
that impacts dimerization does not include C360.
Due to the modest destabilizing effect in Tm upon zinc binding to the caspase-8
C360A variant, we aimed to further interrogate this shift by incubation with other metals
(Figure 26). Thermal stability measurements after incubation with zinc continued to
display a 5°C destabilizing effect, however, incubation with iron, calcium, and copper
failed to significantly alter the
Tm for caspase-8 C360A. This
result confirmed our previous
observation

that

the

destabilizing effect shown by a
shift in Tm is due to zinc
binding and is not simply due
to the presence of cations in
solution.

	
  

Figure 26: Caspase-8 C360A is Only Destabilized by Zinc
Thermal stability assay for the caspase-8 catalytically inactive
variant (C360A) after incubation with zinc, iron, calcium, or
copper. Only incuabation with zinc destabilized the caspase-8
C360A.
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Caspase-7 Binds Zinc at the Catalytic Dyad
Caspase-9 was observed to bind two zincs, one at the active site and a second at
an exosite at the base of the 210s helix. A sequence alignment of this caspase-9 exosite
(H224 and C272 in caspase-9 numbering) with caspase-7 amino acids (H131 and C171)
suggests caspase-7 lacks a critical cysteine necessary to bind zinc in the same manner as
caspase-9 at an exosite. However, an investigation of the caspase-7 structure reveals that
there is indeed a cys-his cluster with potential for zinc binding. To determine if this site is
important in caspase-7, both the histidine (H131 in caspase-7 numbering) and the
cysteine (C171) were replaced with alanine in caspase-7. This variant was then incubated
in the presence and absence of ZnCl2 (Figure 27A). This caspase variant was inhibited by
zinc in a similar fashion to wild-type, suggesting this exosite has no inhibitory potential
for caspase-7 and may be unique to caspase-9. As a result, we next interrogated the active
site of caspase-7 as the binding site for the singular zinc.
The cysteine-histidine dyad comprising every caspase active site is also a
potential zinc binding site. However, when a caspase is bound to a peptide-based activesite inhibitor, the substrate binding groove is sterically blocked and the cysteine-histidine
dyad is covalently blocked, and therefore unavailable to bind zinc. To determine if
caspase-7 and caspase-3 bind zinc using active-site residues, we first incubated each
caspase with a known covalent inhibitor, zVAD-FMK, which occupies the caspase active
site. After a two hour incubation zVAD-FMK completely inhibited both caspase-7 and
caspase-3 (Figure 27B). After incubation with inhibitor, each caspase was subjected to
increasing molar equivalents of zinc in the presence of zincon to assess zinc
stoichiometry in the presence of a sterically filled substrate-binding groove active site.
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Caspase-7 was unable to bind the single zinc that we observed in the absence of zVADFMK (Figure 27C). However, caspase-3 showed only a modest alteration in the zincon
response in the presence of zVAD-FMK (Figure 27D). This suggests that caspse-3 can
bind three equivalents of zinc and at the same time interact with a covalent active site
inhibitor. This result is consistent with a previous report that zinc and a fluorescently
labeled caspase-3 active site inhibitor are able to simultaneously react with caspase-3.29
This prior analysis went on to suggest that the active site histidine was a zinc ligand but
the active site cysteine is not.

	
  

Figure 27: Substrate-Mimic Occupying the Active Site Disrupts Zinc Binding to Caspase-7 but
Not to Caspase-3
(A) The activity of the caspase-7 variant H131A/C171A was tested in the absence and presence of
ZnCl2. (B) Activity of caspase-7 and caspase-3 after a two hour incubation alone, or in the presence of
an active site inhibitor zVAD-FMK. (C) Caspase-7 alone (top) and caspase-7 with its active site
occupied by zVAD (bottom) were analyzed by increasing equivalents of zinc and stoichiometry of zinc
binding was determined by measuring zincon absorbance at 620 nm. (D) Zincon measurements were
repeated for caspase-3 (top) and caspase-3 incubated with zVAD (bottom). Data represent the mean ±
SEM for three separate experiments on three separate days.	
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Buffer Components Cloud Interpretation of Caspase-7 Thermal Melts
Determining that the caspase-7 active site is responsible for binding zinc is an
important discovery. We recognize that it is also important to understand the residues
responsible for this interaction in order to fully comprehend the inhibitory mechanism.
We aimed to use differential scanning fluorimetry to test a panel of variants in which
potential zinc-liganding residues had been replaced by alanine to assess the effect of zinc
on their thermal stability. Initial experiments exhibited difficulties with data
interpretation for caspase-7 based on a high background signal from the SYPRO orange
fluorescent dye. Therefore, we tested three buffers in order to optimize detection of the
melting properties (Figure 28A). Unfortunately, minimal buffers such as the standard
zinc assay buffer (100 mM HEPES pH 7.5, 100 mM NaCl, and 1 mM TCEP) or zinc
assay buffer including 10% sucrose, had detrimental effects on data interpretation due to
an usual baseline and multiple transitions, which has been reported for some buffers.41
However, caspase-7 activity assay buffer (100 mM HEPES pH 7.4, 5 mM CaCl2, 10%
PEG 400, 0.1% CHAPS, and 1mM TCEP) seemed to give reasonable raw data, despite
the presence of two transitions. Differential scanning fluorimetry was performed using
the SYPRO Orange dye on full-length caspase-7 and catalytic dyad variants C186A,
H144A or H144A/C186A (Figure 28 B-E). The raw data for all four experiments showed
an elevated baseline reading even at 20°C with the addition of zinc, an outcome possibly
due to an interaction of the buffer with these particular variants. In addition, thermal shift
assays were repeated with cleaved wild-type caspase-7 in the presence and absence of
zinc (Figure 28F) and there appears to be two transitions. The caspase-7 data (Figure 28
A-F) was then compared to previous differential scanning fluorimetry data for caspase-8
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(Figure 28 G). Caspase-8 exemplifies a very typical and easily interpretable thermal melt.
Both the caspase-8 and the caspase-8 incubated with zinc have a comparable baseline
with a single transition, as observed for typical differential scanning fluorimetry melting
curves. It is also important to note the loss of fluorescence after the melting transition,
which is observed in every sample (Figure 28 A-G), is a typical observation for these
types of experiments.42,43. This decreasing signal at high temperatures is due to dye
dissociation and protein aggregation and is commonly observed after the protein melts in
differential scanning fluorimetry.42,43

Figure 28: Comparison of Raw
Data for Caspase-8 and Caspase-7
Differential Scanning Fluorimetry
(A) Caspase-7 thermal stability
assay using three different buffers.
Raw data for relative fluorescent
units was plotted for thermal
stability assays of full-length
caspase-7 in the absence (black
lines) and presence of zinc (blue
lines). This included the (B) wildtype and mutants of the catalyitic
dyad (C) C186A, (D) H144A, and
(E) H144A/C186A. (F) Cleaved
caspase-7 in the absence (black line)
and presence of zinc (blue line). (G)
Caspase-8
wild-type
thermal
stability assay raw data in the
absence (black line) and presence of
zinc (blue line).
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Despite the unusual raw data from the caspase-7 melts, the transitions can be
plotted and Tm measurements can be calculated at the midpoint of each curve. The data
for caspase-7 full-length wild-type as well as the active site variants in the presence and
absence of zinc was plotted (Figure 29 A-D) and the thermal stabilities tabulated (Table
4). The result was unexpected, with zinc having a stabilizing effect on each sample,
despite the removal of two potential zinc binding ligands (H144A/C186A). It would be
beneficial to interrogate the effect of zinc on these caspase-7 active site variants by a
complimentary approach, such as circular dichroism or perhaps tryptophan fluorescence.
These experiments will be carried out by another lab member in the future.

Figure 29: Thermal Shift Assays
for Full-Length Caspase-7 and
Active Site Variants
Thermal shift assays for the fulllength caspase-7 variants were
processed at the transition,
normalized, and fit to a boltzmann
distribution in order to determine
the Tm. This was done in the
absence (black lines) or presence
of ZnCl2 (dark blue) or ZnSO4
(light blue) on (A) caspase-7 fulllength wild-type (B) C186A (C)
H144A and (D) H144A/C186A.
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Table 4: Thermal Stability Measurements for Caspase-7

	
  
The thermal stability of caspase-3 was also investigated by differential scanning
fluorimetry. ZnCl2 and ZnSO4 both had a stabilizing effect of approximately 13°C on the
cleaved caspase-3 wild-type. However, this stabilization effect was diminished to only
2.4°C when the full-length caspase-3 catalytically inactive (C163A) variant was
incubated with zinc. It is interesting to note the fact that the C163A variant showed a 6°C
stabilization over the wild-type cleaved caspase-3 when melting the caspase alone.
Nonetheless, the addition of zinc continued to stabilize the C163A version of caspase-3.
Due to the fact that three zincs bind caspase-3, it is difficult to attribute the increase in
stability to a zinc binding the catalytic cysteine or if there is simply a smaller effect using
the full-length caspase-3. In order to interrogate this query, current experiments are being
performed on the full-length catalytic histidine to alanine variant. In addition, the
processing sites on caspase-3 are being mutated to alanine in order to preserve the fulllength protein (D169A/D175A). Thermal stability measurements carried out on variants
in this construct would determine differences in zinc binding between the full-length and
cleaved forms of caspase-3.
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Figure 30: Caspase-3 is Stabilized by Zinc
Caspase-3 stability assessed by differential scanning fluorimetry to determine stability.
(A) Caspase-3 cleaved or (B) full-length catalytically inactive caspase-3 C163A were tested
alone (black lines) or with ZnCl2 (dark blue) or ZnSO4 (light blue).

	
  

Discussion
As our understanding of zinc in biology continues, it has become increasingly
important to dissect the interactions of this essential metal with the diverse array of
proteins it appears to regulate. The discovery of zinc transporters and intracellular
buffering capabilities has shifted the spotlight of zinc biology toward the role of zinc as a
signaling moiety. The careful regulation of the intracellular pool of available zinc by ZIPs
and ZnTs can affect a variety of pathways including gene expression of MTF144,45 and
the balance of phosphorylation10,46,47 (Figure 31). Maintaining proper regulation of this
intracellular zinc pool is imperative. This is evident in the fact that overexpression of
particular zinc importers have been linked to cancer, including ZIP6,48 7,49 8,50 and 10.51
The recent appreciation for zinc as a signaling moiety1,10,52 creates an important need to
identify zinc targets, the resulting effect upon zinc binding, the relative affinity, and the
mechanism by which zinc alters protein function.
The family of apoptotic caspases are known to be responsive to zinc, linking zinc
signaling to a powerful cell death pathway. Zinc inhibition extends to both the extrinisic
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and intrinsic apoptotic pathways, with evidence that zinc inhibits apical caspases -816 and
-9.18 In addition, zinc also can act downstream and silence the executioner caspases -3, 6, and -716 (Figure 31). Previous investigations have uncovered the molecular details of
zinc binding and inhibiting both caspase-619 and caspase-9.18 In addition, zinc binding to
caspase-3 has been shown to be extremely potent27 and another study has proposed a

	
  

Figure 31: The Influence of Zinc on Caspases and Apoptosis
The pool of available intracellular zinc is dynamically regulated by both zinc importers (ZIPs) and zinc
exporters (ZnTs). These membrane associated ZIPs and ZnTs move zinc to and from the cytosol from
the extracellular space or intracellular compartments. This fluctuating pool of available zinc can affect a
variety of proteins with numerous downstream effects including the inhibition of phosphatases and thus
the increase in kinase activity, as well as regulating transcription factors such as MTF1. The available
zinc is also able to regulate caspase activity in an anti-apoptotic fashion. Zinc inhibition of caspase-8
blocks its ability to contribute to the extrinsic apoptotic pathway while zinc interactions with caspase-9
interfere with the intrinsic apoptotic pathway. These apoptotic pathways converge on the executioner
caspases -3, -6, and -7, which are also directly inhibited by zinc. Zinc targets multiple junctions of the
apoptotic cascade and as a consequence the caspases cannot cleave their substrates and apoptotic cell
death is obstructed.
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unique binding site on caspase-3.29 However, there was a paucity of information
regarding the inhibition of caspase-7 and caspase-8 by zinc. We have shown here that
zinc is the only biologically relevant metal to inhibit caspase-3, -7, and -8. In addition,
this inhibition is evident for cleavage of tetrapeptide substrates as well as known
apoptotic protein substrates.
Zinc binding to the apoptotic caspases -3, -6, -7, and -8 is an extremely tight
interaction. The IC50 and inhibitory constants determined here reveal nearly a 1:1
stoichiometry of added zinc correlating to inhibited caspase. This was true for caspase-3,
-6, and -8, while caspase-7 had a weaker response by approximately 1.5 orders of
magnitude. In addition, the measurement for caspase-3 agrees well with previous
studies.27 It is extremely important to carefully consider the conditions under which these
assays are performed (for review see Patton et al53) in order to fully understand the zinc
binding affinity. It is crucial to use a pH buffering component with low metal binding
affinity, a reducing agent lacking a thiol to minimize metal chelation, and a zinc buffering
agent with the appropriate zinc buffering capacity for the interaction intended to be
measurable. Here we deliberately used HEPES as the low affinity pH buffer, TCEP as the
reducing agent, and NTA for the tight binding caspases -3, -6, and -8 and citrate for
caspase-7. This approach has been utilized previously, with one specific example being
the protein-tyrosine phosphatase β.11,54 In this study they observed that zinc indeed
inhibits this phosphatase at orders of magnitude lower than previously reported. This
discovery was owed to attentive and deliberate formulation of the zinc buffering during
kinetic analysis. Similarly, we observe a dramatic increase in affinity for zinc with the
apoptotic caspases, observing inhibition undoubtedly in the biologically relevant range of
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intracellular available zinc. In addition, the inhibition measured here is at the upper limit
of detection.
Small fluctuations in the available zinc pool can have dramatic downstream
consequences. Therefore, uncovering the means by which zinc inhibits each caspase is
essential to further our understanding of zinc and its role in apoptosis. Caspase-6 and
caspase-9 are inhibited by zinc through two very different mechanisms, suggesting that
zinc inhibition may be nuanced to each caspase. Deciphering these differences would
provide salient information in the pursuit of therapeutic intervention. Our examination
regarding caspase-8 inhibition by zinc has unique details compared to previously
determined zinc-caspase inhibition mechanisms. Caspase-8 binds two zincs with an
observed threefold effect: complete inhibition of the enzyme, alterations to the oligomeric
state, and an overall destabilization of the enzyme. Changing the active site cysteine
residue to alanine altered the stoichiometry of zinc binding, reducing it to approximately
one zinc per caspase-8 monomer. This suggests that zinc binds the catalytic dyad, similar
to caspase-9.18 Caspase-8 exists in a concentration dependent equilibrium between the
monomeric and dimeric state.39 Dimerization is necessary in order for caspase-8 to be
active.22 Zinc binding prevents caspase-8 dimerization and heavily shifts the equilibrium
towards the monomeric, inactive state. This observation is in contrast to zinc inhibition of
caspase-9, which had no influence on oligomeric state.18 In addition, zinc had a
destabilizing effect on the thermal stability of caspase-8 and the caspase-8 catalytically
inactive C360A. If destabilization by zinc is concomitant with the alteration of the
oligiomeric state, then this data suggests a second zinc binding site, beyond the C360
active site, is responsible for blocking caspase-8 dimerization. This would offer two
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different mechanisms for zinc inhibition for the same enzyme, offering the hypothesis
that one site targets procaspase-8 by blocking dimer formation and the other targets any
form in which the active cysteine is exposed.
The catalytic dyad for the dimeric caspase-3 and caspase-7 is also a potential zinc
binding site, and a previous work has suggested that zinc binding to these two
executioners could involve the catalytic histidine but not the cysteine.29 We targeted the
active site for both of these molecules as a possible inhibitory site for zinc. Blocking the
active site with a known peptide inhibitor completely abolished zinc binding to caspase7. This suggests that perhaps zinc simply binds the catalytic dyad in the caspase-7 active
site. However, blocking the active site of caspase-3 did not change the stoichiometry of
zinc binding as determined by a colorometric zincon assay. This results suggests (1)
substrate and zinc can bind concurrently and (2) perhaps zinc binding does not involve
the catalytic cysteine, as suggested previously.29
It is also important to note that caspase-3 binds three zincs per monomer, an
observation in agreement with previous ICP-OES analysis.19 It is intriguing to consider
that, despite the previous proposal for zinc blocking the catalytic histidine, there are still
two more zinc binding sites. If zinc simply binds the histidine and prevents substrate
turnover, what is the need for two additional zinc binding sites or do these other sites play
roles in caspase-3 biology? This is also observed for caspase-9, wherein the activity is
ablated by zinc binding to the active site, yet there remains a second site established to
bind zinc. These extra binding sites could be exosites that alter the ability of the caspase
to recognize or interact with other proteins, or may have no structural or functional
impact. For example, if we assume that cadmium and zinc share binding sites on caspase-
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3, then binding an exosite would inhibit cleavage of a protein substrate more compared to
a small peptide substrate. In fact, we observed this with caspase-3 and the protein
substrate PAK2 (Figure 20). Cadmium inhibits caspase-3 from cleaving peptide
substrates approximately 61%, but fully inhibits the cleavage of the protein substrate
PAK2. Further investigations, such as crystallography, could provide meaningful
information about the nature of these additional zinc binding sites.
We have shown in this work that zinc inhibits caspase-3, -6, -7, and -8 in the low
nanomolar range in correlation with biologically relevant levels of available zinc. This
inhibition by zinc is specific and does not apply to other metals found in biology. We
specifically interrogated the zinc mechanism of action against caspase-8, which had not
been investigated previously. Caspase-8 binds two zincs, including one at the active site
cysteine C360. The zinc binding also destabilizes caspase-8 and alters the oligomeric
state to favor the inactive monomer. Such a mechanism of inhibition by zinc is thus far
unique to caspase-8. In addition, caspase-7 binding zinc is in direct competition with
substrate binding at the active site. This data, taken together unveils an important target
for zinc and its regulation of the apoptotic cascade. The biochemical details discerned
from this work provide essential information regarding caspase inhibition by zinc that
adds fuel to the ever-expanding discoveries centered around zinc biology.
Materials and Methods
DNA Expression Constructs
Expression constructs for human caspase-355 and caspase-956 both in pet23b, were
obtained from Addgene. The expression construct for human caspase-7 in pET 23b was a
gift from Guy Salvesen55 and human caspase-8 in pET 15b55 was a gift from JB Denault.
The wild-type caspase-6 human gene was a constitutive two-chain (CT) construct in
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pET11a.57 The expression construct for human p21 activated kinase 2 (PAK2), which
was used as a caspase substrate, was in pET28b58 and was a gift from John Kuriyan’s lab.
The expression construct for Human Rhinovirus 3c protease (HR3cPro) in the pGEX
vector was a gift from M. Romanowski.
Caspase Cleavage of Peptide Substrates with Various Metals
Caspase-3, -7, and -8 were incubated with a panel of metal salts to test the effect of each
metal on catalytic activity. Caspase-3 (10 nM enzyme) was incubated in minimal
cleavage buffer (100 mM HEPES pH 7.5, 100 mM NaCl, and 1 mM TCEP) along with
250 nM of each metal for 30 minutes at room temperature. The activity was assessed by
the addition of 100 µM of the fluorogenic peptide substrate DEVD-AMC (N-acetyl-AspGlu-Val-Asp-AMC (7-amino-4-methylcoumarin), Enzo Lifesciences; Ex. 365 nm / Em.
495 nm). Assays were performed in duplicate at 37°C in 100 µL volumes in a 96 well
black bottom microplate, using a Molecular Devices Spectramax spectrophotometer.
Initial velocities were measured as a function of time in order to determine the relative
activity. Caspase-7 and caspase-8 (100 nM enzyme) were incubated in minimal cleavage
buffer with 2.5 µM metal in an identical fashion to the that described above for caspase-3.
Caspase-7 activity in the presence of each metal was assessed by the addition of DEVDAMC, while caspase-8 activity was assessed using the fluorogenic substrate LEHD-AMC
(N-acetyl-Leu-Glu-His-Asp-AMC (7-amino-4-methylcoumarin), Enzo Lifesciences; Ex.
365 nm / Em. 495 nm).
Caspase Cleavage of Protein Substrates with Various Metals
Caspase-3, -7, and -8 were each incubated with a preferred protein substrate under the
influence of a panel of metals in order to determine an effect on the ability to cleave a
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folded protein. Each caspase (all 1 µM) was incubated in minimal cleavage buffer (100
mM HEPES pH 7.5, 100 mM NaCl, and 1 mM TCEP) with 25 µM of each metal for 30
minutes at room temperature. The protein cleavage reactions were initiated with the
addition of 2 µM of a protein substrate. Caspase-3 was incubated with the protein
substrate PAK2 for 60 minutes at 37°C; caspase-7 was incubated with the protein
substrate PAK2 for 120 minutes at 37°C; and caspase-8 was incubated with the fulllength caspase-7 C186A catalytically inactive mutant as a substrate for 120 minutes at
37°C. Reactions were stopped by the addition of Laemmli buffer and heating at 95°C for
10 minutes. Cleavage was assessed by SDS-PAGE.
Zn Inhibition Assays using Zinc Buffering
The conditions for achieving each free Zn concentration were calculated using
Maxchelator.59 For caspase-3, -6, and -8, 1 mM NTA was incubated with the calculated
amount of zinc in minimal assay buffer (100 mM HEPES pH 7.5, 100 mM NaCl, and 1
mM TCEP) for 15 minutes at room temperature. Due to the difference in inhibition for
caspase-7, 1 mM citrate was used to buffer the free Zn to achieve the desired free Zn
concentrations. Each caspase enzyme was added to the reaction mixture at a final
concentration of 10 nM. The enzyme was allowed to incubate with the free Zn for 1 hour
at 25°C. The fluorogenic peptide substrate was then added to the reaction to a final
concentration of 100 µM, and the activity was measured by monitoring fluorescence as a
function of time. Caspase-3 and -7 were assayed with the fluorogenic peptide substrate
DEVD-AMC (see above). Caspase-6 was monitored with VEID-AMC (N-acetyl-ValGlu-Ile-Asp-AMC (7-amino-4-methylcoumarin), Enzo Lifesciences; Ex. 365 nm / Em.
495 nm). Caspase-8 was monitored using LEHD-AMC (see above).
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Determination of Zinc Stoichiometry using Zincon
Zincon was used as a spectrophotometric reagent to determine the stoichiometry of zinc
binding to caspases. A 1-mL reaction containing 10 µM caspase, 25 µM Zincon, and 1
mM TCEP was equilibrated at room temperature in a buffer containing 100 mM HEPES
pH 7.5 and 100 mM NaCl. Each reaction was placed in a cuvette and titrated with ZnCl2
where the optical absorption spectrum was taken after each addition of Zn(II). The
change in absorbance at 620 nm was recorded and plotted against the molar equivalents
of Zn(II) added per caspase monomer. Assays were performed at 25°C on three separate
days and monitored in a Molecular Devices Spectramax spectrophotometer. Zincon has
been reported to bind Zn(II) with a Kd value 12.6 µM.37,60
Caspase-8 Size Exclusion Chromatography
Caspase-8 was concentrated using Amicon Ultra – 0.5 mL Centrifugal Filters 3K MWCO
(EMD Millipore) and the buffer was exchanged in the same device three times to remove
residual DTT present from the purification using a sizing column buffer (100 mM
HEPES pH 7.5, 100 mM NaCl, 1 mM TCEP). A Superdex 200 increase 10/300 GL (GE
Lifesciences) was equilibrated with 7 column volumes of buffer at room temperature with
a flow rate of 0.5 mL/min. 100 µL of Blue Dextran (2,000 kDa) was injected over the
column with 0.5 mL of sizing column buffer at 0.5 mL/min. The void volume of the
column was determined to be 8.56 mL. 100 µL of a standard mixture of ferritin (440
kDa), aldolase (158 kDa), conalbumin (75 kDa), ovalbumin (44 kDa) and ribonuclease A
(13.7 kDa) was injected with 0.5 mL of sizing column buffer at 0.5 mL/min. Caspase-8
wild-type (10 µM) was incubated alone, or with 50 µM covalent inhibitor zVAD-FMK
(carbobenzoxy-Val-Ala-Asp-fluoromethylketone; known to induce dimerization), or with

	
  

100	
  

50 µM zinc chloride for 1 hour at room temperature. 100 µL of each sample was injected
with 0.5 mL of sizing column buffer at 0.5 mL/min and eluted with 1.5 column volumes
of sizing column buffer. Chromatograms of both standards and unknowns were integrated
using Unicorn 5.10 software (GE Healthcare) to determine retention times and peak
elution volumes. The molecular weight of each peak (monomer and dimer of caspase-8)
was determined using the standard curve generated by the mixture of standards. The total
volume of caspase-8 was calculated by adding the volumes from the area under the
curves of both monomeric and dimeric caspase-8. The ratio of monomer to dimer was
determined by dividing the volume of either monomer/dimer by the total volume of
caspase-8. Three trials were performed on three separate days, and data were plotted
using GraphPad Prism. The column was cleaned between replicates with 5 column
volumes of 1 mM EDTA to remove any residual zinc, and then re-equilibrated with 7
column volumes of sizing column buffer.
Thermal Stability Analysis by Differential Scanning Fluorimetry
The thermal stability of each caspase and respective variants was measured in the
presence and absence of zinc or other metals. Caspases were incubated at 5 µM in
minimal assay buffer (100 mM HEPES pH 7.5, 100 mM NaCl, and 1 mM TCEP) in the
presence or absence of 10x molar excess zinc or other metal. Stability was measured in
the presence of 2x SYPRO® Orange dye (ThermoFisher) using a CFX Connect RealTime PCR detection system (BioRad). Reactions were 50 µL in a 96 well plate.
Fluorescence intensity was recorded at increasing temperatures by 0.5°C intervals from
25 to 95°C. Thermal melting points (Tm) values were calculated by curve fitting analysis
using Prism (GraphPad) software.
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Caspase-3 Expression and Purification
Plasmids encoding human caspase-3 and all variants were transformed into BL21(DE3)
E. coli cells. Cultures were grown in 2xYT media with ampicillin (100 µg/mL,
ThermoFisher) at 37°C until they reached an OD600 of 0.6. The temperature was reduced
to 30°C and cells were induced with 1 mM Isopropyl β-D-1-thiogalactopyranoside
(IPTG) for 3 hours. Cell pellets were stored at -80°C, freeze-thawed and lysed in a
microfluidizer (Microfluidics, Inc.) in a buffer containing 50 mM sodium phosphate pH
8.0, 300 mM NaCl, and 2 mM imidazole. Lysed cells were centrifuged at 27,000 rcf to
remove cellular debris. The supernatant was loaded onto a 5 mL HiTrap Ni-affinity
column (GE Healthcare). The column was washed with a buffer of 50 mM sodium
phosphate pH 8.0, 300 mM NaCl, and 50 mM imidazole. Caspase-3 was eluted with a
step gradient to 300 mM imidazole. The eluted caspase-3 was diluted 6-fold into a buffer
containing 20 mM Tris pH 8.5 and 2 mM DTT to reduce the salt concentration. This
protein was loaded onto a 5 mL HiTrap Q column (GE Healthcare). The column was
developed with a linear NaCl gradient. Protein eluted in 110 mM NaCl and was assessed
for purity by SDS-PAGE and stored at -80°C.
Caspase-7 Expression and Purification
Plasmids encoding human caspase-7 and all variants were transformed into BL21(DE3)
E. coli cells. Cultures were grown in 2xYT media with ampicillin (100 µg/mL,
ThermoFisher) at 37°C until they reached an OD600 of 0.6. The temperature was reduced
to 18°C and cells were induced with 1 mM Isopropyl β-D-1-thiogalactopyranoside
(IPTG) for 18 hours. Cell pellets were stored at -80°C, freeze-thawed and lysed in a
microfluidizer (Microfluidics, Inc.) in a buffer containing 50 mM sodium phosphate pH
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8.0, 300 mM NaCl, and 2 mM imidazole. Lysed cells were centrifuged at 27,000 rcf to
remove cellular debris. The supernatant was loaded onto a 5 mL HiTrap Ni-affinity
column (GE Healthcare). The column was washed with a buffer of 50 mM sodium
phosphate pH 8.0, 300 mM NaCl, and 50 mM imidazole. Caspase-7 was eluted with a
step gradient to 300 mM imidazole. The eluted fraction was diluted 6-fold into a buffer
containing 20 mM Tris pH 8.5 and 2 mM DTT to reduce the salt concentration. This
protein was loaded onto a 5 mL HiTrap Q column (GE Healthcare). The column was
developed with a linear NaCl gradient. Protein eluted in 120 mM NaCl and was assessed
for purity by SDS-PAGE and stored at -80°C in elution buffer.
For several sets of experiments it was imperative that the caspase-7 retained its fulllength uncleaved zymogen form, however, during expression in E. coli the prodomain is
self-proteolyzed as a function of time. Therefore, full-length caspase-7 was produced by a
10 min induction at 37°C. The 6x His tag was removed off the C-terminus of caspase-7
by HR3cPro Prior to the His tag, a linker for the preferred precision protease cleavage
site was inserted as amino acids –GGGSLEVLFQGP. After the Q column purification
step the pooled fractions were subjected to a HR3cPro digestion in a suitable buffer (50
mM Tris pH 7.5, 150 mM NaCl, and 1 mM EDTA). A total of 1 mg of HR3cPro was
added to 55 mg of purified caspase-7 protein and allowed to incubate overnight.
Complete digestion was confirmed via differential migration of the small subunit
assessed by SDS PAGE. To further purify the protein and remove the HR3cPro, the
digested caspase-7/HR3cPro mixture was concentrated to 5 mL and loaded on to a
HiLoad Superdex 75 26/60 size exclusion column equilibrated a buffer containing 50
mM Tris pH 7.5, 150 mM NaCl, and 2 mM DTT. Samples were eluted with lysis buffer
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and fractions corresponding to the elution peak on the chromatogram were pooled and
concentrated. Purity was assessed via SDS-PAGE and aliquots were stored at -80°C.
Human Rhinovirus 3C protease (HR3cPro) Expression and Purification
The expression construct encoding HR3cPro was transformed into BL21(DE3) E. coli
cells. Cultures were grown in 2xYT media with ampicillin (100 µg/mL, ThermoFisher) at
37°C until they reached an OD600 of 0.6. The temperature was reduced to 30°C and cells
were induced with 1 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) for 3 hours. Cell
pellets were stored at -80°C, freeze-thawed and lysed in a microfluidizer (Microfluidics,
Inc.) in 1x PBS. Lysed cells were centrifuged at 27,000 rcf to remove cellular debris. The
supernatant was loaded onto a packed GST column (GE Healthcare) and washed with 1x
PBS until the absorbance reached baseline. The column was subsequently washed with
wash buffer (50 mM Tris pH 8.5, 150 mM NaCl) and protein was eluted in 50 mM Tris
pH 8.5, 150 mM NaCl, 10 mM reduced glutathione, and 1 mM DTT. The eluted
HR3cPro was analyzed by SDS-PAGE for purity and stored at -80°C.
Caspase-8 Expression and Purification
The expression construct encoding human caspase-8 was transformed into BL21(DE3) E.
coli cells. Cultures were grown in 2xYT media with ampicillin (100 µg/mL,
ThermoFisher) at 37°C until they reached an OD600 of 0.6. The temperature was reduced
to 25°C and cells were induced with 1 mM Isopropyl β-D-1-thiogalactopyranoside
(IPTG) for 3 hours. Cell pellets were stored at -80°C, freeze-thawed and lysed in a
microfluidizer (Microfluidics, Inc.) in a buffer containing 50 mM sodium phosphate pH
8.0, 500 mM NaCl, and 2 mM imidazole. Lysed cells were centrifuged at 27,000 rcf to
remove cellular debris. The supernatant was loaded onto a 5 mL HiTrap Ni-affinity
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column (GE Healthcare). The column was washed with a buffer of 50 mM sodium
phosphate pH 8.0, 500 mM NaCl, and 8 mM imidazole. Caspase-8 was eluted with a step
gradient to 300 mM imidazole. The eluted fraction was diluted 6-fold into a buffer
containing 20 mM Tris pH 8.5 and 2 mM DTT to reduce the salt concentration. This
sample was loaded onto a 5 mL HiTrap Q column (GE Healthcare). The column was
developed with a linear NaCl gradient. Caspase-8 eluted in 120 mM NaCl and was
assessed for purity by SDS-PAGE and stored at -80°C in elution buffer.
Caspase-9 Expression and Purification
An expression construct for full-length human caspase-9 was transformed into BL21
(DE3) E. coli cells. The cultures were grown in 2xYT media with ampicillin (100 µg/mL,
ThermoFisher) at 37°C until they reached an OD600 of 0.9. The temperature was reduced
to 15°C and cells were induced with 1 mM IPTG to express soluble His-tagged caspase9. Cells were harvested after 3 hrs to obtain single site processing at D315.18 Cell pellets
stored at -80°C were freeze-thawed and lysed in a microfluidizer (Microfluidics, Inc.) in
50 mM sodium phosphate pH 8.0, 300 mM NaCl, 2 mM imidazole. Lysed cells were
centrifuged at 27,000 rcf to remove cellular debris. The filtered supernatant was loaded
onto a 5 mL HiTrap Ni-affinity column (GE Healthcare). The column was washed with
50 mM sodium phosphate pH 8.0, 300 mM NaCl, 2 mM imidazole until the absorbance
returned to baseline. The protein was eluted using a 2-100 mM imidazole gradient over
the course of 270 mL. The eluted fractions containing protein of the expected molecular
weight and composition were diluted 10-fold into a buffer containing 20 mM Tris pH 8.5
and 5 mM DTT to reduce the salt concentration. This caspase-9 sample was loaded onto a
5 mL HiTrap Q column (GE Healthcare). The column was developed with a linear NaCl
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gradient and eluted in a buffer containing 20 mM Tris pH 8.5, 180 mM NaCl, and 5 mM
DTT. The eluted protein was stored at -80°C in the elution buffer and was analyzed by
SDS-PAGE for purity.
Caspase-6 Expression and Purification
Plasmids encoding human caspase-6 and all variants were transformed into BL21(DE3)
E. coli cells. Cultures were grown in 2xYT media with ampicillin (100 µg/mL,
ThermoFisher) at 37°C until they reached an OD600 of 0.6. The temperature was reduced
to 20°C and cells were induced with 1 mM Isopropyl β-D-1-thiogalactopyranoside
(IPTG) for 18 hours to express soluble proteins. Cell pellets were stored at -80°C, freezethawed and lysed in a microfluidizer (Microfluidics, Inc.) in a buffer containing 50 mM
Tris pH 8.5, 300 mM NaCl, 5% glycerol, and 2 mM imidazole. Lysed cells were
centrifuged at 27,000 rcf to remove cellular debris. The supernatant was loaded onto a 5
mL HiTrap Ni-affinity column (GE Healthcare). The column was washed with a buffer of
50 mM Tris pH 8.5, 300 mM NaCl, 5% glycerol, and 50 mM imidazole. Caspase-6 was
eluted with a step gradient to 300 mM imidazole. The eluted fraction was diluted 6-fold
into a buffer containing 20 mM Tris pH 8.5 and 2 mM DTT to reduce the salt
concentration. This protein was loaded onto a 5 mL HiTrap Q column (GE Healthcare).
The column was developed with a linear NaCl gradient. Protein eluted in 120 mM NaCl
and was assessed for purity by SDS-PAGE and stored at -80°C in elution buffer.
PAK2 T402E Expression and Purification
An expression construct for human p21 activated kinase 2 (PAK2) T402E was
transformed into BL21(DE3) E. coli cells. Cultures were grown in 2xYT media with
kanamycin (40 µg/mL, ThermoFisher) at 37°C until they reached an OD600 of 0.6. The
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temperature was reduced to 25°C and cells were induced with 1 mM Isopropyl β-D-1thiogalactopyranoside (IPTG) for 3 hours. Cell pellets were stored at -80°C, freezethawed and lysed in a microfluidizer (Microfluidics, Inc.) in a buffer containing 50 mM
sodium phosphate pH 8.0, 300 mM NaCl, 0.05% Tween-20, and 2 mM imidazole. Lysed
cells were centrifuged at 27,000 rcf to remove cellular debris. The supernatant was
loaded onto a 5 mL HiTrap Ni-affinity column (GE Healthcare). The column was washed
with a buffer of 50 mM sodium phosphate pH 8.0, 300 mM NaCl, 0.05% Tween-20, and
10 mM imidazole. PAK2 was eluted with a step gradient to 300 mM imidazole. The
eluted fraction was diluted 6-fold into a buffer containing 20 mM Tris pH 8.5 and 2 mM
DTT, to reduce the salt concentration. This protein sample was then loaded onto a 5 mL
HiTrap Q column (GE Healthcare). The column was developed with a linear NaCl
gradient. Protein eluted in 120 mM NaCl and was assessed for purity by SDS-PAGE and
stored at -80°C in elution buffer.
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CHAPTER IV
REACTIVE SELF-ASSEMBLY OF POLYMERS AND PROTEINS TO
REVERSIBLY SILENCE A KILLER PROTEIN
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Abstract
Conjugation of biologically active proteins to polymeric materials is of great interest in
the treatment of cancer and other diseases of protein deficiency. The conjugation of such
biomacromolecules is challenging both due to their hydrophilicity and propensity to
denature under non-native conditions.

We describe a novel reactive self-assembly

approach to “wrap” a protein with polymers, simultaneously protecting its delicate folded
state and silencing its enzymatic activity. This approach has been demonstrated using
caspase-3, an apoptosis-inducing protein, as the first case study. The protein-polymer
conjugation is designed to be reversed under the native conditions for caspase-3, that is,
the reducing environment found in the cytosol. The current strategy allowed release and
recovery of up to 86% of caspase activity and nanogel-caspase-3 conjugates induced 7080% apoptotic cell death shortly thereafter. This approach is widely generalizable and
should be applicable to the intracellular delivery of a wide range of therapeutic proteins
for treatment of complex and genetic diseases.
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Introduction
Proteins perform vital biological functions, ranging from gene regulation to
catalysis of metabolic reactions and cell signaling to programmed cell death. Proteins are
widely used as therapeutics (‘biologics’), because they exhibit higher specificity and offer
more nuanced functions than can be achieved by small synthetic molecules.1,2 For
example, small-molecule-based drugs often suffer from off-target activities, especially
because of their inability to differentiate within protein sub-classes. These off-target
effects can be avoided by using a deficient, repressed or down-regulated protein as a drug
directly. However, in vivo stability of proteins has been a significant issue with this
approach.

PEGylation of proteins has been effective in the in vivo stabilization of

protein-therapeutics,3,4 but complementary approaches are necessary as this approach can
result in irreversible modification of the surfaces of the protein cargo. Many of the
biologically important proteins also have inherent liabilities for manipulation and direct
administration, including conformational flexibility, a metastable “folded” state, large
size, propensity to aggregate and susceptibility to oxidation or degradation. As a result,
the development of new protein-polymer nanoconjugates to stabilize and deliver proteins
is gaining tremendous interest.5–8 Traditionally, conjugation of proteins to polymeric
nanocarriers has been quite challenging due to the propensity of proteins to denature
during polymer conjugation, which often requires using organic solvents and harsh
conditions for synthesis.9,10
The past decade has seen some brilliant contributions to address this need.
Conjugation of proteins to telechelic, branched, star polymers and polymeric
supramolecular molecules has been achieved without compromising the activity or
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integrity of certain proteins.11–15 Since most of the current approaches use irreversible
covalent conjugation to reactive, surface exposed residues of proteins (such as lysines
and cysteines), and since multiple copies of these amino acids might be present on the
surface, there have been efforts to genetically modify proteins whereby reactive
functional groups can be placed in specific locations,16–21 but not without risks to the
inherent immunogenicity. We are interested in developing a strategy that provides for
complete reversibility in the protein-polymer conjugation and utilizes native proteins.
More specifically, we are also interested in an approach that allows for turning-off the
protein activity, and then turning the activity ‘on’ when it reaches its target environment
using a specific biological trigger.
A commonly used strategy for reversibility involves the utilization of electrostatic
complementarity, which has advantages because of the simplicity in obtaining the
formulation.22–25 Since there is a significant literature that suggests that charge-neutral
nanoscopic systems are desired for long circulation times, we particularly focus on
methods that can conveniently provide a charge-neutral surface. Inverse mini-emulsion
methods use large volumes of organic solvents, where the aqueous phase is the dispersed
phase. This dispersed phase can be utilized to trap water-soluble monomers, crosslinkers,
and proteins and then encapsulate the protein using a polymerization reaction.9,10,26–29 We
are interested in developing a reactive self-assembly of a precursor polymer to conjugate
proteins, where: (i) the conjugation is covalent, but reversible; (ii) the process does not
use organic solvents; (iii) the protein is in its native form; (iv) the protein is encapsulated
to be protected from proteases in order to avoid premature degradation; (v) the protein
activity is turned-off in the encapsulated form; and (vi) the protein activity is recovered in
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its native environment. In this manuscript, we disclose a reactive self-assembly strategy
that provide a polymer-protein nanoassembly with all these characteristics.
We use a caspase protein to demonstrate the utility of the approach outlined here.
Caspases are cysteine proteases that are known for their exquisite specificity for cleaving
after particular aspartic acid residues and rapidly inducing apoptotic cell death.30,31 Their
ability to trigger apoptosis makes them attractive cargo for selective cell killing,
especially in cancer therapeutics. However, caspases are inherently fragile because they
contain dynamic loops, reactive cysteines poised for chemistry at their active site, and are
prone to aggregation due to their tetrameric composition. These qualities therefore
necessitate a delivery system that will not damage the protein and protect it
simultaneously. Among the family of apoptotic caspases, caspase-3 is of special interest
due to its major role in cleaving substrates during apoptosis32 as well as its high catalytic
rate.33 Reversible conjugation with silenced activity, targeted in this study, is also ideal to
study with this protein, because accidental release of active caspases can lead to
irreversible proteolytic damage or even unwanted apoptotic death. Thus, the therapeutic
potential of caspases for inducing cell death using intrinsic biological pathways could be
ultimately harnessed, if it were possible to silence caspase activity through polymer
conjugation and then recover its activity in response to a specific trigger.
Results and Discussion
Since caspases are active in the cytosol, it is clear that these proteins are active
under the reducing conditions of high glutathione (GSH) concentrations. Therefore, we
were interested in developing a nanogel where the crosslinkers are based on disulfides.
In this case, the protein will be stably encapsulated in the low GSH concentration (µM)
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of the serum, but will be released at high GSH concentration of the cytosol (mM) due to
the disulfide bond cleavage in the polymeric nanogel. Accordingly, we attempted the
preparation of caspase-encapsulated nanogels using inverse emulsion polymerization. In
this case, free radical polymerization of a variety of PEG-functionalized acrylates was
carried out in the presence of caspase-3 as the cargo and a diacrylamide derived from
cystine as the crosslinker. Although we were able to achieve protein encapsulation, we
also found that the process had an irreversibly detrimental effect on caspase-3 activity
(data not shown). A number of experiments were then performed to assess the effect of
the photoinitiator (Igracure) with light, the acrylate monomer alone, and another common
initiator/catalyst combination (APS/TEMED) on caspase-3 activity. The results (Figure
32a) led us to conclude that an irreversible reaction between the surface functional groups
of caspase-3 and the reactants utilized for this inverse emulsion polymerization,
specifically the acrylic monomers, destroyed the protein’s activity. In fact, incubation of
caspase-3 with the PEG-acrylate monomer alone indeed irreversibly damaged the activity
of the protein.
This observation of irreparable damage to the protein function led us to reassess
our polymer linkage to this fragile enzyme. We hypothesized that the reactive cysteines at
the active site of the protein were interacting with the polymerization agents and asked if
we could use reversible thiol chemistry to our advantage. Since pyridyldisulfide
undergoes a selective thiol-disulfide exchange with reduced thiols of cysteines, we
treated caspase-3 with cysteinyl-2-pyridyl disulfide. The product disulfide acts as a
protecting group to completely silence the caspase-3 activity in an oxidized state, but
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upon exposure to a reducing environment the protein is able to regain full activity (Figure
32b).

	
  

Figure 32: Recovery of caspase-3 activity after treatment with various polymerization agents. (a)
Caspase-3 was incubated with a set of polymerization agents, all of which had severe effects on the
activity compared to the control. These agents included: (1) a common photoinitiator, Igracure,
followed by UV treatment (2) an acrylate monomer frequently used in inverse emulsion
polymerization methods and (3) an ammonium persulfate (APS) initiator and catalyst
tetramethylethylenediamine (TEMED). (b) Caspase-3 was silenced when reacted with cysteinyl-2pyridyl disulfide (protecting group) in the absence of reductant. However, this silenced caspase
regained 94% activity after treatment with the reductant DTT.

We were inspired by these results at the possibility of a reactive self-assembly
approach to encapsulate proteins in a way that would turn-off its activity and then
reversibly recover the activity under the native conditions of the enzyme. There are five
reduced cysteines that are surface exposed in a caspase monomer (Figure 33). If we were
to mix caspase-3 with a copolymer that contains pyridyldisulfide moieties as side chains,
then we hypothesized that the cysteines in the protein would react with the polymer to
afford a self-assembled protein-polymer conjugate due to the thiol-disulfide exchange
reaction.

	
  

Pyridyldisulfide (PDS) is a hydrophobic functional group and when
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copolymerized with a PEG-containing
monomer,

the

copolymer

amphiphilic

assembly.

We

forms
have

previously used a 7:3 ratio of PDS and
oligoethyleneglycol

(OEG)

based

monomers to obtain robust amphiphilic
assemblies to sequester hydrophobic guest
molecules.34 However, for the reactive
self-assembly with a protein that we
envision here, it is essential that the

Figure 33: Surface exposed cysteine residues in
caspase-3. Cysteine residues are represented by
spheres and the thiol colored gold.
(PDB ID 1QX3)

	
  

polymer is more dynamic. Therefore, we targeted a polymer that contains a lower
percentage of the hydrophobic PDS-based monomer and used a 1:1 ratio of these two
monomers for the self-assembly.
The random copolymer nanogel precursor was obtained by the reversible
addition-fragmentation chain transfer (RAFT) polymerization of OEG-methacrylate and
PDS-methacrylate. The feed ratio of the monomers was 50:50 and experimentally the
resulting copolymer was found to contain 48% OEG units and 52% PDS groups, as
discerned by NMR (Figure 34). Polydispersity and Mn was found to be 1.5 and 20K,
respectively.

To encapsulate the protein using the reactive self-assembly strategy,

caspase-3 and the amphiphilic polymer were added simultaneously to aqueous media.
The protein was presumably wrapped in the assembly by initiating thiol-disulfide
exchange reactions between PDS groups; the assembly was further locked-in with the
addition of a precise amount of DTT (Scheme 1, NG-Casp-In). It is likely that the
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Figure 34: NMR spectra of p(PEGMA-co-PDSMA)

	
  

exposed cysteines on the caspase play a critical role in this reactive self-assembly
process.
Concurrently, we also targeted a control nanogel, where the nanoassembly did not
contain any encapsulated protein (NG-empty). In an aqueous solution, the polymer forms
an aggregate, which was locked-in using a self-crosslinking process enabled by intra- and
inter-chain disulfide cross-linking of the PDS groups in the presence of the reducing
agent dithiothreitol (DTT). The nanogel formation process was monitored by tracing the
absorption spectra of 2-pyridinethione (byproduct of the disulfide crosslinking) at 343 nm
(Figure 35).34 Based on the 2-pyridinethione released, the crosslink density of these
nanogels was 18% (Figure 35A). As an additional control, we also prepared a nanogel,
where the caspase-3 is covalently conjugated to the surface of the nanogel. Here, we first
prepared the cross-linked nanogels (similar to NG-empty); caspase-3 was then covalently
attached on its surface using the cysteine residues of the protein and unreacted PDS
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Scheme 1: Preparation of Nanogel-Caspase-3 Conjugates: Covalent Conjugation of Caspase-3 in the
Interior or on the Surface of Polymeric redox-Sensitive Nanogels through Disulfide Linkages

groups (Scheme 1, NG-Casp-Out). This effectively decorated the nanogel with caspase-3
attached to the outside. Due to their hydrophobic nature, we suspected that the unreacted
PDS groups might collapse into the core of the nanogels and therefore might not be
available for surface functionalization.

This seems to be not the case and surface

functionalization can indeed be achieved with reasonable efficiency.
To ultimately evaluate these nanogels in both passive and activated cellular
uptake pathways, we also prepared nanogels with cell penetrating capabilities by
incorporating a cysteine-containing tri-arginine peptide35–37 on the surface of these
nanogels to generate NG-EmptyRRR, NG-Casp-InRRR, NG-Casp-OutRRR (Scheme 1).
Incorporation of the peptide on the surface was confirmed by further increase in the 2pyridinethione absorption spectrum (Figure 35 D, E, and F).
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Based on the 2-

	
  

Figure 35: Absorption spectra of nanogel-caspase conjugates (A) NG Empty (0.1 mg/mL) (B) NGFITC-Casp-In (0.1 mg/mL) (C) NG-FITC-Casp-Out (0.1 mg/mL) (D) NG EmptyRRR (0.05 mg/mL)
(E) NG-FITC-Casp-InRRR (0.05 mg/mL) (F) NG-FITC-Casp-OutRRR (0.05 mg/mL).

pyridinethione released, we found that the presence or absence of caspase had no overall
impact on the ability to conjugate a second molecular entity. The crosslinking densities
of these nanogels NG-EmptyRRR, NG-Casp-InRRR, NG-Casp-OutRRR were each found to
be ~18%, suggesting that peptide had been incorporated.
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To further characterize these nanogel-protein conjugates, we evaluated their size
by dynamic light scattering (DLS) and found that the hydrodynamic diameter of free
caspase-3, NG-Empty and NG-EmptyRRR were 6, 12, and 10 nm respectively (Figure 36).
After the conjugation of caspase to the nanogels, there was an increase in the size of the
conjugates, indicative of protein conjugation (12 nm – 18 nm, Figure 36a and b).
Caspase-3 is negatively charged (pI 6.1), whereas CRRR is positively charged due to the
arginine residues. These differences led us to evaluate the change in the surface charge of
these conjugates by zeta potential measurements. After conjugation of caspase-3, the
surface charge of NG-Casp-In (-19 mV) did not change significantly from the value
observed in the original NG-Empty (-17 mV, Figure 36c). In the case of NG-Casp-Out,
the zeta potential value obtained shifted towards -7 mV, similar to the value observed for
free caspase-3 (-8 mV). Although these are PEG-functionalized surfaces, these studies
suggest that the nanogels carry a slight, apparent negative charge, which has been
previously seen with PEG-functionalized surfaces.38,39 After surface decoration of
nanogels with CRRR, we expected that NG-EmptyRRR would show a positive zeta
potential value since these nanogels do not have caspase-3 conjugated. As expected, the
surface charge for NG-EmptyRRR was found to be +18 mV. With caspase-3 conjugation,
the surface charge became less positive: +4 mV for NG-Casp-InRRR and +9 mV for NGCasp-OutRRR (Figure 36d). These results, along with the UV-vis absorption spectra
recorded during the nanogel-caspase conjugates synthesis (Figure 35), suggest that
unreacted PDS groups from the nanogels were sterically available to covalently react
with the surface exposed cysteine residues from caspase-3. Furthermore, despite the
presence of a large and bulky biomacromolecule on these polymeric nanogels,
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Figure 36: Nanogel-Caspase Conjugates Characterization. (a) DLS of nanogel-caspase conjugates (b)
DLS of nanogel-caspaseRRR conjugates (c) ζ-potential of nanogel-caspase conjugates (d) ζ-potential of
nanogel-caspaseRRR conjugates (e) Summary table of the properties of nanogels, caspase-3 and nanogelcaspase conjugates.

	
  
subsequent surface functionalization by CRRR addition can also be achieved,
demonstrating the prevalent accessibility and reactivity of the PDS groups. The properties
of these nanogel-caspase conjugates are summarized in Figure 36e.
To further assess the covalent protein conjugation to the nanogels, we utilized SDSPAGE to assess caspase dissociation from the nanogels in a reducing environment
(Figure 37). When treated with sodium dodecyl sulfate (SDS) and boiled, caspase-3
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dissociates into the constituent large and small subunits (17 and 12 kDa, respectively),
which migrate as two characteristic bands on SDS-PAGE. We expected that caspase-3
conjugated to the inside or outside of nanogels should not be observable by SDS-PAGE,
because it will remain bound to and migrate (or fail to migrate) with the nanogel. We
expected to observe the two caspase-3 bands only after treatment of the nanogels with a
reducing agent. As anticipated, we did not observe the bands corresponding to caspase-3
in the NG-Casp-In or in the NG-Casp-Out samples in the absence of reductant (Figure
37a). This suggests that caspase-3 is covalently conjugated through disulfide bonds and
not simply associated through physical adsorption. Since disulfide bonds can be cleaved
at high concentrations of the reducing agent, we hypothesized that we should be able to
“unlock” the protein from the assembly by exposing the conjugates to DTT. The
appearance of the characteristic caspase-3 bands for the large and small subunits in both
samples, NG-Casp-In and NG-Casp-Out, indicated that the protein was released after the
reduction of disulfide bonds. This confirmed the conjugation of caspase-3 in both the “in”
and “out” configurations (Figure 37b) and demonstrated that these nanogels respond to a

	
  

Figure 37: SDS-PAGE gel validating the nanogel-caspase conjugation through reducible disulfide
linkages. (a) Nanogel-caspase conjugates under non-reducing conditions (b) Nanogel-caspase
conjugates under reducing conditions (c) Nanogel-caspaseRRR conjugates under non-reducing
conditions (d) Nanogel-caspaseRRR under reducing conditions.
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specific redox stimulus, namely DTT. We estimated the concentration of caspase-3
released from each conjugate by comparing the intensity of the bands from nanogelreleased caspase to known concentrations loaded into neighboring wells. Both nanogelcaspase conjugates (50 µg) released about 2 µg of caspase-3. Similar results were
observed for the nanogels functionalized with the cell-penetrating peptide, RRR. Under
non-reducing conditions, no caspase bands were observed for the NG-Casp-InRRR and
NG-Casp-OutRRR samples (Figure 37c). When the samples were exposed to reducing
conditions, we observed the appearance of the bands indicative of free caspase-3 released
from NG-Casp-InRRR and NG-Casp-OutRRR (Figure 37d). The concentration of released
caspase-3 from 50 µg NG-Casp-InRRR and NG-Casp-OutRRR was found to be 1 µg and 0.5
µg, respectively.
We had hypothesized that the encapsulation of proteins would protect these cargo
from protease degradation.

We had also hypothesized that the proteins could be

encapsulated within the interior of these nanogels or conjugated to the surface of the
nanogels by simply altering the order of protein conjugation and crosslinking steps. To
test both of these hypotheses, we performed an enzymatic degradation study. The
conjugates were exposed to acetonitrile (20% of the total volume) to denature the protein,
then added trypsin, a serine protease that hydrolyzes peptide bonds strictly after the basic
residues arginine and lysine. These fragments were then analyzed by mass spectrometry
(MS).

First, caspase-3 itself was subjected to trypsin digest and the MS analysis

displayed seven major peaks (Figure 38a). The caspase-3 fragments that each of these
peaks represent are shown in Figure 38e.
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Figure 38: Mass Spectrometry of nanogel-caspase conjugates.
Mass spectra of (a) caspase-3, (b) NG-Empty, (c) NG-Casp-In, and (d) NG-Casp-out. A summary of the
peptides and their m/z values are tabulated in (e).
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We also analyzed empty nanogels by the same method; as expected, no peaks were
observed in the MS (Figure 38b). In the case of NG-Casp-In, we expected that if the
caspase-3 was in fact encapsulated within the crosslinked core of the assembly, trypsin
would not be able to reach the caspase-3 and therefore no signal would be observed.
Indeed, none of the peaks observed previously for caspase-3 were present, suggesting that
the protein is “wrapped” and protected from proteolytic digestion within the nanogels
(Figure 38c). On the other hand, in the case of NG-Casp-Out, peaks with m/z matching
those observed for caspase-3 were detected, demonstrating that these caspase molecules
are indeed on the outside of the nanogel assemblies and are not protected from
proteolysis like those in the NG-Casp-In state (Figure 38d). These results demonstrate the
versatility of the reactive self-assembly to covalently bind proteins and “cage” the protein
cargo within the nanogel, protecting it from enzymatic degradation.
A unique aspect of this system is the versatility of these polymeric nanogels to
silence enzymatic activity, when conjugated. This capability is only useful if protein
cargos retain enzymatic activity upon release from the nanogels. The enzymatic activities
of caspase-3 conjugated to the nanogels or released after redox stimulus were assessed
using a fluorogenic substrate cleavage assay. Based on quantification of caspase release
(Figure 37), the activity from the precise quantity of nanogels encapsulating 50 nM
caspase-3 was measured under non-reducing conditions (Figure 39).

The catalytic

cysteine of caspase-3 requires a reducing environment to be active, so a small amount of
DTT (0.5 mM) was added for the “non-reducing conditions.” This was enough reductant
to assess activity of any unbound caspase, but not enough to promote disassembly of the
nanogels. Under these conditions, none of the conjugates exhibited caspase-3 activity,
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suggesting that there is no unbound active caspase and the enzyme conjugated to the
nanogel is effectively catalytically silenced. This silencing could be due to the structural
constraints imposed by the nanogels and/or the lack of accessibility to the peptide
substrate. The fact that no caspase-substrate cleavage was observed, even in the NGCasp-Out nanogels, suggests that even non-encapsulated caspase have been catalytically
silenced. Caspase-3 contains a free and highly reactive surface cysteine as part of its
catalytic diad (Cys-285). Due to its reactivity, it is likely that this cysteine is involved in
the conjugation to the nanogel.

Thus, the surface incorporated caspase could be

catalytically silent due to covalent conjugation of the active site cysteine-285.
The nanogel-caspase conjugates were then incubated in the presence of 100 mM
DTT to release the caspase-3 cargo. Recovery of enzymatic activity under these
conditions confirmed that the protein is active upon release from the nanogel (Figure 39a
and c). Released caspase-3 activity reached 17% (Figure 39b) upon release from NGCasp-In and 15% for NG-Casp-Out and 74% for NG-Casp-InRRR and 60% for NG-CaspOutRRR (Figure 39d). An earlier protocol for the construction of caspase-containing
nanogels utilized lyophilization. Caspase-3 is an obligate heterotetramer, which does not
refold spontaneously with high yields, so it is not surprising that dramatically lower
yields of functional protein (0.24-3%) were released from lyophilized nanogels using the
older protocol (Figure 40). Given the 15-74% recovery rates observed currently, it is safe
to conclude that the conjugation process itself is mild and that the nanogels protect the
caspase, helping it to avoid denaturation and thus retain enzymatic activity. We were
surprised to note the higher fraction of recovered caspase-3 activity upon release from the
triarginine-containing nanogels, NG-Casp-InRRR and NG-Casp-OutRRR (Figure 39d),
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Figure 39: Protein Enzymatic Activity. (a) Enzymatic activity of caspase-3 (b) Caspase-3 percent
activity recovered from nanogel-caspase conjugates was measured under essentially non-reducing (0.5
mM DTT) or fully-reducing (100 mM DTT) conditions. At 0.5 mM DTT no disassembly of nanogels
was observed, whereas at 100 mM DTT, full disassembly was observed (c) enzymatic activity of
caspase-3 (d) percent activity recovered	
   from nanogel-caspase RRR conjugates. This experiment was
performed in duplicate on each of two days.

	
  

compared to those from NG-Casp-In and NG-Casp-Out (Figure 39b). This result was
puzzling, since both these types of nanogels had very similar abilities to induce cellular
apoptosis (vide infra). A key difference between these nanogels is that the nonfunctionalized nanogels (NG-Casp-In, NG-Casp-Out) contain unreacted PDS moieties,
while these functional groups have been consumed during conjugation of the RRR
peptide in the functionalized nanogels (NG-Casp-InRRR and NG-Casp-OutRRR). We
hypothesized that, during the release from the non-functionalized nanogels, the added
DTT is initially increasing the percent crosslinking (toward 100%) leaving only a fraction
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of DTT to liberate the caspase from
what

is

then

a

much

more

extensively crosslinked nanogel. To
test this hypothesis, we prepared the
non-functionalized

nanogel-

conjugates as before, with an 18%
crosslinking density and then reacted
away the remaining PDS groups
using thiol-terminated PEG (MW 1k)

Figure 40: Caspase-3 activity recovered after an early
protocol for the construction of caspase-containing
nanogels. Both the	
   control and the released caspase are
estimated to be 50 nM.	
  

to generate NG-Casp-InPEG and NG-Casp-OutPEG.

	
  

Next, the enzymatic activity of

capase-3 was assessed after exposing the conjugates to 100 mM DTT. SDS-PAGE of the
nanogel-caspase PEG-thiol conjugates validated the caspase conjugation (Figure 41a and
b).

Once the non-functionalized nanogel-conjugates were protected from additional

crosslinking by the addition of PEG groups, it was possible to release and recover a high
percentage of caspase activity (79% and 86%, Figure 41c) comparable to those observed
for the nanogel-caspaseRRR conjugates. The extent of recovered caspase-3 activity is quite
remarkable considering the lability of the caspase heterotetramer and its dependence on
proper formation of the active-site loop bundle for activity. This high yield indicates that
these nanogels incorporate their cargo without damaging it, while at the same time
remaining robust and responding specifically to a redox stimulus.
The ultimate goal for the use of these nanogel-protein conjugates is to deliver
enzymes in their inactive form and activate them using the innate intracellular
environment in mammalian cells. In this case, such caspase delivery is expected to result
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Figure 41: SDS-PAGE gel validating the nanogel-caspase conjugation through reducible disulfide
linkages. (a) Nanogel-caspasePEG conjugates under non-reducing conditions (b) nanogel-caspasePEG
conjugates under reducing conditions (c) percent activity recovered from nanogel-caspasePEG
conjugates.

in cell killing.

	
  

To determine whether caspase-conjugated nanogels are capable of

internalization in living cells, we monitored the cellular uptake of nanogels upon
incubation of the conjugates with HeLa cells. Caspase-3 was labeled with fluorescein
isothiocyanate (FITC) to enable intracellular visualization; the cell nucleus was stained
with DRAQ5. The fluorescence distribution of FITC and DRAQ5 was observed by
confocal fluorescence microscopy (Figure 42).

FITC-caspase-3 was observed for

nanogels caspase on the surface or inside of nanogels (Figure 42a, b), whereas no
fluorescence was visible in cells treated with FITC-labeled caspase-3 (Figure 43),
suggesting that the protein is not capable of penetrating the cells by itself and requires
nanogel conjugation for efficient internalization. Cellular uptake of nanogel conjugates is
slow unless peptides for uptake are attached. This trend mirrors previous reports showing
no significant internalization of polymeric nanogels at doses of 0.1 mg/mL after 6 hours
in HeLa cells.40 As expected, incorporation of triarginine containing peptides onto
caspase-containing nanogels (NG-Casp-OutRRR and NG-Casp-InRRR; Scheme 1)
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Figure 42: Cellular internalization of nanogel-caspase conjugates with FITC labeled caspase-3. (a) NGFITC-Casp-In (b) NG-FITC-Casp-Out (c) NG-FITC-Casp-InRRR (d) NG-FITC-Casp-OutRRR at 0.5 mg/mL
on HeLa cells. Within each image set, the top left panel is the FITC channel (green; caspase-3), top right is
the DRAQ5 channel (red; nucleus), bottom left is the DIC image and bottom right is the overlap of all
three. This experiment was performed with triplicate visualization on one day. One representative field is
shown for each condition.
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displayed

higher

accumulation

of

caspase-3 both on the membrane and in
the cell within this short time frame
(Figure 42c, d). This is likely due to the
increased local concentration of the
positively

charged

RRR

and

the

negatively charged cellular membrane.
Caspase-3 plays a critical role
during the apoptotic process, so we
anticipated strong cell death-inducing
potential

of

these

	
  

Figure 43: No observed cellular internalization of
FITC-caspase-3 alone after 4 hours. Top left is the
FITC channel, top right is the DRAQ5 channel
showing red for the nucleus. Bottom left is the DIC
image and the bottom right is all three images
merged.

nanogel-caspase

conjugates, which release up to 75% of the caspase-3 cargo in an active form. The extent
of cell death was measured in HeLa cells treated with increasing doses of the nanogel
conjugates (Figure 44).

Staurosporine, a protein kinase inhibitor known to induce

apoptosis41 was used as a positive control. After 24 hours, cell viability was measured
using an Alamar Blue assay. Apoptosis is characterized by the marked changes in cell
morphology such as cell shrinkage and membrane blebbing.42 HeLa cells treated with
nanogel caspase conjugates appeared to be rounded and shrinking similar to those
undergoing apoptosis induced by staurosporine, suggesting that killing was via an
apoptotic route.
We anticipated that bare nanogels would be relatively non-toxic and that those
conjugated to caspase-3 should exhibit significantly higher rates of cell death induction.
NG-Empty exhibited low cellular toxicity at concentrations up to 1 mg/mL (Figure 44a),
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whereas nanogel-caspase conjugates displayed a strong dose response for cell death. At a
concentration of 1 mg/mL, the cell viability for both NG-Casp-In and NG-Casp-Out was
reduced to nearly 20%. To confirm that the cell death observed in the nanogel-caspase
conjugates was induced by the intracellular release of active caspase-3 aided by the
nanogels and not by the action of caspase-3 in solution, cells were exposed to free
caspase-3 utilizing the amount of protein fed during the synthesis of 0.1, 0.5 and 1.0
mg/mL nanogels (50:1 weight ratio, nanogel:caspase-3). Since caspase-3 alone is not
expected to effectively penetrate the cell membrane, we anticipated that the protein itself
should not induce cell death. Indeed, the cell viability observed for caspase-3 was
approximately 80% for a concentration up to 1 mg/mL, indicating that the vast majority
of the cell death observed corresponded to apoptosis induced by the intracellular release
of active caspase-3 from the polymeric nanogels. Similar results were observed for the
case of nanogels decorated with RRR peptide (Figure 44b). At a concentration of 1
mg/mL, the cell viability for NG-EmptyRRR was about 80% (Figure 44b); this may be
because positively charged RRR peptides directly penetrate the cell membrane, causing
rupture or damage, thus introducing slightly higher toxicity.

Similar to the

nonfunctionalized nanogel caspase conjugates, the RRR caspase nanogels induced cell
death in a dose responsive manner. Cell viability for NG-Casp-InRRR and NG-CaspOutRRR was reduced to about 30-35% at a concentration up to 1 mg/mL. Although
nanogels lacking any targeting peptides (Figure 42a, b) show much less cell
internalization than the RRR nanogels, they are more capable of inducing cell death. At
first this result was perplexing, with cell internalization studies seemingly uncorrelated
with increases in cell death. However, upon further investigation we observed that the
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RRR-decorated nanogels appear to be accumulating on cell membranes, rather than being
fully incorporated in the cytoplasm where caspases can be released and activated. Note
that caspases work optimally under the reducing and the neutral pH conditions of the
cytosol.

The activity of these enzymes are substantially reduced under non-native

conditions. For examples, although caspase-3 is optimally active at pH 7.4, its activity
significant decreases at lower pH values,43,44 dropping to just 10% remaining activity at
pH 6.0.33 Thus, although far fewer NG-Casp exist in cells and NG-CaspRRR are more
abundant overall, the NG-Casp have greater cell-killing potential, presumably due to their
more favorable intracellular localization. This points to an important finding. Optimal
delivery of caspases ultimately require localization in the cytosol. The fact that the
nanogels (without the cell penetrating peptides) exhibit excellent apoptotic efficiency
suggests that these nanocarriers are already doing well in this capacity.

Future

generations of caspase-containing nanogels that utilize alternate targeting ligands that are
capable of cytosolic delivery, rather than the triarginine peptides, should yield even more

	
  

Figure 44: Cell viability after 24 hr exposure of HeLa cells with the conjugates.
(a) nanogel-caspase conjugates; (b) nanogel-caspaseRRR. The concentration in the caspase-3 samples is the
feed amount of caspase-3 used when preparing 0.1, 0.5, and 1 mg/mL solutions. Nanogel/caspase-3 (50:1).
Data in (a) were collected from a single experiment performed in triplicate on one day. Data in (b) were
collected from two experiments in triplicate on two separate days. Data from day 1 is shown.
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productive delivery systems, capable of selective cell killing via apoptosis at even lower
doses.
Conclusion
We report a novel reactive self-assembly strategy to conjugate active enzymes to
polymeric nanogels with responsive characteristics, where caspase-3 has been used as the
active protein cargo. In this study, we show that: (i) the proteins can be effectively
encapsulated inside a polymeric nanogel by simply mixing the polymer and the protein in
this reactive self-assembly strategy. (ii) Conjugation of the protein after the nanogel
formation affords a control conjugate, where the protein is attached to the surface of the
nanogel.

(iii) The activity of the protein is completely turned off in both these

approaches, a feature that is critical when delivering cargos that could have deleterious
consequences in off-target locations. (iv) The redox sensitive unlocking event causes the
protein to be reactivated, allowing recovery of ~80% of the activity. In addition to
showing the versatility of these approaches, the fact that these have been demonstrated
with a protein that is very prone to irreversible unfolding suggests that this approach is
broadly applicable to other proteins.

(v) The recovery of activity under reducing

conditions can be utilized to recover the enzymatic activity of caspases inside cells,
where the reducing environment of the cytosol due to high glutathione concentrations is
targeted as the triggering mechanism. This was discerned by the fact that both
conjugation approaches provide robust cellular entry, protein release, and apoptotic
activity. (vi) The nanogel-protein conjugate was able to gain cellular entry, while the
protein by itself did not enter the cells. These results, combined with the fact that the
nanogel by itself is not cytotoxic, suggest that these conjugates are promising protein
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carriers. (vii) The protein conjugated to the surface of the nanogel is prone to proteolysis,
while the encapsulated protein is not accessible to proteolytic enzymes. These results
suggest that while both approaches are versatile for in vitro protein delivery, the
encapsulation approach is more promising for future in vivo applications. (viii) The
nanogel-protein conjugates, decorated with cell-penetrating peptides, gain cellular entry
much more rapidly compared to the unfunctionalized nanogels. However, the overall
apoptotic efficiency of the unfunctionalized nanogels is comparable to (or even better
than) those functionalized with RRR.

These results show that the unfunctionalized

nanogels end up in the cytosol more effectively, as these are not hampered by
electrostatic association with cellular membranes. The fact that the unfunctionalized
nanogels are slow in cellular uptake, but are more effective in releasing the cargo, bodes
well for utilizing these vehicles for targeted delivery of a broad range of protein cargos.
These efforts are currently underway in our laboratories.
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Materials and Methods
Materials
Polyethylene glycol monomethyl ether methacrylate (PEGMA; MW 475), 2,2’dithiodipyridine,

2,2’-azobis-

(2-methylpropionitrile)

(AIBN),

4-cyano-4-

(phenylcarbonothioylthio) pentanoic acid (chain transfer agent), D,L-dithiothreitol (DTT),
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and other conventional reagents were obtained from commercial sources and were used
without further purification, except for AIBN, which was purified by recrystallization.
Pyridyl disulfide ethyl methacrylate (PDSMA) was prepared using the previously
reported procedure (Macromolecules 2006, 39, 5595-5597). 1H NMR spectra were
recorded on a 400 MHz Bruker NMR spectrometer using the residual proton resonance of
the solvent as the internal standard. Chemical shifts are reported in parts per million
(ppm). Molecular weight of the polymer was estimated by gel permeation
chromatography (GPC) in THF using poly(methyl methacrylate) (PMMA) standards with
a refractive index detector. Dynamic light scattering (DLS) measurements were
performed using a Malvern Nanozetasizer. UV-visible absorption spectra were recorded
on a Varian (Model EL 01125047) spectrophotometer. Size exclusion chromatography
was performed on Amersham Biosciences chromatography system equipped with a GE
health care life sciences superdex 75 10/300 GL column. Activity assay was performed
utilizing Spectramax M5 spectrophotometer. MALDI-MS analyses were performed on a
Bruker Autoflex III time-of-flight mass spectrometer. All mass spectra were acquired in
the reflectron mode, and an average of 200 laser shots at an optimized power (60%) was
used. Cell imaging was performed using Zeiss 510 META confocal microscope.
Synthesis of p(PEGMA-co-PDSMA) (P1)
A mixture of PDSMA (536.8 mg, 2.1 mmol), PEGMA (1 g, 2.1 mmol), 4-cyano-4(phenylcarbonothioylthio) pentanoic acid (21 mg, 0.0756 mmol), and AIBN (1.2 mg,
0.00756 mmol) were dissolved in 3 mL of THF in a 10 mL Schlenk flask and degassed
by performing three freeze-pump-thaw cycles with an argon inflow into the reaction. The
reaction vessel was sealed and placed in a preheated oil bath at 70 °C for 12 h. The
product polymer P1 was then purified by precipitation in cold ether (20 mL) to yield the
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random copolymer. Yield: 90%. GPC (THF) Mn: 20 K. Đ: 1.5. 1H NMR (400 MHz,
CDCl3): δ 8.45, 7.66, 7.09, 4.20-4.06, 3.80-3.42, 3.01, 2.10-1.65, 1.10-0.80. The molar
ratio between the two monomers was determined by the integration of the methoxy
proton in the polyethylene glycol unit and the aromatic proton in the pyridine and found
to be 48:52% (PEG/PDS).
Synthesis of Nanogel-Caspase Conjugates
NG Empty: The polymer (3 mg) was dissolved in 1 mL of 1× PBS buffer pH 7.4 and the
solution was left stirring at 20 °C for 15 min. A calculated amount of DTT was added to
the micellar aggregates and the solution was allowed to cross-link for 1 h at 20 °C. The
resulting nanogels were dialyzed at 20°C using a 7000 Da MWCO membrane.
NG-Casp-In: The polymer (3 mg) was dissolved in 1 mL of 1× PBS buffer pH 7.4 and
the solution was left stirring at 20 °C for 15 min. To this micellar aggregate solution, 0.06
mg of caspase-3 was added, and the mixture was left reacting for 1 h at 20°C. Then a
calculated amount of DTT was added to the solution and was stirred for another hour at
20°C to allow for cross-linking. The resulting nanogels were dialyzed at 20°C using a
7000 Da MWCO membrane and unbound caspase-3 was removed by Amicon Ultra
Centrifugal Filters MWCO 100000.
NG-Casp-Out: The polymer (3 mg) was dissolved in 1 mL of PBS buffer pH 7.4, and the
solution was left stirring at 20°C for 15 min. A calculated amount of DTT was added to
the micellar aggregates and the solution was allowed to cross-link for 1 h at 20°C. Then,
0.06 mg of caspase-3 was added, and the mixture was left reacting for another hour at
20°C. The resulting nanogels were dialyzed at 20°C using a 7000 Da MWCO membrane
and unbound caspase-3 was removed by Amicon Ultra Centrifugal Filter MWCO 100k.
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NG EmptyRRR: To functionalize the surface of the nanogels, the same procedure described
above for nanogels was followed. In addition, CRRR peptide (50% by weight compared
to the polymer) was added and then stirred for another hour at 20°C. The resulting
nanogels were dialyzed at 20°C using a 7000 Da MWCO membrane. To functionalize the
surface of the nanogels, the same procedure described above for NG-Casp-In was
followed. In addition, an excess of the ligand (5 mg), CRRR, was added and then stirred
for another hour at 20°C. The resulting nanogels were dialyzed at 20°C using a 7000 Da
MWCO membrane and unbound caspase-3 was removed by Amicon Ultra Centrifugal
Filters MWCO 100000 Da.
NG-Casp-OutRRR: To functionalize the surface of the nanogels, the same procedure
described above for NG-Casp-Out was followed. In addition, CRRR peptide (50% by
weight compared to the polymer) was added and then stirred for another hour at 20°C.
The resulting nanogels were dialyzed at 20°C using a 7000 MWCO membrane and
unbound caspase-3 was removed by Amicon Ultra Centrifugal Filters MWCO 100000.
Activity Assay
For measurement of caspase-3 activity, various amounts of nanogel, ranging from 13 to
230 µg, were used in order to release 50 nM caspase-3 in each experiment. These
nanogel-caspase conjugates were incubated in 100 mM DTT for 1 h in order to fully
release the cargo caspase-3. Identical samples were subject to 0.5 mM DTT treatment in
an identical fashion in order to assay for any free, or unbound, caspase-3. The caspase-3
activity was then assayed over a 7 min time course in caspase-3 activity assay buffer
containing 20 mM HEPES pH 7.5, 150 mM NaCl, 5 mM CaCl , and 10% PEG 400. In
this experiment, caspase-3 hydrolyzes the peptide substrate, N-acetyl-
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Asp-Glu-Val-Asp-7-amino-4-methylcoumarin, resulting in the release of the 7-amino-4methylcoumarin (AMC) moiety as a fluorophore that can be quantified over time. The
fluorogenic substrate N-acetyl-Asp-Glu-Val-Asp-AMC, Enzo Lifesciences (Ac-DEVDAMC), Ex 365/ Em495, was added to a final concentration of 100 µM to initiate the
reaction. These 100 µL assays were performed in duplicate in a 96-well microplate at
37°C using a spectramax M5 spectrophotometer.
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CHAPTER V
HARNESSING THE APOPTOTIC POTENTIAL: INTERROGATING CASPASE
STRUCTURE TO CONTROL FUNCTION
Investigating Regulation of the Apoptotic Caspases
The meticulous nature by which our human cells are able to manage a multitude
of intersecting and continuous biological processes is both fascinating and near
impossible to fully imagine. The scores of machinery and tiers of regulation seem to
extend beyond comprehension; but within this labyrinth scientists have managed to
decipher information bit by bit, slowly building a wealth of knowledge. It is the
exploitation of this information that has allowed development of drugs and therapeutics
that attempt to counteract any malfunctions within such a complex system.
One of the most pertinent and powerful pathways for therapeutic intervention is
that of controlled cell death. This process, governed by a family of cysteine proteases,
must be regulated flawlessly to prevent disease or even organismal death. Dysregulation
has been implicated as a cause or a contributing factor to a myriad of diseases. This
dissertation has focused on understanding the regulation of the apoptotic caspases that are
at the heart of this gene-directed suicide pathway. It is imperative to understand caspases
from a mechanistic perspective in order to fully comprehend their regulation, activation,
and subsequent activity. Only then can we effectively exert any therapeutic control.
The idea of targeting caspase activity for drug development has been pursued by
many pharmaceutical companies and academics, but certain challenges have not yet been
overcome. This fact only underscores the continued need to uncover further details
concerning the function and regulation of these proteases. These efforts have been
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twofold: in chapters II and III I have recorded the attempt to enable regulated inhibition
of caspases in order to prevent unwanted cell death and in chapter IV I have recorded
delivery of active levels of caspases to terminate aberrant or problematic cells. The
former has applications in diseases such as neurodegenerative disorders, stroke, liver and
heart disease. Meanwhile, the latter directly applies to the lack of apoptosis in both cancer
and autoimmune disease.
The work presented here chronicles detailed structural and mechanistic
investigations of caspase regulation in order to provide information for future therapeutic
applications. Uncovering the dual regulatory mechanism of caspase-7 phosphorylation
(Chapter II) provides much needed details surrounding regulation of a powerful
executioner caspase. Meanwhile, studies regarding zinc specific inhibition (Chapter III)
took a more global approach to caspase metal-mediated regulation. Kinetic and
mechanistic strategies revealed biologically relevant levels of zinc have an effect on
caspase activity. Furthermore, seeking to exploit our detailed knowledge of caspase
activity, we aimed to utilize the cell killing potential of caspases by packaging and
delivering these enzymes to cancer cells (Chapter IV). A delivery system was developed
wherein a caspase cargo could be encapsulated by a polymeric nanogel and kept
enzymatically silent until subjected to a redox trigger. Caspase-3 was successfully
incorporated into a nanogel vehicle, delivered to cancer cells, released intracellularly, and
activated to produce an apoptotic response.
Caspase-7 and PAK2 Co-Regulation
The duality of the caspase-kinase relationship has momentous consequences when
considering the effect of each posttranslational modification. The dynamic relationship

	
  

146	
  

between these two enzymes is remarkable, where phosphorylation by the corresponding
kinase results in cell life while conversely, cleavage by the caspase culminates in
apoptotic programmed cell death.
Deciphering the mechanism of inhibition of caspase-7 by PAK2 phosphorylation
provides crucial details about both enzymes. First and foremost, phosphorylation of
caspase-7 identifies two sensitive sites within the protein that could be exploited for
control over caspase activity. This interrogation is twofold: the first relates to caspase-7
specifically, and the second reveals information that can be applied to the family of
apoptotic caspases. The effects of phosphorylation at S30 of caspase-7 is a critical
discovery. Chapter II dives into detail about how this modification slows processing by
the upstream initiator caspases -8 and -9. It further outlines how phosphorylation at this
site blocks interactions with caspase-9, thus inhibiting activation of the executioner
caspase-7. The N-terminal region of caspase-7 has been shown to be a significant factor
in aiding recognition of specific apoptotic substrates.1 A basic lysine patch, just eight
residues from S30, directly contributes to substrate recognition. Additionally,
phosphorylation at S30 is far in sequence from the linker region that is recognized and
cleaved by the initiator caspase-9. This provides a compelling argument that S30 acts as
an exosite for recognition that promotes cleavage and thus, activation. This information
reveals a sensitive site on the executioner caspase-7 that could be targeted as a means to
prevent caspase-7 activation, and perhaps prevent or slow apoptosis. For example, if a
small molecule targeted the S30 region, it could mask the necessary interactions that
promote caspase-9 mediated cleavage, thus keeping caspase-7 uncleaved and catalytically
inactive. This could also be applied to the S239 phosphorylation site. However, S239 is
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housed on loop 3, a key active site loop that must attain a particular conformation in
order to properly bind and hydrolyze the substrate. PAK2 phosphorylation at this residue
is a more obvious disruption to caspase activity.
A second detail that stands out from the structural aspect of the phosphorylation
study (Chapter II) of caspase-7 is the importance of the caspase-7 conformation. In the
full-length form, activated PAK2 recognizes a set of substrates and plays a role in cell
motility, mitosis, and survival. However, upon cleavage by caspases, the PAK2 kinase
domain is translocated to the nucleus where it phosphorylates substrates that propagate
the apoptotic response.2 We have found that the conformational state of caspase-7,
particularly the orientation of the active site loops, can dictate phosphorylation of S239
by PAK2. This is an extremely important observation when considering caspase-7
regulation, and can be applied to other apoptotic caspases as well. One could speculate
that cancerous cells with hyperactive PAK2 might also overproduce a naturally-occurring
regulatory small-molecule that might bind caspase-7 and hold the loops in a conformation
favorable for PAK2 recognizing and phosphorylating S239. This potential allosteric
interaction could operate in tandem with PAK2 working synergistically to inactivate
caspase-7 and prevent an apoptotic response.
PAK2 is not the only kinase to have significant cross-talk with its caspase
substrates.3–5 Interrogating the caspase-kinase battle for determining the fate of the cell
has revealed that when caspases triumph, they often leave remnants of a functioning
kinase. For example, caspase cleavage of receptor tyrosine kinases abrogates their ability
to bind signaling proteins that help produce a prosurvival response. However, much like
PAK2 after caspase-mediated cleavage, the cleaved kinase domain of the receptor
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tyrosine kinases often exhibit proapoptotic behavior in the cytosol.6 It would be very
interesting to interrogate whether the proapoptotic kinase domain liberated after caspase
processing has the same affinity for phosphorylating caspase substrates following
cleavage. It has been shown that cleavage of kinases can result in transporting the kinases
to a new cellular compartment, but perhaps cleavage also exposes some exosites that
completely redefine the kinase substrate profile. Both possibilities open the door for the
potential to control kinase location and substrate recognition.
In addition to S30 and S239 phosphorylation of caspase-7, it had been suggested
that T173 is also phosphorylated by PAK2.7 Our in vitro assays never detected
phosphorylation at this threonine, nor did the T173E phosphomimic show any functional
effect. While a number of possibilities can explain this observation (see Chapter II,
Discussion), it raises the question whether or not there is some caspase conformation or
condition not yet explored, which might lead to a functional phosphorylation on caspase7 at T173. For example, the base of the helix where T173 resides contains potential zinc
binding residues. In addition, caspase-9 binds a zinc at a very similar location at the base
of an analogous helix.8 Perhaps under certain conditions PAK2 phosphorylates caspase-7
at T173 and creates a zinc binding site. Posttranslational modifications can contribute to
metal binding, as has been seen with (1) vitamin-K dependent carboxylase creating γ–
carboxyglutamic acid residues for the chelation of calcium,9 (2) hydroxylation by α–
ketoglutarate-dependent dioxygenase acting on substrates to convert aspartates and
asparagines to their β-hydroxy counterparts for metal binding,10 and (3) kinases that
convert serine to phosphoserine. There are several cases specific to a phosphoserine/threonine/tyrosine modification generating a metal binding site, including
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phosphoproteins storing calcium during tooth and bone development,11 two adjacent
phosphoserines in the egg yolk protein phosvitin that act as ligands binding iron at close
to attomolar affinity,12 and a phosphotyrosine in an α-synuclein peptide which enhances
its affinity for calcium binding.13 In addition, a free phosphate has been observed
crystallographically as a zinc ligand at the base of a helix in ZntR.14 It would be
interesting to explore the possibility of regulation by phosphorylation and zinc crossing
paths at the base of this caspase-7 helix.
Overall, the structural and mechanistic analysis of caspase-7 phosphorylation has
provided a wealth of information regarding caspase-7 structure-function relationships. It
has identified the molecular basis for inhibition at two sensitive sites on the caspase-7
protease that can be targeted for therapeutic control of such an enzyme. The information
obtained here can be applied to caspase-7 and its role in apoptosis, as well as its other
emerging non-apoptotic roles.15 More broadly, it is clear that the conformational state of
caspase-7 plays a significant role in its ability to be posttranslationally modified. Nature
found a way to maximize the silencing of caspase-7 activity by phosphorylating at two
different locations with two very different inhibitory mechanisms, yet generating the
same overall biological result at two different points within apoptosis.
Apoptotic Caspases: Inhibition by Zinc
The cell biology of zinc and its substantial role in numerous cellular pathways is
an evolving field that has gained considerable interest in recent years.16 The influence of
this metal has proven to be essential for growth, development, metabolism, gene
transcription and many more biological processes. As a means of maintaining tight
control over zinc concentrations, there exists a pool of labile intracellular zinc as well as
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stores of zinc in various proteins and membrane structures. The pool of available zinc is
extremely small, but minor fluctuations have incredible significance. This is highlighted
when considering zinc as a signaling molecule, with a prominent example being the
regulation of transcription factors such as metal-regulatory transcription factor 1
(MTF1).17,18 Small fluxes in zinc can activate MTF1 and alter the transcription of a
number of genes. In addition, zinc ‘waves’ have been shown to release an excess pool of
intracellular zinc via particular zinc transporters, and can have lasting results.19,20 One
such result is the inactivation of certain tyrosine phosphatases and the resulting increase
in kinase activity. When considering the effects of zinc as a regulatory or signaling
substance, dysregulation of zinc homeostasis can have dramatic effects, with links to
Alzheimer’s,21 cancer,22 and diabetes.23,24
Studies centering on zinc inhibition of tyrosine phosphatases have uncovered a
number of details with far-reaching implications. Originally, it was thought that these
tyrosine phosphatases were inhibited by zinc at high zinc concentrations that were not
biologically relevant. However, careful kinetic studies revealed that PTP1B, a centrally
situated phosphatase, has an affinity for zinc around 5 nM.25 This discovery forced
further investigations that now implicate PTP1B in cancer. The overexpression of certain
zinc transporters in cancer could be releasing a small excess of zinc that is turning off
tyrosine phosphatases and amplifying kinase activity, resulting in a twofold effect
favoring the cancerous phenotype. This work stresses the need to mechanistically and
kinetically interrogate zinc regulation. The PTP1B example underscores the fact that
careful biochemical studies must be carried out in order to understand the true effect of
zinc. This dissertation has followed a similar approach with caspases. The work in
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Chapter III highlights the zinc inhibition of caspases and reveals biologically relevant
levels of zinc affect the apoptotic caspases.
Investigating zinc inhibition of caspase-3, -6, -7, and -8 will have implications in
drug discovery. The effect of zinc inhibiting apoptosis is well established, and the fact
that caspases are affected by zinc at biologically-relevant levels further emphasizes them
as targets for apoptotic control. This knowledge can be integrated with drug discovery
efforts aiming to activate the apoptotic cascade. Many attempts of turning on apoptotic
programmed cell death, in cancer applications for example, have focused upstream of
caspases but have had little success. However, both the intrinsic and extrinsic apoptotic
pathways converge on the executioner caspases, so it would be advantageous to target
their activation in order to evade the complicated upstream regulatory elements. Relief of
zinc-mediated inhibition is one mechanism by which others have attempted to activate
executioner caspases, in particular procaspase-3. The small molecule PAC-1 chelates zinc
and as a result allows the activation of procaspase-3.26 This has proven to be an effective
strategy in a number of cancers and has excellent potential with certain combination
therapies. Perhaps the most interesting aspect is lack of toxicity thus far due to the fact
that the affinity of PAC-1 for zinc does not exceed that of essential zinc-binding
proteins.27
In addition to uncovering the biologically relevant levels of zinc inhibition of
apoptotic caspases, Chapter III also focused on other important biochemical aspects of
zinc binding to apoptotic caspases. Much of the information regarding the mechanism of
zinc inhibition of caspase-8 has potential for directing future studies. For example, the
discovery that two zincs bind to caspase-8 with seemingly different affinities suggests
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there are two sensitive sites that quite possibly have two different effects when bound to
zinc. The fact that zinc destabilizes the dimer population of caspase-8 reveals that zinc
binding has a distinct effect on the oligomeric state of caspase-8. In addition to its
apoptotic roles, caspase-8 has non-apoptotic roles in embryonic development and
differentiation,28 as well as cell motility.29 It is perhaps possible that zinc functions as a
modulator of caspase-8 activity under these non-apoptotic conditions.
Another very interesting observation from the work presented in this dissertation
pertains to the effect of cadmium on caspase activity. Cadmium sits just below zinc as a
group 12 metal with a d10 valence electronic configuration. Given such similar chemical
properties it was assumed that cadmium and zinc would bind and inactivate caspases in
an identical fashion, however, that is not what was observed (Figure 20). Cadmium seems
to have a nuanced inhibition for caspase-3, -7, and -8 for both peptide and protein
substrates that differs from the global inhibition seen with zinc. For caspase-3, cadmium
blocks both peptide and substrate cleavage, while cadmium has no inhibitory effect on
peptide substrates for caspase-7. Interestingly, cadmium completely inhibits caspase-8
from cleaving peptide substrates but does not have nearly the same effect on protein
substrates. Information derived from this data could shed light on where zinc could be
binding, assuming zinc and cadmium share a binding site. For example, one might
hypothesize that because cadmium blocks peptide substrate cleavage by caspase-8, it
could be active site based inhibition. Meanwhile, caspase-8 binding a protein substrate
could shift the conformation of the enzyme to favor dimerization, which could compete
with the metal and result in marginal activity against a protein substrate.

	
  

153	
  

In addition, caspase-3 binds three zincs per monomer (Figure 22 and VelázquezDelgado et al.30). This begs the question why nature would select for what appears to be
such a redundant function. Why would an enzyme evolve three metal binding sites when
just binding one at the active site would be sufficient for silencing activity? One could
speculate that (1) each zinc binding site plays a non-redundant functional role in different
aspects of the caspase activity, whether it be in apoptosis or other non-apoptotic
pathways, or even blocking a specific exosite (2) each zinc binding site has varying
affinity for zinc and act as a slow activation mechanism where loss of all three is required
to achieve full caspase-3 activity (3) three zincs are needed to act together in order to
hold the procaspase-3 enzyme completely in the off-state and shift the equilibrium so that
it heavily favors a conformation that is unable to recognize substrate. In any of these
hypotheses or any other imagined scenario, it would be extremely beneficial to obtain a
crystal structure of caspase-3 bound to zinc(s). Crystallographic avenues for both
caspase-3 and caspase-7 are currently under pursuit by another talented graduate student,
Derek MacPherson, in the Hardy lab.
Exploiting Caspase Cell Death Potential via Nanogel Delivery
The successful delivery of an active caspase-3 that was then able to terminate
cancer cells represents an important advance for protein delivery utilizing this nanogel
strategy. This delivery data (Chapter IV) solidified an approach wherein the cell-killing
potential of the executioner caspase-3 was exploited in an application to execute cancer
cells. From the encapsulation perspective, this study has established a platform with
extensive potential for use in a variety of therapeutic applications. The apoptotic caspases
are a class of enzymes that are difficult to manipulate and control. They have very
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flexible active site loops, rigid requirements for maintaining catalytic activity such as pH
sensitivity, and susceptibility to misfold under the wrong conditions. Despite these
challenges, the nanogel delivery vehicle was able to easily encapsulate the caspase cargo,
silence its enzymatic activity while conjugated, and recover up to 86% caspase activity
after a specific redox trigger. In addition, these nanogel assemblies were able to gain
cellular entry and dose-dependently kill a population of cancer cells.
The successes of this nanogel-caspase conjugate in Chapter IV pave a path
forward to utilize this platform in what seems like endless possibilities. First and
foremost, it provides a means to deliver a cell-killing enzyme, something that could be
incredibly useful in the treatment of diseases like cancer that could benefit from a
controlled programmed cell death. In addition, these nanogels can be easily
functionalized in order to target specific populations of cells. One example (currently
under investigation by Kishore Raghupathi in the Thayumanavan group) is targeting a
cancer overexpressing a certain receptor, such as the folate receptor,31 for a more focused
delivery. In addition, exploring other apoptotic inducing proteins and small molecules in
combination could be a powerful avenue to optimize the cell-killing potential of these
nanogel conjugates (currently being explored by the skillful Francesca Anson). The
beauty of this encapsulation method is that it is not limited to caspase delivery and
inducing cell death. One could imagine this approach being utilized for the intracellular
delivery of a variety of therapeutic proteins to treat a number of diseases. This could
further be expanded to other biomacromolecules, such as nucleic acids, which creates a
tempting platform for other applications such as delivering CRISPR components.
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The success found with caspases in this system was in part due to the clever thiol
chemistry engineered by the Thayumanavan lab. The five surface exposed cysteines in
each monomer of caspase-3 were targeted by the polymer during the reactive selfassembly, facilitating its encapsulation. Using this system with non-cysteine containing
proteins may require a variation on the encapsulation method. A current collaboration
with Kishore Raghupathi has adopted an encapsulation method that utilizes an inversion
emulsion polymerization approach to incorporate hydrophilic biomolecules within a
nanogel. This has a unique advantage because it forces the cargo inside the hydrophilic
center of the polymer aggregate during assembly, thus entrapping cargo with a high
efficiency. Ongoing work has established this inverse emulsion method and successfully
entrapped a variety of proteins including caspase-3, PAK2, lysozyme, and GFP. These
protein cargoes maintain their activity and interestingly, the GFP remains fluorescent
even after encapsulation within the nanogel.
Future applications of this delivery system will surely require nuances to the
nanogel polymerization method in order to take full advantage of the diverse set of
proteins under investigation. After these adjustments are made to the system as a whole,
it is important to confirm that intracellular release of the protein cargo is maintained
under the stringent control of the intracellular redox trigger. It would be of great benefit
to develop a tool in order to predetermine (1) if the cargo stays inside the nanogel, (2) if
the nanogel can release its contents unperturbed, and (3) if the cargo can reach the
cytosol. A tool that will satisfy these requirements is an adapted version of the split GFP.
The cells in question could be transfected with the short 11th strand of GFP, and the
newly formed nanogels in question could entrap GFP 1-10. When the transfected cells are
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exposed to the nanogel conjugate, there will be GFP fluorescence if and only if the
nanogel was taken up by the cells, the GFP 1-10 was properly released, and the GFP 1-10
reaches the cytosol. A tool of this nature would be extremely beneficial when
interrogating different nanogels with variable synthetic routes.
The Killing Blow
Ultimately it is the apoptotic caspases that deliver the killing blow in the
controlled termination of cells amongst all eukaryotes. The need to fully understand
caspase activation, regulation, structure, and function has become essential in order to
therapeutically harness the true potency of programmed cell death. By interrogating
phosphorylation, zinc binding, and caspases themselves as biologics, this dissertation
hopes to add to the biochemical knowledge regarding caspase activity and positively
influence further studies targeting this powerful class of enzymes.
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